Rna-guided gene editing and gene regulation

Abstract

To provide: clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-based (Cas) 9-associated system related compositions; methods of using the CRISPR / Cas9-associated system related compositions for gene expression and genome engineering; compositions and methods of using the compositions for gene expression and genetic engineering in muscle, such as skeletal muscle and cardiac muscle.SOLUTION: A fusion protein comprises two heterologous polypeptide domains. The first polypeptide domain comprises a clustered regularly interspaced short palindromic repeats associated (Cas) protein. The second polypeptide domain has activity selected from the group consisting of transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nuclease activity, nucleic acid association activity, methylase activity, and demethylase activity.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] Cross-references to related applications This application claims priority to U.S. Provisional Patent Application No. 61 / 831,481, filed June 5, 2013, U.S. Provisional Patent Application No. 61 / 839,127, filed June 25, 2013, U.S. Provisional Patent Application No. 61 / 904,911, filed November 15, 2013, U.S. Provisional Patent Application No. 61 / 967,466, filed March 19, 2014, and U.S. Provisional Patent Application No. 61 / 981,575, filed April 18, 2014, all of which are incorporated herein by reference in their entireties. Government Ownership Statement This invention was made with government support under Federal Grant Nos. DP2-OD008586 and R01DA036865 awarded by the NIH and CBET-1151035 awarded by the National Science Foundation. The U.S. Government has certain rights in the invention.

[0002] Technical Field The present disclosure relates to the field of gene expression alteration, genome engineering and genomic modification of genes using clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas)9-based systems and viral delivery systems. The present disclosure also relates to the field of genome engineering and genomic modification of genes in muscle (e.g., skeletal and cardiac muscle). [Background technology]

[0003] Synthetic transcription factors have been engineered to control gene expression in mammalian systems for many different medical and scientific applications, including stimulating tissue regeneration, drug screening, compensating for gene defects, activating silenced tumor suppressors, controlling stem cell differentiation, performing genetic screens, and creating synthetic gene circuits. These transcription factors can be targeted to promoters or enhancers of endogenous genes or can be purposely designed to recognize sequences independent of the mammalian genome for transgene regulation. The most common strategies to engineer novel transcription factors that target user-defined sequences are based on the DNA-binding domains of zinc finger proteins and transcription activator-like effectors (TALFs). Both of these approaches involve exploiting the principles of protein-DNA interactions of these domains to engineer novel proteins with unique DNA-binding specificities. Although these methods have met with widespread success for many applications, the protein engineering required to engineer protein-DNA interactions is laborious and requires specialized expertise.

[0004] Moreover, these novel proteins are not always effective. The reason is still unclear, but it may involve the influence of epigenetic modifications and chromatin state on the binding of the protein to the genomic target site. In addition, it is extremely difficult to ensure that these novel proteins are delivered to each cell as well as other components. Existing methods to deliver these novel proteins and their various components include delivery to cells by separate plasmids or vectors, which result in highly variable expression levels due to differences in copy number. Moreover, gene activation after transfection is transient due to dilution of the plasmid DNA, and the transient gene expression is not sufficient to produce a therapeutic effect. Furthermore, this approach is not amenable to cell types that are not easily transfected. Therefore. Another limitation of these novel proteins is the efficiency of transcriptional activation.

[0005] Position-specific nucleases can be used to introduce position-specific double-strand breaks at targeted genomic loci. This DNA break stimulates natural DNA repair mechanisms, resulting in one of two possible repair pathways. In the absence of a donor template, the break is repaired by non-homologous end joining (NHEJ), an error-prone repair pathway that results in small insertions or deletions of DNA. This method can be used to intentionally disrupt, delete, or modify the reading frame of the target gene sequence. However, when a donor template is provided along with the nuclease, the cellular machinery will repair the break by homologous recombination, which is enhanced by several orders of magnitude in the presence of DNA breaks. This method can be used to introduce specific changes in the DNA sequence at the target site. Engineered nucleases have been used for gene editing in various human stem cells and cell lines or gene editing in mouse liver. However, a major hurdle for the implementation of these techniques is their in vivo delivery to specific tissues in a manner that promotes effective, efficient, and successful genome modification.

[0006] Inherited genetic diseases devastatingly affect children in the United States. These diseases have so far offered no cure, and can only be managed by attempts to alleviate symptoms. For decades, the field of gene therapy has offered the promise of a cure for these diseases. However, technical hurdles related to the safe and efficient delivery of therapeutic genes to cells and patients have limited this approach. Duchenne muscular dystrophy (DMD) is the most common monogenic disease, occurring in 1 in 3500 males. DMD is the result of inherited or accidental mutations in the dystrophin gene. Dystrophin is an essential component of a protein complex required to regulate muscle cell integrity and function. DMD patients typically lose the ability to physically support themselves during childhood, and frailty progresses during the teen years, leading to death in their twenties. Previous experimental gene therapy strategies for DMD require repeated administration of temporary gene delivery vehicles or rely on permanent integration of foreign genetic material into genomic DNA. Both of these methods have significant safety concerns. Furthermore, these strategies have been limited by the inability to deliver the large and complex dystrophin gene sequence. Summary of the Invention [Means for solving the problem]

[0007] The present invention is directed to a fusion protein comprising two heterologous polypeptide domains. The first polypeptide domain comprises an assembled regularly interspaced short palindromic repeats-associated (Cas) protein, and the second polypeptide domain has an activity selected from the group consisting of: transcriptional activation activity, transcriptional repression activity, transcription deactivator activity, histone modification activity, nuclease activity, nucleic acid binding activity, methylase activity, and demethylase activity. The Cas protein can comprise Cas9. The Cas9 can comprise at least one amino acid mutation that knocks out the nuclease activity of Cas9. The at least one amino acid mutation can be at least one of D10A and H840A. The Cas protein can comprise iCas9 (amino acids 36-1403 of SEQ ID NO:1). The second polypeptide domain can have transcriptional activation activity. The second polypeptide domain can comprise at least one VP16 transcriptional activation domain repeat. The second polypeptide domain can comprise a VP16 tetramer ("VP64") or a p65 activation domain. The fusion protein can further comprise a linker linking the first polypeptide domain to the second polypeptide domain. The fusion protein can comprise iCas9-VP64.

[0008] The present invention is directed to a DNA targeting system comprising said fusion protein and at least one guide RNA (gRNA). The at least one gRNA can comprise a 12-22 base pair complementary polynucleotide sequence of the target DNA sequence followed by a protospacer adjacent motif. The at least one gRNA can target a promoter region of a gene, an enhancer region of a gene, or a transcribed region of a gene. The at least one gRNA can target an intron of a gene. The at least one gRNA can target an exon of a gene. The at least one gRNA can target a promoter region of a gene selected from the group consisting of ASCL1, BRN2, MYT1L, NANOG, VEGFA, TERT, IL1B, IL1R2, IL1RN, HBG1, HBG2, and MYOD1. The at least one gRNA can comprise at least one of SEQ ID NOs: 5-40, 65-144, 492-515, 540-563, and 585-625. The present invention is directed to a DNA targeting system comprising Cas9 and at least one guide RNA (gRNA) that binds to the dystrophin gene. The at least one gRNA can target an intron of the dystrophin gene. The at least one gRNA can target an exon of the dystrophin gene. The at least one guide RNA can comprise at least one of SEQ ID NOs: 5-40, 65-144, 492-515, 540-563 and 585-625. The DNA targeting system can comprise one to ten different gRNAs. The present invention is directed to an isolated polynucleotide encoding said fusion protein or said DNA targeting system. The present invention is directed to a vector comprising the isolated polynucleotide. The present invention is directed to a cell comprising said isolated polynucleotide or said vector.

[0009] The present invention is directed to a method of modulating expression of a mammalian gene in a cell, the method comprising contacting a cell with the fusion protein, the DNA targeting system, the isolated polynucleotide, or the vector. Gene expression can be inducible. The present invention is directed to a method of transdifferentiating or inducing differentiation of a cell. The method includes contacting a cell with the fusion protein, the DNA targeting system, the isolated polynucleotide, or the vector. The cell can be a fibroblast or an induced pluripotent stem cell. The fibroblast can be transdifferentiated into a neuronal cell or a myogenic cell. The DNA targeting system can be contacted with the cell, and at least one gRNA targets a promoter region of at least one gene selected from the group consisting of ASCL1, BRN2, MYOD1, and MYT1L. The DNA targeting system can include at least one gRNA that targets a promoter region of the ASCL1 gene and at least one gRNA that targets a promoter region of the BRN2 gene. The DNA targeting system can include 1 to 20 different gRNAs. The DNA targeting system can include 8 to 16 different gRNAs. The DNA targeting system can include dCas9-VP64. The DNA targeting system can be delivered to the cell virally or non-virally.

[0010] The present invention is directed to a method for correcting a mutated gene in a cell. The method comprises administering to a cell comprising the DNA targeting system, the isolated polynucleotide or the vector. Correcting the mutated gene can comprise homology-directed repair. The method can further comprise administering donor DNA to the cell. The mutated gene can comprise a frameshift mutation resulting in a premature stop codon and a truncated gene product. Correcting the mutated gene can comprise nuclease-mediated non-homologous end joining. Correcting the mutated gene can comprise deletion of a premature stop codon, disruption of a splice acceptor site, deletion of one or more exons or disruption of a splice donor sequence. Deletion of one or more exons can result in a correction of the reading frame. The present invention is directed to a method of treating an animal subject carrying a mutant dystrophin gene in need thereof, the method comprising administering to the animal subject the DNA targeting system, the isolated polynucleotide or the vector. The animal subject may be afflicted with Duchenne muscular dystrophy.

[0011] The present invention is directed to a method for correcting a mutant dystrophin gene in a cell. The method includes administering the DNA targeting system, the isolated polynucleotide, the vector, or the cell to a cell containing a mutant dystrophin gene. The mutant dystrophin gene can include a premature stop codon, a reading frame disrupted by a gene defect, an aberrant splice acceptor site, or an aberrant splice donor site, where the target region is upstream or downstream of the premature stop codon, the disrupted reading frame, the aberrant splice acceptor site, or the aberrant splice donor site. Correcting the mutant dystrophin gene can include homology-directed repair. The method can further include administering donor DNA to the cell. The mutant dystrophin gene can include a premature stop codon and a frameshift mutation resulting in a truncated gene product. Correcting the mutant dystrophin gene can include nuclease-mediated non-homologous end joining. Correction of the mutant dystrophin gene can include deletion of a premature stop codon, correction of a disrupted reading frame, or modulation of splicing by disruption of a splice acceptor site or disruption of a splice donor sequence. Correction of the mutant dystrophin gene can include deletion of exons 45-55 or exon 51. The present invention is directed to a kit comprising said fusion protein, said DNA targeting system, said isolated polynucleotide, said vector or said cell.

[0012] The present invention is directed to a method of modulating mammalian gene expression in a cell. The method includes contacting a cell with a polynucleotide encoding a DNA targeting system. The DNA targeting system includes the fusion protein and at least one guide RNA (gRNA). The DNA targeting system can include 1 to 10 different gRNAs. The different gRNAs can bind to different regions within a target gene. The target regions can be separated by at least one nucleotide. The target regions can be separated by about 15 to about 700 base pairs. Each of the different gRNAs can bind to at least one different target gene. The different target genes can be located on the same chromosome. The different target genes can be located on different chromosomes. The at least one target region can be within a non-open chromatin region, an open chromatin region, a promoter region of a target gene, an enhancer region of a target gene, a transcribed region of a target gene, or a region upstream of a transcription start site of a target gene. The at least one target region can be located about 1 to about 1000 base pairs upstream of a transcription start site of a target gene. The at least one target region may be located about 1 to about 600 base pairs upstream of the transcription start site of the target gene. Gene expression may be induced. The DNA targeting system may include 2 different gRNAs, 3 different gRNAs, 4 different gRNAs, 5 different gRNAs, 6 different gRNAs, 7 different gRNAs, 8 different gRNAs, 9 different gRNAs, or 10 different gRNAs. The at least one guide RNA may target a promoter region of a gene selected from the group consisting of ASCL1, BRN2, MYT1L, NANOG, VEGFA, TERT, IL1B, IL1R2, IL1RN, HBG1, HBG2, and MYOD1. The at least one guide RNA may include at least one of SEQ ID NOs: 5-40, 65-144, 492-515, 540-563, and 585-625. The at least one target region may be within an intron or exon of the target gene.

[0013] The present invention is directed to a composition for inducing mammalian gene expression in a cell, said composition comprising said fusion protein and at least one guide RNA (gRNA). The present invention is directed to a composition for inducing mammalian gene expression in a cell, the composition comprising an isolated polynucleotide sequence encoding the fusion protein and at least one guide RNA (gRNA). The at least one guide RNA can target a promoter region of a gene selected from the group consisting of ASCL1, BRN2, MYT1L, NANOG, VEGFA, TERT, IL1B, IL1R2, IL1RN, HBG1, HBG2 and MYOD1. The at least one guide RNA can comprise at least one of SEQ ID NOs: 5-40, 65-144, 492-515, 540-563 and 585-625. The invention is directed to a cell comprising said composition for inducing mammalian gene expression in the cell. The invention is directed to a kit comprising said composition for inducing mammalian gene expression in a cell, or said cell containing said composition for inducing mammalian gene expression in a cell. The present invention is directed to a kit for inducing mammalian gene expression in a cell, said kit comprising said composition for inducing mammalian gene expression in a cell, or said cell comprising said composition for inducing mammalian gene expression in a cell.

[0014] The present invention is directed to a composition for genome editing in muscle of a subject animal. The composition comprises a modified adeno-associated virus (AAV) vector and a nucleotide sequence encoding a site-specific nuclease. The muscle is skeletal muscle or cardiac muscle. The modified AAV vector may have enhanced cardiac and skeletal muscle tissue tropism. The site-specific nuclease may comprise a zinc finger nuclease, a TAL effector nuclease, or a CRISPR / Cas9 system. The site-specific nuclease is capable of binding to a gene or locus in a muscle cell. The gene or locus may be a dystrophin gene. The composition may further comprise a donor DNA or a transgene. The present invention is directed to a kit comprising said composition for genome editing in the muscle of a target animal. The present invention is directed to a method of genome editing in muscle of a subject animal, the method comprising administering to the muscle of the subject animal a composition for genome editing in the muscle, the muscle being a skeletal muscle or a cardiac muscle. The genome editing can comprise correction of a mutant gene or insertion of a transgene. The correction of a mutant gene can comprise deletion, rearrangement or replacement of the mutant gene. The correction of a mutant gene can comprise nuclease-mediated non-homologous end joining or homology-directed repair. The present invention is directed to a method of treating a subject animal, the method comprising administering to a muscle of the subject animal the composition for genome editing in the muscle of the subject animal, the muscle being a skeletal muscle or a cardiac muscle. The subject animal may suffer from a skeletal muscle condition or genetic disease. The subject animal may suffer from Duchenne muscular dystrophy. The present invention is directed to a method for correcting a mutant gene in a subject, the method comprising administering the composition for genome editing in a muscle of the subject. The muscle is a skeletal muscle or a cardiac muscle. The composition can be injected into a skeletal muscle of the subject. The composition can be injected systemically into the subject. The skeletal muscle can be the tibialis anterior muscle.

[0015] The present invention is directed to a modified lentiviral vector for genome editing in a subject animal, the vector comprising a first polynucleotide sequence encoding the fusion protein and a second polynucleotide sequence encoding at least one sgRNA. The first polynucleotide sequence can be operably linked to a first promoter. The first promoter can be a constitutive promoter, an inducible promoter, a repressible promoter, or a regulatable promoter. The second polynucleotide sequence can encode 1 to 10 different sgRNAs. The second polynucleotide sequence can encode 2 different sgRNAs, 3 different sgRNAs, 4 different sgRNAs, 5 different sgRNAs, 6 different sgRNAs, 7 different sgRNAs, 8 different sgRNAs, 9 different sgRNAs, 10 different sgRNAs. Each of the polynucleotide sequences encoding the different sgRNAs can be operably linked to a promoter. Each of the promoters operably linked to the different sgRNAs can be the same promoter. Each of the promoters operably linked to the different sgRNAs can be different promoters. The promoter can be a constitutive promoter, an inducible promoter, a repressible promoter, or a regulatable promoter. The sgRNA can bind to a target gene. Each of the sgRNAs can bind to a different target region in one target locus. Each of the sgRNAs can bind to a different target in a different locus. The fusion protein can include a Cas9 protein or an iCas9-VP64 protein. The fusion protein can include a VP64 domain, a p300 domain, or a KRAB domain. Two or more endogenous genes can be transcriptionally activated. Two or more endogenous genes can be repressed.

[0016] The present invention is directed to a method of activating an endogenous gene in a cell. The method comprises contacting a cell with the modified lentiviral vector. The endogenous gene can be transiently activated. The endogenous gene can be stably activated. The endogenous gene can be transiently repressed. The endogenous gene can be stably repressed. The fusion protein can be expressed at similar levels as the sgRNA. The fusion protein can be expressed at different levels than the sgRNA. The cell can be a primary human cell. The present invention is directed to a method of complex gene editing in a cell. The method comprises contacting a cell with the modified lentiviral vector. The complex gene editing can include correction of at least one mutated gene or insertion of a transgene. The correction of the mutated gene can include deletion, rearrangement or replacement of at least one mutated gene. The correction of the at least one mutated gene can include nuclease-mediated non-homologous end joining or homology-directed repair. The complex gene editing can include deletion of at least one gene, where the gene is an endogenous normal gene or a mutated gene. The complex gene editing can include deletion of at least two genes. The complex gene editing can include deletion of between two and ten genes. The present invention is directed to a method of modulating gene expression of at least one target gene in a cell, the method comprising contacting a cell with the modified lentiviral vector. The gene expression of at least two genes can be modulated. The gene expression of two to ten genes can be modulated. The gene expression of at least one target gene can be modulated when the gene expression level of the at least one target gene is increased or decreased compared to the normal gene expression level of the at least one target gene. [Brief description of the drawings]

[0017] [Figure 1]Activation of the human IL1RN gene by RNA-guided iCas9-VP64. (a, b) Inactivated Cas9 (iCas9, D10A / H840A) was fused to the VP64 transactivation domain to generate an RNA-guided transcriptional activator. iCas9-VP64 recognizes genomic target sites via hybridization of the guide RNA (gRNA) with a 20 bp target sequence. (c) Expression plasmids for four gRNAs or crRNA / tracrRNA targeting sequences in the IL1RN promoter were co-transfected with the iCas9-VP64 expression plasmid into HEK293T cells. Activation of IL1RN expression was determined by qRT-PCR. (d) The four gRNA expression plasmids were co-transfected with iCas9-VP64 individually or together. Robust gene activation was observed by qRT-PCR only in response to the combined gRNAs. (e) Activation of IL1RN expression was confirmed by determining secretion of the IL-1ra gene product into the culture medium by ELISA. IL-1ra was only detected in 3 of 6 samples treated with gRNAs combined. For (ce), data are shown as mean ± sem (n = 3 independent experiments). Treatment with gRNAs combined was statistically different from all other treatments by Tukey's test (*P < 0.02). (f) RNA-seq was performed on empty expression vector treated samples (n = 2) or samples co-transfected with iCas9-VP64 targeting IL1RN and expression plasmids for the four gRNAs (n = 2). The only statistically significant changes in gene expression between these treatments were increases in the four IL1RN isoforms (false discovery rate < 3x10-4) and decreases in IL32 (false discovery rate = 0.03). [Diagram 2]RNA-guided activation of human genes relevant for cell and gene therapy, gene reprogramming, and regenerative medicine. HEK293T cells were transfected with iCas9-VP64 expression plasmid and four gRNAs individually or together. Target gene expression was measured by qRT-PCR and normalized to GAPDH mRNA levels. Data are presented as mean ± sem (n = 3 independent experiments). Treatment with gRNAs together was statistically different from all other treatments by Tukey's test (*P < 0.05). [Diagram 3] Figure 1 shows the expression of iCas9-VP64. Expression of iCas9-VP64 in transfected HEK293 cells was confirmed by Western blot against the N-terminal Flag epitope tag. The wtCas9 expression plasmid does not contain an epitope tag. [Figure 4-1] The gRNA target sites and DNAse hypersensitive locations of human target genes are shown. The four gRNA target sites for each locus are shown as custom tracks for each gene above, and DNase-seq data showing DNAse hypersensitive open chromatin regions are shown for each gene below. DNase-seq was performed in HEK293T cells to identify DNase hypersensitive regions as previously described (Song et al., Cold Spring Harbor protocols 2010, pdb prot5384, 2010; Song et al. Genome Res 21, 1757-1767, 2011). The results indicate that open chromatin is not a requirement for gene activation by the combination of gRNA and iCas9-VP64. [Figure 4-2]The gRNA target sites and DNAse hypersensitive locations of human target genes are shown. The four gRNA target sites for each locus are shown as custom tracks for each gene above, and DNase-seq data showing DNAse hypersensitive open chromatin regions are shown for each gene below. DNase-seq was performed in HEK293T cells to identify DNase hypersensitive regions as previously described (Song et al., Cold Spring Harbor protocols 2010, pdb prot5384, 2010; Song et al. Genome Res 21, 1757-1767, 2011). The results indicate that open chromatin is not a requirement for gene activation by the combination of gRNA and iCas9-VP64. [Figure 4-3] The gRNA target sites and DNAse hypersensitive locations of human target genes are shown. The four gRNA target sites for each locus are shown as custom tracks for each gene above, and DNase-seq data showing DNAse hypersensitive open chromatin regions are shown for each gene below. DNase-seq was performed in HEK293T cells to identify DNase hypersensitive regions as previously described (Song et al., Cold Spring Harbor protocols 2010, pdb prot5384, 2010; Song et al. Genome Res 21, 1757-1767, 2011). The results indicate that open chromatin is not a requirement for gene activation by the combination of gRNA and iCas9-VP64. [Figure 4-4]The gRNA target sites and DNAse hypersensitive locations of human target genes are shown. The four gRNA target sites for each locus are shown as custom tracks for each gene above, and DNase-seq data showing DNAse hypersensitive open chromatin regions are shown for each gene below. DNase-seq was performed in HEK293T cells to identify DNase hypersensitive regions as previously described (Song et al., Cold Spring Harbor protocols 2010, pdb prot5384, 2010; Song et al. Genome Res 21, 1757-1767, 2011). The results indicate that open chromatin is not a requirement for gene activation by the combination of gRNA and iCas9-VP64. [Diagram 5] This shows that there is no nuclease activity by iCas9-VP64. Wild-type Cas9 or inactivated (D10A, H840A) iCas9-VP64 expression plasmid was co-transfected with expression plasmids for four different guide RNAs targeting the IL1RN promoter. Nuclease activity was determined by surveyor assay (Guschin et al., Methods Mol Biol 649, 247-256, 2010). Low molecular weight bands and DNA repair by non-homologous end joining, indicators of nuclease activity, were only present after treatment with wild-type Cas9, supporting the abolition of nuclease activity by iCas9-VP64. [Figure 6]RNA-seq for samples treated with gRNAs targeting HBG1 and HBG2 is shown. RNA-seq was performed on samples treated with a control empty expression vector (n=3) or co-transfected with iCas9-VP64 and expression plasmids for four gRNAs targeting HBG1 (n=2). Three of these gRNAs also targeted HBG2. Increases were observed for both HBG1 and HBG2 relative to controls, but were not statistically significant due to low expression levels. The only statistically significant changes in gene expression between these treatments were decreases in IL32 (false discovery rate=0.0007) and TNFRS9 (false discovery rate=0.002). [Figure 7] Figure 1 shows upregulation of Ascl1 and γ-globin by iCas9-VP64. HEK293T cells were transfected with iCas9-VP64 and four gRNAs targeting the ASCL1 or HBG1 promoter. Corresponding Ascl1 and γ-globin protein levels were determined by Western blot. Low levels of these proteins could be detected in HEK293T cells, and increased expression could be detected after iCas9-VP64 treatment in two separate experiments. [Figure 8-1] Activation of downstream targets of Ascl1 in murine embryonic fibroblasts treated with iCas9-VP64. Mouse embryonic fibroblasts (MEFs) were transfected with a control GFP expression plasmid or an iCas9-VP64 expression plasmid and four gRNA expression plasmids targeting ASCL1 at a ratio of 50:50 or 75:25. (a) The gRNA target site in the human ASCL1 promoter (SEQ ID NO:3) is conserved in the mouse ASCL1 promoter (SEQ ID NO:4). The target site is indicated by a solid line and the transcribed region is indicated by a dotted line. [Figure 8-2]Activation of downstream targets of Ascl1 in murine embryonic fibroblasts treated with iCas9-VP64. Mouse embryonic fibroblasts (MEFs) were transfected with a control GFP-expressing plasmid or an iCas9-VP64-expressing plasmid and four gRNA-expressing plasmids targeting ASCL1 at a ratio of 50:50 or 75:25. (b) ASCL1 expression in MEFs was increased 2 days after iCas9-VP64 / gRNA treatment as determined by qRT-PCR. (ch) After 10 days in neural induction medium, cells were stained for Ascl1 and Tuj1 (early markers of neuronal differentiation) (cd) or for Tuj1 and MAP2 (markers of more mature neuronal differentiation) (df). Some Tuj1-positive cells adopted neuronal morphology (fg) and single cells were found to be Tuj1 and MAP2 positive (g). (h) Tuj1 positive cells were readily identified in iCas9-VP64 / gRNA treated cultures (~0.05%) but were absent in controls. n=3 independent experiments. Data are shown as mean ± standard error of the mean. gRNA 75 / 25 was significantly different from gRNA 50 / 50 and control (*P<0.01, Tukey test). [Figure 9A] (a) The iCas9-VP64 protein sequence (SEQ ID NO: 1). [Figure 9B] (b) The sequence of the gRNA expression cassette with the U6 promoter (SEQ ID NO: 2) is shown. [Figure 10-1] Standard curves for qRT-PCR are shown. For each gene, the experimental sample with the highest expression level was diluted to generate a standard curve. The standard curve was assayed by qRT-PCR to ensure efficient amplification over an appropriate dynamic range. The efficiency of the overall amplification reaction was 90-115%. [Figure 10-2] Standard curves for qRT-PCR are shown. For each gene, the experimental sample with the highest expression level was diluted to generate a standard curve. The standard curve was assayed by qRT-PCR to ensure efficient amplification over an appropriate dynamic range. The efficiency of the overall amplification reaction was 90-115%. [Figure 11]Figures 11(a)-11(b) show the efficacy of RNA-guided repair. Figure 11(a) shows the results of a surveyor assay of genomic DNA harvested from HEK293T cells 2 days after co-transfecting the cells with Cas9 along with an empty vector (negative control) or gRNA. Figure 11(b) shows the location of the gRNA target. Figure 11(c) shows the expected cleavage size for each gRNA. [Figure 12] Figure 2 shows RNA-guided repair in DMD8036(del48-50) cells as shown by Surveyor assay. [Figure 13] Figure 1 shows RNA-guided repair in DMD8036(del48-50) cells as demonstrated by PCR across the entire locus. PCR of the wild-type dystrophin gene results in a fragment of 1447 bp in size, whereas PCR of the mutant gene in the DMD8036 cell line shows a deletion of approximately 817 bp. After introduction of the CRISPR / Cas9-based system, the deletion band was approximately 630 bp. [Figure 14] FIG. 1 shows RNA-guided repair in DMD8036(del48-50) cells as shown by Western blot (using MANDYS8 (anti-dystrophin antibody) and GAPDH antibody (positive control)). [Figure 15]

[0036] Figure 1 shows ChIP-sequencing data demonstrating specific binding of iCas9-VP64 targeting the IL1RN promoter. HEK293T cells were transfected with iCas9-VP64 targeting the IL1RN promoter. [Figure 16]CRISPR / Cas9 targeting of the dystrophin gene. (A) sgRNA sequences were designed to bind to sequences in the mutational hotspot region of exons 45-55 of the dystrophin gene to allow gene editing to restore dystrophin expression resulting from a wide variety of patient-specific mutations. Arrows in introns indicate sgRNA targets designed to delete entire exons from the genome. Arrows in exons indicate sgRNA targets designed to create targeted frameshifts in the dystrophin gene. (B) Example of frame correction following small insertion or deletion by NHEJ DNA repair of exon 51 using CR3 sgRNA. (C) Schematic of composite sgRNA targeting designed to delete exon 51 and restore the dystrophin reading frame in a patient mutation with a deletion of exons 48-50. (D) Schematic of composite sgRNA targeting designed to delete the entire exon 45-55 region to accommodate a wide variety of DMD patient mutations. [Figure 17] 1 shows a TBE-PAGE gel image used to quantify the results of the Surveyor assay measuring the genetic modification on day 3 in Table 7. The asterisks indicate the expected band sizes indicative of nuclease activity. [Figure 18] 1 shows a TBE-PAGE gel image used to quantify the results of the Surveyor assay measuring day 10 gene alterations in Table 7. The asterisks indicate the expected band sizes indicative of nuclease activity. [Figure 19]Fluorescence-activated flow sorting to enrich for genetically modified DMD myoblasts. (A) A plasmid expressing human codon-optimized SpCas9 protein linked to a GFP marker using a T2A ribosomal skipping peptide sequence was co-electroporated into human DMD myoblasts with one or more plasmids carrying sgRNA expression cassettes. (B) The indicated sgRNAs were separately co-transfected into HEK239T with separate plasmids expressing SpCas9 with (bottom) or without (top) GFP linked to SpCas9 by a T2A ribosomal skipping peptide sequence. Genetic modification frequency was determined by surveyor assay 3 days after transfection. (C) DMD myoblasts carrying a deletion of exons 48-45 of the dystrophin gene were treated with sgRNA that corrects the dystrophin reading frame in these patient cells. Genetic modification was determined in unsorted (bulk) or GFP+ sorted cells 20 days after electroporation. (D) GFP expression in DMD myoblasts 3 days after electroporation with the indicated expression plasmids. Transfection efficiency and sorted cell populations are indicated by the gated regions. [Figure 20]Targeted frameshifting to restore the dystrophin reading frame using CRISPR / Cas9 is shown. (A) The 5' region of exon 51 was targeted using sgRNA CR3 (which binds immediately upstream of the first out-of-frame stop codon). PAM: protospacer adjacent motif. (B) The exon 51 locus was PCR amplified from HEK293T cells treated with SpCas9 and the CR3 expression cassette. Individual clones were sequenced by Sanger sequencing. The top sequence (bold, exons in red) is the native unmodified sequence. The number of clones for each sequence is indicated in brackets. (C) Summary of overall gene editing efficiency and reading frame conversion resulting from the gene modifications shown in (B). (D) Western blot of dystrophin expression in human DMD myoblasts treated with SpCas9 and a CR3 sgRNA expression cassette (FIG. 19C), which generates a target-induced frameshift that restores the dystrophin reading frame. Dystrophin expression was probed using an antibody against the rod domain of the dystrophin protein after 6 days of differentiation. [Figure 21]Deletion of exon 51 in the human genome using combined CRISPR / Cas9 gene editing. (A) End-point genomic PCR across exon 51 in human DMD myoblasts harboring a deletion of exons 48-50. The top arrow indicates the expected location of the full-length PCR amplicon, and the bottom two arrows indicate the expected location of the PCR amplicon harboring the deletion caused by the indicated sgRNA combinations. (B) PCR products in (A) were cloned and individual clones sequenced to determine the insertions and deletions present at the targeted locus. The top row shows the wild-type unmodified sequence, and the triangles indicate the SpCas9 cleavage sites. On the right are representative chromatograms showing the expected deletion junction sequences. (C) End-point RT-PCR analysis of dystrophin mRNA transcripts in CRISPR / Cas9 modified human Δ48-50 DMD myoblasts treated with the indicated sgRNAs. Representative chromatograms of the expected deletion PCR products are shown on the right. Asterisk: band resulting from hybridization of the deletion product strand with the unmodified strand. (D) Restoration of dystrophin protein expression by CRISPR / Cas9 genome editing was determined by Western blot for dystrophin protein (GAPDH was used as a loading control). The arrow indicates the expected repaired dystrophin protein band. [Figure 22]Figure 1 shows deletion of the complete exon 45-55 region in human DMD myoblasts by combined CRISPR / Cas9 gene editing. (A) End-point genomic PCR of genomic DNA detecting the region between intron 44 and intron 55 after treatment of HEK293T or DMD myoblasts with the indicated sgRNAs. (B) Individual clones of PCR products with the expected size for the deletion from DMD myoblasts in (A) were analyzed by Sanger sequencing to determine the sequence with the genomic deletion present at the targeted locus. At the bottom, a representative chromatogram showing the expected deletion junction sequence. (C) End-point RT-PCR analysis of dystrophin mRNA transcripts from CRISPR / Cas9 modified human Δ48-50 DMD myoblasts treated with the indicated sgRNAs. Representative chromatograms of the expected deletion PCR products are shown on the right. (D) Analysis of restored dystrophin protein expression by Western blot after electroporation of DMD myoblasts with sgRNAs targeting intron 44 and / or intron 55. [Figure 23] Shown is flow cytometric evidence of enrichment of genetically modified DMD myoblasts used in in vivo cell transplantation experiments. DMD myoblasts were treated with Cas9 in the presence or absence of sgRNA expression vectors for CR1 and CR5 and GFP+ cells were selected by flow cytometry. Deletion at the exon 51 locus was detected by end-point PCR using primers flanking the locus. Neg ctrl:DMD myoblasts were treated with Cas9 alone and selected for GFP+ cells. [Figure 24]Figure 19 shows restored human dystrophin expression after transplantation of CRISPR / Cas9-treated human DMD myoblasts into immunodeficient mice. Human Δ48-50 DMD myoblasts were treated with SpCas9, CR1 and CR5 to delete exon 51 and sorted for GFP expression as shown in Figure 19. These sorted cells and untreated control cells were injected into the hind limbs of immunodeficient mice and human-specific protein expression in muscle fibers was assessed 4 weeks after transplantation. Frozen sections were stained with anti-human spectrin (spectrin is expressed in both uncorrected and corrected myoblasts fused to mouse muscle fibers) or anti-human dystrophin antibodies as indicated. White arrows indicate human dystrophin-positive muscle fibers. [Diagram 25] Further immunofluorescence images probing human dystrophin expression are shown. Serial sections stained with anti-human spectrin are shown at the top left. (AC) Sections of muscle injected with untreated human DMD myoblasts. (DF) Sections of muscle injected with CR1 / 5-treated human DMD myoblasts enriched by flow cytometry. White arrows indicate dystrophin-positive fibers. [Figure 26]Evaluation of CRISPR / Cas9 toxicity and off-target effects of CR1 / CR5-mediated deletion of exon 51 in human cells. (A) Results of cytotoxicity assay in HEK293T cells treated with human optimized SpCas9 and the indicated sgRNA constructs. Cytotoxicity is based on survival of GFP-positive cells co-transfected with the indicated nucleases. I-SceI is a well-characterized non-toxic meganuclease and GZF3 is a known toxic zinc finger nuclease. (B) Surveyor analysis of off-target sites in selected hDMD cells treated with expression cassettes encoding Cas9 and the indicated sgRNAs. These three off-target sites tested in hDMD cells were identified from a panel of 50 predicted sites tested in HEK293T cells (Figure 27 and Table 4). TGT: on-target locus of the indicated sgRNA. OT: off-target locus. (C,D) Endpoint nested PCR to detect chromosomal translocations in HEK293T cells treated with Ca9 and CR1 (C) or selected hDMD cells treated with Cas9, CR1 and CR5 (D). Schematic diagram shows the relative positions of nested primer pairs customized for each translocation event. The expected size of each band was estimated based on the primer size and the position of the expected sgRNA cleavage site at each locus. Asterisks indicate bands detected at the expected size. Identification of the bands in (C) was verified by Sanger sequencing of each end (Figure 30). Representative chromatograms of P2 / P5 translocations in HEK293T cells are shown. [Figure 27] 1 shows a TBE-PAGE gel image used to quantify the results of the Surveyor assay to measure on-target and off-target gene modifications in Table 4. The asterisks indicate the expected size of the bands that are indicative of nuclease activity. [Figure 28]Figure 1 shows end-point nested PCR to detect chromosomal translocations resulting from CRISPR / Cas9 off-target activity against CR3 and CR6 / CR36 in human cells. Nested end-point PCR analysis was used to detect translocations in (A) HEK239T or selected hDMD cells treated with Cas9 and CR3 as indicated, (B) HEK293T cells treated with Cas9 and CR36 alone, or (C) selected hDMD cells treated with Cas9, CR6 and CR36 expression cassettes. A second nested PCR reaction for translocations was amplified with custom primers for each predicted translocation locus to maximize specificity (see Table 4). A schematic shows the relative positions of nested primer pairs used to probe for the presence of translocations. Each possible translocation event was first amplified from genomic DNA isolated from cells treated with or without the indicated sgRNA. A second nested PCR reaction was performed with primers within the PCR amplicon predicted to result from the translocation. Expected sizes were estimated based on the indicated primer binding sites and predicted sgRNA cleavage sites for each locus. * indicates bands detected at the expected size and verified by Sanger sequencing at each end. # indicates amplicons where Sanger sequencing showed sequences other than the predicted translocation (possibly a result of mispriming during nested PCR). [Figure 29] Sanger sequencing chromatograms of the bands detected in Figure 28 resulting from a translocation between CR3 and CR3-OT1 (located on chromosomes X and 1, respectively) in HEK239T cells treated with Cas9 and CR3 gene cassettes. Arrows indicate regions with homology to the indicated chromosomes near the predicted breakpoints introduced by the appropriate sgRNA. Note that the sequencing reads do not match near the breakpoints due to error-prone DNA repair properties by non-homologous end joining. [Diagram 30]Sanger sequencing chromatograms for the bands detected in Figure 26C are shown, which are the result of translocations between CR1 and CR1-OT1 (located on chromosomes X and 16, respectively) in HEK293T cells treated with Cas9 and CR1 gene cassettes. Arrows indicate the regions of homology to the indicated chromosomes near the predicted breakpoints induced by the appropriate sgRNA. Note that the sequencing reads do not match near the breakpoints due to error-prone DNA repair properties by non-homologous end joining. [Diagram 31] An outline of in vivo AAV injection and tissue collection is shown. [Diagram 32] Surveyor analysis of Rosa26 ZFN activity in skeletal muscle in vitro and in vivo after AAV-SASTG-ROSA delivery. Arrows indicate expected bands resulting from Surveyor cleavage. nd = not detected. (a) Proliferating C2C12 were transduced with the indicated amounts of virus and harvested 4 days post-infection. Arrows indicate expected band sizes resulting from Surveyor cleavage. (b) C2C12 were incubated in differentiation medium for 5 days and subsequently transduced with the indicated amounts of AAV-SASTG-ROSA virus in 24-well plates. Samples were harvested 10 days post-transduction. (c) The indicated amounts of AAV-SASTG-ROSA were injected directly into the tibialis anterior muscle of C57BL / 6J mice and muscles were harvested 4 weeks post-infection. Harvested TA muscles were divided into 8 separate strips for genomic DNA analysis. Each is shown in a separate lane. [Diagram 33] The Rosa T2A opt DNA sequence (sequence number 434) and the Rosa T2A opt protein sequence (sequence number 435) are shown. [Figure 34-1] The SASTG capsid DNA sequence (SEQ ID NO:436) is shown. [Figure 34-2] The SASTG capsid peptide sequence (SEQ ID NO:437) is shown. [Diagram 35]The DZF16 ZFN target site sequence (SEQ ID NO: 442), the DZF16-L6 left complete amino acid sequence (SEQ ID NO: 443), and the DZF16-R6 right complete amino acid sequence (SEQ ID NO: 444) are shown. [Diagram 36] The E51C3 ZFN target site sequence (SEQ ID NO: 445), the E51C3-3L left complete amino acid sequence (SEQ ID NO: 446) and the E51C3-3R right complete amino acid sequence (SEQ ID NO: 447) are shown. [Figure 37] The DZF15 ZFN target site sequence (sequence number: 448), the DZF15-L6 left complete amino acid sequence (sequence number: 449), the DZF15-R6 right complete amino acid sequence (sequence number: 450), the DZF15-L5 left complete amino acid sequence (sequence number: 451), and the DZF15-R5 right complete amino acid sequence (sequence number: 452) are shown. [Figure 38] The E51C4 ZFN target site sequence (SEQ ID NO: 453), the E51C4-4L left complete amino acid sequence (SEQ ID NO: 454) and the E51C4-4R right complete amino acid sequence (SEQ ID NO: 455) are shown. [Figure 39] Schematic diagrams of the "single vector, multiple CRISPR system", the "dual vector, multiple CRISPR system" and the "single vector, single gRNA system" are shown. [Diagram 40] The nucleotide sequences of SaCas9-NLS (NLS is underlined) (SEQ ID NO: 64) and SaCas9 gRNA (SEQ ID NO: 116) are shown. [Diagram 41] NmCas9 (NLS1 underlined, NLS2 underlined and bold, HA tag shown in bold), NmCas9 short hairpin (Source: Thomson PNAS 2013) (SEQ ID NO: 118), and NmCas9 long hairpin (Source: Church Nature Biotech 2013) (SEQ ID NO: 119) are shown. [Diagram 42]Validation of sgRNA and lentiviral Cas9 expression constructs is shown. (a) HEK293T cells were transfected with constructs encoding a native PolIII promoter expressing sgRNAs targeting the AAVS1 locus or constructs containing a hU6 promoter immediately followed by poly-thymidine ("polyT") for expression termination. End-point RT-PCR was used to probe for expression of the indicated promoter / sgRNA, respectively, 2 days post-transfection. -RT: no reverse transcriptase control. (b) HEK293T were transfected with expression vectors encoding AAVS1 zinc finger nuclease or Cas9-T2A-GFP and the indicated promoter / sgRNA expression cassettes, and gene modification levels were determined using a Surveyor assay 3 days post-transfection. (c) HEK293T cells were transduced with lentiviral constructs encoding the indicated Cas9-T2A-GFP constructs in the absence of sgRNA, and Cas9 expression was determined by Western blot by probing for the FLAG epitope tag at the N-terminus of the Cas9 protein 7 days post-transduction. [Diagram 43] Golden Gate assembly of a single lentiviral CRISPR / Cas9 expression cassette. [Diagram 44] Single lentiviral delivery of the combined CRISPR / Cas9 system. (a) Four sgRNAs targeting distinct genomic loci were cloned into a lentiviral vector expressing an active Cas9 nuclease. (b) HEK293 and primary human dermal fibroblast cells were transduced with lentiviruses expressing the indicated sgRNAs and assayed for cleavage events using the Surveyor assay. HEK293 cells were assayed 7 days after transduction. Human fibroblast cells were assayed 10 days after transduction. [Diagram 45]Transient gene activation in HEK293T stably expressing dCas9-VP64. HEK293T were transduced with lentivirus to stably express dCas9-VP64 and subsequently transfected with plasmids expressing the indicated sgRNA combinations. By varying the number of sgRNAs delivered, tunable endogenous gene activation of the endogenous IL1RN (a) and HBG1 (b) loci was achieved 3 days after transfection. Peak levels of endogenous IL1RN (c) and HBG1 (d) were observed 3-6 days after transfection, with activation levels returning to background levels from days 15 to 20. Importantly, the cell line could be reactivated 20 days after a second transfection, although the levels were lower than those observed previously. [Diagram 46] Figure 1 shows stable gene activation in HEK293T using a single lentiviral composite dCas9-VP64 vector. HEK293T were lentivirally transduced to stably express dCas9-VP64 and the indicated gRNA combinations. By varying the number of sgRNAs delivered, tunable endogenous gene activation of the endogenous IL1RN (a) and HBG1 (b) loci was achieved 7 days after transduction. Peak levels of endogenous IL1RN (c) and HBG1 (d) were observed 6 days after transduction, and the activation levels persisted until day 21. [Figure 47] IL1RN mRNA expression levels are shown. [Figure 48] FIG. 2 shows a schematic diagram depicting the direct conversion of fibroblasts into neurons by ectopic expression of BAM neuronal transcription factors. [Figure 49] (A) Schematic diagram of the dCas9-VP64 construct. dCas9-VP64 is a catalytically inactive form of the Cas9 protein fused to a tetramer of the VP16 transcription activation domain. (B) Schematic diagram showing the RNA-guided recruitment mechanism of dCas9-VP64 to genomic targets. (C) Schematic diagram of the experimental protocol to generate iNs by CRISPR / Cas9 transcription factors. [Figure 50]Endogenous ASCL1 expression at day 3 was determined by (A) qRT-PCR or (B) immunofluorescence for total ASCL1 protein in MEFs transduced with dCas9-VP64 and further transfected with gRNAs targeting the ASCL1 promoter, ASCL1 cDNA, or luciferase. Asterisks (*) indicate a significant (p<0.05) increase in ASCL1 expression with co-delivery of eight gRNAs compared to four gRNAs. Ectopic expression of ASCL1 produced more protein than that induced by dCas9-VP64 and eight gRNAs targeting the ASCL1 promoter, but did not activate the endogenous locus by day 3 in culture. [Figure 51] (B) TUJ1- and MAP2-positive cells generated by ectopic BAM elements or by dCas9-VP64 and gRNAs targeting the BRN2 and ASCL1 promoters, (C) cells with neuronal morphology expressing the hSyn-RFP reporter at day 11 in N3 medium. [Figure 52-1] (A) Cells with neuronal morphology are shown to be positive for the GCaMP5 calcium indicator in the presence (bottom) or absence (top) of KCl in culture medium. Figure 52 shows activation of downstream targets of Ascl1 and Brn2 (i.e., master regulatory genes) in iCas9-VP64-treated murine embryonic fibroblasts upon conversion of fibroblasts to neurons using dCas9-VP64 transcription factor. Murine embryonic fibroblasts (MEFs) were transfected with a control GFP-expressing plasmid or an iCas9-VP64-expressing plasmid and a combination of eight gRNA-expressing plasmids targeting Ascl1 and BRN2. The dCas9 transcription factor was delivered virally. After 10 days in neural induction medium, cells were stained for Tuj1 (an early marker of neuronal differentiation) and MAP2 (a differentiation marker of more mature neurons). Conversion to neurons was efficient. [Figure 52-2](B) Normalized fluorescence intensity traces over time showing cell depolarization in response to addition of KCl. Figure 52 shows activation of downstream targets of Ascl1 and Brn2 (i.e., master regulatory genes) in iCas9-VP64-treated murine embryonic fibroblasts upon conversion of fibroblasts to neurons using dCas9-VP64 transcription factor. Murine embryonic fibroblasts (MEFs) were transfected with a control GFP-expressing plasmid or an iCas9-VP64-expressing plasmid and a combination of eight gRNA-expressing plasmids targeting Ascl1 and BRN2. The dCas9 transcription factor was delivered virally. After 10 days in neural induction medium, cells were stained for Tuj1 (an early marker of neuronal differentiation) and MAP2 (a differentiation marker of more mature neurons). Conversion to neurons was efficient. [Figure 53] Illustrates the CRISPR / Cas9 platform for regulatory control of mammalian genes. A. Cas9-based effectors bind to genomic sequences in the presence of chimeric gRNA molecules consisting of constant regions (preceded by an exchangeable 20 bp protospacer that confers target site specificity) that form a complex with Cas9. B. Cas9-based synthetic transcription factors repress transcription of target genes by interfering with RNA polymerase activity or by binding within the promoter to block binding sites for endogenous transcription factors. Targeting regulatory elements (e.g. enhancers) can also block expression of multiple distant genes. [Figure 54] We show targeting of the HS2 enhancer using CRISPR / dCas9-KRAB. The HS2 region is a potent enhancer that can distally regulate the expression of globin genes more than 10 kb downstream. A set of single gRNAs was designed to target sites along the enhancer region. [Figure 55-1] We show that a single gRNA targeting the HS2 enhancer leads to strong transcriptional repression of globin genes. A. dCas9 and dCas9-KRAB repressor are delivered by lentiviral vectors. Single gRNA was transiently transfected for screening. [Figure 55-2] As assayed by quantitative RT-PCR 3 days after transfection, K562 expressing dCas9-KRAB achieved up to 80% suppression of the γ-globin gene (B), ε-globin gene (C), and β-globin gene (D) compared to control cells that did not receive gRNA treatment. [Figure 55-3] As assayed by quantitative RT-PCR 3 days after transfection, K562 expressing dCas9-KRAB achieved up to 80% suppression of the γ-globin gene (B), ε-globin gene (C), and β-globin gene (D) compared to control cells that did not receive gRNA treatment. [Figure 55-4] As assayed by quantitative RT-PCR 3 days after transfection, K562 expressing dCas9-KRAB achieved up to 80% suppression of the γ-globin gene (B), ε-globin gene (C), and β-globin gene (D) compared to control cells that did not receive gRNA treatment. [Figure 55-5] D. Protein expression in cells expressing dCas9 or dCas9-KRAB and treated with Cr4 or Cr8 shows a modest suppression of γ-globin expression at day 3 compared to β-actin controls. [Figure 56A] Figure 1 shows gene expression at the globin locus by delivering various doses of gRNA plasmid to cells treated with: A. Lentivirus-free. Increasing doses of Cr4 gRNA plasmid delivered enhanced suppression in dCas9-KRAB-treated cells, suggesting that both the dCas9-KRAB effector and the targeted gRNA play a role in achieving suppression. [Figure 56B] Figure 1 shows gene expression at the globin locus by delivering different doses of gRNA plasmid to cells treated with B. dCas9 lentivirus. Increasing doses of Cr4 gRNA plasmid delivered enhanced suppression in dCas9-KRAB treated cells, suggesting that both the dCas9-KRAB effector and the targeted gRNA play a role in achieving suppression. [Figure 56C] C. Gene expression at the globin locus by delivering different doses of gRNA plasmid to cells treated with dCas9-KRAB lentivirus. Increasing doses of Cr4 gRNA plasmid delivered enhanced repression in dCas9-KRAB treated cells, suggesting that both the dCas9-KRAB effector and the targeted gRNA play a role in achieving repression. [Figure 57-1] Stable delivery of a single gRNA along with dCas9-KRAB to silence expression of globin genes. A. dCas9 and dCas9-KRAB repressors were co-expressed in a lentiviral vector along with a single gRNA. K562 expressing dCas9-KRAB achieved up to 95% suppression of γ-globin (B), ε-globin (C), and β-globin (D) compared to control cells that did not receive lentiviral treatment, as assayed by quantitative RT-PCR 7 days after transduction. [Figure 57-2] Stable delivery of a single gRNA along with dCas9-KRAB to silence expression of globin genes. A. dCas9 and dCas9-KRAB repressors were co-expressed in a lentiviral vector along with a single gRNA. K562 expressing dCas9-KRAB achieved up to 95% suppression of γ-globin (B), ε-globin (C), and β-globin (D) compared to control cells that did not receive lentiviral treatment, as assayed by quantitative RT-PCR 7 days after transduction. [Figure 58] Isolation of the p300HAT "core" for histone-targeted epigenetic modification exclusively via dCas9 fusions. [Figure 59] Simplified schematics of S. pyogenes dCas9-VP64 fusion (top) and dCas9-p300 core fusion (bottom) are shown. The protospacer adjacent motif (PAM) is indicated by an arrow at the locus of the target gene, and the synthetic guide RNA (gRNA) is indicated by a hatched arrow. [Figure 60A] 60A-60C show representative data at three human loci demonstrating the efficacy of activation using dCas9-p300 in human 293T cell culture lines compared to dCas9-VP64 and dCas9 without any fused effector domain. [Figure 60B] 60A-60C show representative data at three human loci demonstrating the efficacy of activation using dCas9-p300 in human 293T cell culture lines compared to dCas9-VP64 and dCas9 without any fused effector domain. [Figure 60C] 60A-60C show representative data at three human loci demonstrating the efficacy of activation using dCas9-p300 in human 293T cell culture lines compared to dCas9-VP64 and dCas9 without any fused effector domain. [Figure 61A] 61A-61C show the amino acid sequences of the Cas9 constructs. All descriptions of Figures 61A-61C are shown in Figure 61A. [Figure 61B] 61A-61C show the amino acid sequences of the Cas9 constructs. All descriptions of Figures 61A-61C are shown in Figure 61A. [Figure 61C] 61A-61C show the amino acid sequences of the Cas9 constructs. All descriptions of Figures 61A-61C are shown in Figure 61A. [Figure 62] 1 shows that the HAT-dCas9-p300 fusion protein cannot activate gene expression. [Figure 63] The gRNAs are also shown to act synergistically with the dCas9-p300 core. [Figure 64]dCas9-p300 and dCas9-VP64 (different molecules) have no additive effect on transactivation. [Figure 65] dCas9-p300 non-synergistically activates the MyoD distal regulatory region. [Figure 66] TALEN-mediated integration of mini-dystrophin into the 5'UTR of the DP427m skeletal muscle isoform of dystrophin in skeletal myoblast cell lines derived from human DMD patients carrying various deletions in the dystrophin gene. DMD patient cells were electroporated with constructs encoding active TALEN pairs in the 5'UTR and donor templates carrying the mini-dystrophin gene. (a) Schematic diagram showing how mini-dystrophin is integrated into the 5'UTR. (b) Hygromycin-resistant clonal cell lines were isolated and screened by PCR for successful site-specific integration into the 5'UTR using the primers shown in (a). The asterisk indicates the clones selected for further analysis in (c). (c) Clonally isolated DMD myoblasts in which integration events were detected were differentiated for 6 days and the expression of the HA tag fused to the C-terminus of mini-dystrophin was determined. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] Detailed Description As described herein, certain methods and engineered CRISPR / CRISPR-associated (Cas) 9-based system compositions have been found to be useful for modifying gene expression, genome engineering, and correcting or mitigating the effects of genetic mutations involved in genetic disease. The CRISPR / Cas9-based system comprises a Cas9 protein and at least one guide RNA, which provides the DNA targeting specificity of the system. In particular, the present disclosure describes Cas9 fusion proteins that combine the DNA sequence targeting function of the CRISPR / Cas9-based system with additional activities, thus allowing the modification of gene expression and / or epigenetic context. This system can also be used for genome engineering and correcting or mitigating the effects of genetic mutations.

[0019] The present disclosure also provides certain compositions and methods for delivering a CRISPR / CRISPR-associated (Cas) 9-based system and a variety of gRNAs targeting one or more endogenous genes. Co-transfection of a variety of sgRNAs targeting one single promoter allows for synergistic activation, however co-transfection of a variety of plasmids results in variable expression levels in each cell due to differences in copy number. Furthermore, gene activation following transfection is transient due to dilution of plasmid DNA over time. Furthermore, many cell types are not easily transfected, and transient gene expression may not be sufficient to induce a therapeutic effect. To address these limitations, a single lentiviral system has been developed that expresses Cas9 and up to four sgRNAs from separate promoters. A platform is disclosed that expresses Cas9 or dCas9 fusion proteins and up to four gRNAs from a single lentiviral vector. This lentiviral vector expresses constitutive or inducible Cas9 or dCas9-VP64 in addition to one, two, three or four gRNAs expressed from separate promoters. This system allows control of both the magnitude and timing of CRISPR / Cas9-based gene regulation. Furthermore, the lentiviral platform provides strong and sustained gene expression levels that facilitate therapeutic use of the CRISPR / Cas9 system in primary cells. Finally, this system can be used to simultaneously edit a wide variety of genes (e.g., for simultaneous knockout of several oncogenes).

[0020] The present disclosure also provides certain compositions and methods for delivering site-specific nucleases to skeletal and cardiac muscle using modified adeno-associated virus (AAV) vectors. Site-specific nucleases, which can be engineered, are useful for altering gene expression, genome engineering, correcting or mitigating the effects of mutations in genes involved in genetic diseases, or manipulating genes involved in skeletal or cardiac muscle or other conditions that affect muscle regeneration. Engineered site-specific nucleases can include zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs), and / or CRISPR / Cas9 systems for genome editing. As described herein, genes in skeletal muscle tissue have been successfully edited in vivo using this unique delivery system. The present disclosure provides a means to rewrite the human genome for therapeutic applications, and a target model species for basic science applications. Gene editing is highly dependent on the cell cycle and complex DNA repair pathways, which vary from tissue to tissue. Skeletal muscle is a highly complex environment, consisting of large muscle fibers with over 100 nuclei per cell. Gene therapy and biologics in general have been limited for decades by hurdles in in vivo delivery. These challenges include in vivo carrier stability, targeting to the desired tissue, obtaining gene products with sufficient gene expression and activity, and avoiding toxicity that may overwhelm activity, which is common with gene editing tools. Other delivery vehicles (e.g., direct injection of plasmid DNA) work for gene expression in skeletal and cardiac muscles in other contexts, but do not work well enough with these site-specific nucleases to achieve detectable levels of gene editing.

[0021] Although many genes are unstable and therefore undeliverable in AAV vectors, these site-specific nucleases are surprisingly stable in AAV vectors. When these site-specific nucleases are delivered and expressed, they remain active in skeletal muscle tissue. The protein stability and activity of site-specific nucleases are highly tissue-type and cell-type dependent. These highly active and stable nucleases can modify gene sequences in the complex environment of skeletal muscle. The present invention provides a method for delivering an active form of this class of therapeutic agent to skeletal or cardiac muscle. The method is effective, efficient, and promotes successful genome modification. The present disclosure also provides a type of epigenetic effector molecule fusion, dCas9-p300 fusion protein. This protein provides a powerful and potentially more widely applicable tool for synthetic transcriptional regulation compared to dCas9-VP64 fusion. Target genes were activated substantially more strongly than dCas9-VP64 fusion protein at all loci tested. In addition, p300 has unique endogenous activity at enhancers in the human genome. dCas9-p300 fusion protein may be able to activate endogenous target gene promoter and enhancer regions. dCas9-p300 fusion proteins can be used in human tissue culture cell lines to activate gene expression. These fusion proteins can be used to precisely and predictably direct the epigenetic landscape of target loci in human cells, leading to controlled differentiation, cellular regulation, and potentially innovative therapeutic applications. Previous techniques have been limited in the strength of activation and the scope and persistence of epigenetic regulation, obstacles that can be eliminated through the use of this novel fusion protein. The headings used in this section and the entire disclosure in this section are for organizational purposes only and are not intended to be limiting.

[0022] 1.Definition Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, this document (including definitions) will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and are not intended to be limiting. As used herein, the terms "comprise," "include," "having," "has," "can," "contain," and variations thereof are open-ended transitional phrases, terms, or words that do not exclude the possibility of additional acts or structures. The singular forms "a," "and," and "the" include plural counterparts unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments that "comprising," "consisting of," and "consisting essentially of" the embodiments or components presented herein, whether or not expressly stated. For the recitation of numerical ranges herein, each intervening number is specifically contemplated with the same precision, for example, for the range 6-9, the numbers 7 and 8 are specifically contemplated in addition to 6 and 9, and for the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are specifically contemplated.

[0023] "Adeno-associated virus" or "AAV" are used interchangeably herein and are small viruses belonging to the Dependovirus genus of the Parvoviridae family that infect humans and some other primate species. AAV has not previously been known to cause disease and, as a result, the virus produces a very mild immune response. As used herein, "binding region" refers to the area within a nuclease target region that a nuclease recognizes and binds to. As used interchangeably herein, "cardiac muscle" and "heart muscle" refer to myocardium, a type of involuntary striated muscle found in the wall and histological foundation of the heart. Cardiac muscle is made up of cardiomyocytes (myocardiocytes). Cardiac muscle cells exhibit striations similar to those of skeletal muscle cells, but contain only one unique nucleus, unlike skeletal muscle cells, which have multiple nuclei. As used herein, "cardiac muscle condition" refers to a condition associated with the myocardium, such as cardiomyopathies, heart failure, arrhythmias, and inflammatory heart disease. As used herein, "coding sequence" or "encoding nucleic acid" refers to a nucleic acid (RNA or DNA molecule) that comprises a nucleotide sequence that codes for a protein. The coding sequence may further comprise start and stop signals that are operably linked to regulatory elements (promoter and polyadenylation signals) capable of directing expression in the cells of an individual or mammal to which the nucleic acid is administered. The coding sequence may be codon optimized. As used herein, "complementary" or "complementarity" refers to nucleic acids that are capable of forming Watson-Crick (e.g., AT / U and CG) or Hoogsteen type base pairing between nucleotides or nucleotide analogs of a nucleic acid molecule. "Complementarity" refers to the property shared between two nucleic acid sequences such that when the two sequences are aligned antiparallel to each other, the nucleotide bases at every position are complementary.

[0024] As used herein, "correction", "genome editing" and "repair" refer to altering a mutated gene that encodes a truncated protein or no protein at all to obtain full-length functional or partially full-length functional protein expression. Correction or repair of a mutated gene can include replacing a region of the gene that has a mutation, or replacing the entire mutated gene with an unmutated copy of the gene using a repair mechanism (e.g., homology-directed repair (HDR)). Correction or repair of a mutated gene can also include repairing a frameshift mutation that results in a premature stop codon, an aberrant splice acceptor site, or an aberrant splice donor site by generating a double-strand break in the gene and subsequently repairing it using non-homologous end joining (NHEJ). NHEJ can add or delete at least one base pair during the repair, which can restore the proper reading frame and remove the premature stop codon. Correction or repair of a mutated gene can also include disruption of the aberrant splice acceptor site or splice donor site. Correction or restoration of a mutated gene can also include deletion of a non-essential gene segment by acting simultaneously with two nucleases on the same DNA strand to remove the DNA between the two nuclease target sites and repair the DNA break via NHEJ, restoring the proper reading frame. "Donor DNA," "donor template," and "repair template," as used interchangeably herein, refer to a double-stranded DNA fragment or molecule that contains at least a portion of a gene of interest. The donor DNA can encode a complete functional protein or a partially functional protein.

[0025] "Duchenne muscular dystrophy" or "DMD", used interchangeably herein, refers to a recessive, lethal, X-linked disorder that leads to muscle degeneration and ultimately death. DMD is a well-known inherited monogenic disease that occurs in 1 in 3500 males. DMD is the result of inherited or accidental mutations that result in nonsense or frameshift mutations in the dystrophin gene. The majority of dystrophin mutations that cause DMD are exon deletions, which disrupt the reading frame of the dystrophin gene and cause premature translation termination. DMD patients typically lose the ability to physically support themselves during childhood, and frailty progresses during the teenage years, leading to death in their twenties. "Dystrophin" as used herein refers to a rod-shaped cytoplasmic protein that is part of a protein complex that spans the cell membrane and links the cytoskeleton of muscle fibers to the surrounding extracellular matrix. Dystrophin provides structural stability to the dystroglycan complex in the cell membrane, which is important for regulating muscle cell integrity and function. The dystrophin gene or "DMD gene," used interchangeably herein, occupies 2.2 megabases at Xp21. The primary transcript is approximately 2,400 kb, and the mature mRNA is approximately 14 kb. 79 exons encode a protein of over 3500 amino acids.

[0026] As used herein, "exon 51" refers to the 51st exon of the dystrophin gene. Exon 51 is frequently adjacent to frame-breaking deletions in DMD patients and has been the target of oligonucleotide-mediated exon skipping clinical trials. Clinical trials of the exon 51 skipping compound eteplirsen recently reported significant functional benefit over 48 weeks, with an average of 47% dystrophin-positive fibers compared to baseline. Exon 51 mutations are ideally amenable to permanent correction by NHEJ-based genome editing. A "frameshift" or "frameshift mutation," as used interchangeably herein, is a type of genetic mutation in which the addition or deletion of one or more nucleotides results in a shift in the reading frame of a codon in an mRNA. A shift in the reading frame can result in an alteration of the amino acid sequence during protein translation, such as a missense mutation or a premature stop codon. As used herein, "functional" and "fully functional" refer to a protein that has biological activity. A "functional gene" refers to a gene that is transcribed into mRNA, which is translated into a functional protein.

[0027] As used herein, a "fusion protein" refers to a chimeric protein created through the joining of two or more genes encoding originally separate proteins. Translation of the fusion gene results in a single polypeptide possessing functional properties derived from each of the original proteins. As used herein, a "genetic construct" refers to a DNA or RNA molecule that contains a nucleotide sequence that codes for a protein. The coding sequence includes start and stop signals operably linked to regulatory elements, including promoters and polyadenylation signals, that are capable of directing expression in the cells of an individual to which the nucleic acid molecule is administered. As used herein, an "expressible form" refers to a genetic construct that contains the necessary regulatory elements operably linked to a coding sequence such that the coding sequence is expressed when present in the cells of an individual. As used herein, a "genetic disease" refers to a disease caused, in part or in whole, directly or indirectly, by one or more abnormalities in the genome, particularly a condition present since birth. The abnormality can affect the coding sequence of a gene or its regulatory sequence. The genetic disease can be, but is not limited to, DMD, hemophilia, cystic fibrosis, Huntington's disease, familial hypercholesterolemia (LDL receptor deficiency), hepatoblastoma, Wilson's disease, congenital hepatic porphyria, inherited disorders of liver metabolism, Lesch-Nyhan syndrome, sickle cell anemia, thalassemia, xeroderma pigmentosum, Fanconi anemia, retinitis pigmentosa, ataxia telangiectasia, Bloom's syndrome, retinoblastoma, and Tay-Sachs disease.

[0028] "Homology-directed repair" or "HDR", used interchangeably herein, refers to an intracellular mechanism that repairs double-stranded DNA damage when homologous DNA pieces are present in the nucleus (mostly in the G2 and S phases of the cell cycle). HDR uses a donor DNA template to guide the repair, and HDR can be used to create specific sequence changes in the genome, including targeted addition of whole genes. If a donor template is provided with a site-specific nuclease (e.g., a CRISPR / Cas9-based system), the cellular machinery will repair the break by homologous recombination, which is enhanced by several orders of magnitude in the presence of DNA breaks. When no homologous DNA pieces are present, non-homologous end joining can occur instead. "Genome editing," as used interchangeably herein, refers to the alteration of a gene. Genome editing can include the correction or restoration of a mutated gene. Genome editing can include the knockout of a gene (e.g., a mutated gene or a normal gene). Genome editing can be used to treat a disease or enhance muscle repair by altering the gene in question. "Identical" or "identity" as used herein with respect to two or more nucleic acid or polypeptide sequences indicates that the sequences have a specified percentage of the same residues over a specified region. The percentage can be calculated by optimally aligning the two sequences, comparing the two sequences over a specified region, determining the number of positions where identical residues occur in both sequences to obtain the number of matching positions, dividing the number of matching positions by the total number of positions in the specified region, and multiplying the result by 100 to obtain the percentage of sequence identity. If the two sequences are of different length or the alignment results in one or more offset ends such that the specified comparison region contains only a single sequence, the residues of the single sequence are included in the denominator but not in the numerator of the calculation. When comparing DNA and RNA, thymine (T) and uracil (U) can be considered equivalent. Identity can be performed manually or using computer sequence algorithms (e.g., BLAST or BLAST 2.0).

[0029] As used interchangeably herein, "mutated gene" or "mutated gene" refers to a gene that has undergone a detectable mutation. A mutant gene has undergone an alteration, such as a loss, gain, or exchange of genetic material, which alteration affects the normal transmission and expression of the gene. As used herein, a "disrupted gene" refers to a mutant gene that has a mutation that results in a premature stop codon. The disrupted gene product is truncated compared to the full-length, non-disrupted gene product. As used herein, the term "non-homologous end joining (NHEJ) pathway" refers to a pathway that repairs double-stranded breaks in DNA by direct joining of the broken ends without the need for a homologous template. Non-template-dependent rejoining of DNA ends by NHEJ is a stochastic, error-prone repair process that introduces random microinsertions and microdeletions (indels) at the DNA breakpoint. This method can be used to intentionally disrupt, delete, or change the reading frame of a targeted gene sequence. NHEJ typically utilizes short homologous DNA sequences, called microhomologies, to guide repair. These microhomologies are often present in single-stranded overhangs at the ends of a double-stranded break. When the overhangs are preferably compatible, NHEJ usually repairs the break accurately, but imprecise repairs resulting in loss of nucleotides can also occur (although the imprecise repairs are much more common when the overhangs are not compatible).

[0030] As used herein, a "normal gene" refers to a gene that has not undergone alteration (e.g., the loss, gain, or exchange of genetic material). A normal gene undergoes normal gene transmission and gene expression. As used herein, "nuclease-mediated NHEJ" refers to NHEJ that is initiated after a nuclease (e.g., Cas9) breaks double-stranded DNA. As used herein, "nucleic acid" or "oligonucleotide" or "polynucleotide" refers to at least two nucleotides covalently linked together. A description of a single strand also defines the sequence of the complementary strand. Thus, a nucleic acid also encompasses the complementary strand of a described single strand. Many nucleic acid variants can be used for the same purpose as a given nucleic acid. Thus, a nucleic acid also encompasses substantially identical nucleic acids and their complements. A single strand provides a probe capable of hybridizing to a target sequence under stringent hybridization conditions. Thus, a nucleic acid also encompasses a probe that hybridizes under stringent hybridization conditions. Nucleic acids may be single-stranded or double-stranded, and may contain portions of both double-stranded and single-stranded sequences. Nucleic acids may be DNA (both genomic and cDNA), RNA, or hybrids, which may contain combinations of deoxyribonucleotides and ribonucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine, and isoguanine. Nucleic acids may be obtained by chemical synthesis methods or by recombinant methods.

[0031] As used herein, "operably linked" means that expression of a gene is under the control of a promoter with which the gene is spatially linked. The promoter can be located 5' (upstream) or 3' (downstream) of the gene under its control. The distance between the promoter and the gene is approximately the same as the distance between the promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variations in this distance can be tolerated without compromising the function of the promoter. As used herein, "partially functional" refers to a protein encoded by a mutated gene that has less biological activity than a functional protein, but more biological activity than a non-functional protein. A "premature stop codon" or "out-of-frame stop codon," as used interchangeably herein, refers to a nonsense mutation in a DNA sequence that results in a stop codon at a position not normally found in the wild-type gene. A premature stop codon results in a truncated or shorter protein compared to the full-length version of the protein.

[0032] As used herein, a "promoter" refers to a synthetic or naturally derived molecule that can confer, activate or enhance expression of a nucleic acid in a cell. A promoter can contain one or more specific transcriptional regulatory sequences to further enhance expression and / or alter its spatial and / or temporal expression. A promoter can also contain distal enhancer or repressor elements, which can be located several thousand base pairs from the transcription start site. Promoters can be derived from sources including viruses, bacteria, fungi, plants, insects and animals. A promoter can regulate expression of genetic components constitutively, differentially with respect to the cell, tissue or organ in which expression occurs, or with respect to the developmental period in which expression occurs, or in response to an external stimulus (e.g., physiological stress, pathogens, metal ions or inducing agents). Representative examples of promoters include the bacteriophage T7 promoter, the bacteriophage T3 promoter, the SP6 promoter, the lac operon promoter, the tac promoter, the SV40 late promoter, the SV40 early promoter, the RSV-LTR promoter, the CMV IE promoter, the SV40 early promoter or the SV40 late promoter and the CMV IE promoter.

[0033] "Repeat variable diresidue" or "RVD", as used interchangeably herein, refers to a pair of adjacent amino acid residues within the DNA recognition motif (also known as an "RVD module", which comprises 33-35 amino acids) of a TALE DNA binding domain. The RVD determines the nucleotide specificity of the RVD module. RVD modules together produce an RVD string. "RVD string length", as used herein, refers to the number of RVD modules that correspond to the length of the nucleotide sequence within the TALEN target region (i.e., the binding region) recognized by the TALEN. As used herein, "site-specific nuclease" refers to an enzyme that can specifically recognize and cleave a DNA sequence. Site-specific nucleases can be engineered. Examples of engineered site-specific nucleases include zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs), and CRISPR / Cas9-based systems. As used herein, "skeletal muscle" refers to a type of striated muscle that is under the control of the somatic nervous system and is attached to bone by collagen bundles known as tendons. Skeletal muscle is made up of individual components known as myocytes or "muscle cells" (sometimes colloquially called "muscle fibers"). Muscle cells are formed by the fusion of developing myoblasts (a type of embryonic progenitor cell that gives rise to muscle cells) during a process known as myogenesis. These long, tubular, multinucleated cells are also called myofibers.

[0034] As used herein, "muscle skeletal condition" refers to conditions associated with skeletal muscles, such as muscular dystrophy, aging, muscle degeneration, wound healing, muscle weakness or atrophy. "Spacer" and "spacer region," used interchangeably herein, refer to a region within a TALEN or ZFN target region that is between, but is not part of, the binding regions for two TALENs or ZFNs. "Subject" and "patient", as used interchangeably herein, refer to any vertebrate animal, including, but not limited to, mammals, such as cows, pigs, camels, llamas, horses, goats, rabbits, sheep, hamsters, guinea pigs, cats, dogs, rats and mice, non-human primates, such as monkeys (e.g., cynomolgus or rhesus monkeys, chimpanzees, etc.), and humans. In some embodiments, the subject can be human or non-human. The subject or patient can receive other forms of treatment. As used herein, "target gene" refers to any nucleotide sequence that encodes a known or hypothesized gene product. A target gene may be a mutated gene involved in a genetic disease. As used herein, "target region" refers to the region of a target gene to which a site-specific nuclease is designed to bind and cleave.

[0035] As used herein, "Transcription Activator-Like Effector" or "TALE" refers to a protein structure that recognizes and binds to a specific DNA sequence. A "TALE DNA binding domain" refers to a DNA binding domain that contains an array of tandem 33-35 amino acid repeats (also known as RVD modules, each of which recognizes a single base pair in DNA). RVDs can be arranged in any order to assemble an array that recognizes a specified sequence. The binding specificity of a TALE DNA-binding domain is determined by an RVD string followed by a single truncated repeat of 20 amino acids. A TALE DNA-binding domain can have 12 to 27 RVD modules, each of which contains an RVD and recognizes a single base pair of DNA. Specific RVDs that recognize each of the four possible DNA nucleotides (A, T, C, and G) have been identified. Because TALE DNA-binding domains are modular, repeats that recognize the four different DNA nucleotides can be linked together to recognize any individual DNA sequence. These targeted DNA-binding domains can then be combined with catalytic domains to generate functional enzymes, including artificial transcription factors, methyltransferases, integrases, nucleases, and recombinases.

[0036] "Transcription activator-like effector nuclease" or "TALEN", as used interchangeably herein, refers to an engineered fusion protein of a catalytic domain of a nuclease (e.g., the endonuclease FokI) and a TALE DNA binding domain designed to target a custom DNA sequence. "TALEN monomer" refers to an engineered fusion protein with a catalytic nuclease domain and an engineered TALE DNA binding domain. Two TALEN monomers can be designed to target and cleave one TALEN target region. As used herein, "transgene" refers to a gene or genetic material comprising a genetic sequence that is isolated from one organism and introduced into a different organism. This non-native DNA segment may retain the ability to produce RNA or protein in the transgenic organism, or may alter the normal function of the genetic code of the transgenic organism. Introduction of a transgene has the potential to alter the phenotype of an organism. "Variant," as used herein with respect to nucleic acids, means: (i) a portion or fragment of a referenced nucleotide sequence; (ii) the complement of a referenced nucleotide sequence or a portion thereof; (iii) a nucleic acid that is substantially identical to a referenced nucleic acid or its complement; or (iv) a nucleic acid that hybridizes under stringent conditions to a referenced nucleic acid, its complement, or a sequence substantially identical thereto.

[0037] A "variant" with respect to a peptide or polypeptide differs in amino acid sequence by insertion, deletion, or conservative substitution of amino acids, but retains at least one biological activity. Variant also refers to a protein having substantially the same amino acid sequence as a reference protein having an amino acid sequence that retains at least one biological activity. Conservative substitutions of amino acids (i.e., replacement of an amino acid with an amino acid of similar properties (e.g., hydrophobicity, degree and distribution of charged regions)) are recognized in the art to typically include minor changes. These minor changes can be identified by considering the hydropathic index of an amino acid, as understood in the art (Kyte et al., J. Mol. Biol. 157:105-132, 1982). The hydropathic index of an amino acid takes into account its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes can be substituted and still retain protein function. In one aspect, amino acids with hydropathic indexes of ±2 are substituted. The hydrophilicity of an amino acid can also be used to indicate substitutions that result in a protein that retains biological function. Consideration of the hydrophilicity of amino acids in the context of a peptide allows for the calculation of the maximum local average hydrophilicity of that peptide. Substitutions can be made with amino acids having hydrophilicities within ±2 of each other. Both the hydrophobicity index and hydrophilicity value of an amino acid are influenced by the individual side chain of that amino acid. Consistent with such observations, it is understood that amino acid substitutions that are compatible with biological function depend on the relative similarity of amino acids, as indicated by hydrophobicity, hydrophilicity, charge, size and other properties, and in particular the side chains of those amino acids.

[0038] As used herein, a "vector" refers to a nucleic acid sequence that includes an origin of replication. The vector can be a viral vector, a bacteriophage, a bacterial artificial chromosome, or a yeast artificial chromosome. The vector can be a DNA vector or an RNA vector. The vector can be a self-replicating extrachromosomal vector, preferably a DNA plasmid. For example, the vector can encode an iCas9-VP64 fusion protein comprising the amino acid sequence of SEQ ID NO:1, or at least one gRNA nucleotide sequence of any one of SEQ ID NOs:5-40, 65-144, 492-515, 540-563, and 585-625. Alternatively, the vector can encode Cas9 and at least one gRNA nucleotide sequence of any one of SEQ ID NOs:5-40, 65-144, 492-515, 540-563, and 585-625.

[0039] As used herein, "zinc finger" refers to a protein structure that recognizes and binds to DNA sequences. Zinc finger domains are the most common DNA-binding motif in the human proteome. A zinc finger contains about 30 amino acids, and typically the domain functions by binding to three consecutive base pairs of DNA through interactions of only one amino acid side chain per base pair. "Zinc finger nuclease" or "ZFN," as used interchangeably herein, refers to a chimeric protein molecule that contains at least one zinc finger DNA binding domain operatively linked to at least one nuclease or portion of a nuclease that, when fully assembled, is capable of cleaving DNA. Unless otherwise specified herein, scientific and technical terms used in connection with this disclosure have the meanings that are commonly understood by those of ordinary skill in the art. For example, the terminology and techniques used in connection with cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are well known and commonly used in the art. The meaning and scope of the terms should be clear, however, in the event of any hidden ambiguity, the definitions provided herein take precedence over any dictionary or non-essential definitions. Furthermore, singular terms include the plural and plural terms include the singular, unless the context otherwise requires.

[0040] 2. Compositions for genome editing The present invention is directed to a composition for genome editing, genome modification or alteration of gene expression of a target gene. The composition can include a viral vector and a fusion protein (e.g., a site-specific nuclease or a CRISPR / Cas9 system) with at least one gRNA. a. Compositions for genome editing in muscle The present invention is directed to compositions for genome editing of target genes in skeletal or cardiac muscle of a subject animal. The compositions include a modified AAV vector and a nucleotide sequence encoding a site-specific nuclease. The compositions deliver an active form of the site-specific nuclease to the skeletal or cardiac muscle. The compositions can further include donor DNA or a transgene. These compositions can be used in genome editing, genome engineering, and correcting or mitigating the effects of mutations in genes involved in genetic diseases and / or conditions in skeletal or cardiac muscle. The target gene may be involved in cell differentiation or any other process in which gene activation, repression or destruction may be desired, or the target gene may have a mutation (e.g., a deletion, an inermshift mutation, or a nonsense mutation). If the target gene has a mutation that results in a premature stop codon, an aberrant splice acceptor site, or an aberrant splice donor site, a position-specific nuclease can be designed to recognize and bind to the nucleotide sequence upstream or downstream of the premature stop codon, the aberrant splice acceptor site, or the aberrant splice donor site. Position-specific nucleases can also be used to disrupt normal gene splicing by targeting splice acceptors and donors to introduce skipping of premature stop codons, or to restore a disrupted reading frame. Position-specific nucleases may or may not mediate off-target changes to protein-coding regions of the genome.

[0041] 3.CRISPR System "Clustered regularly interspaced short palindromic repeats" and "CRISPR", used interchangeably herein, refer to a locus that contains a diverse set of short direct repeats found in approximately 40% of sequenced bacterial and 90% of sequenced archaeal genomes. The CRISPR system is a microbial nuclease system required for defense against invading phages and plasmids that provides a form of acquired immunity. CRISPR loci in microbial hosts contain a combination of CRISPR-associated (Cas) genes as well as non-coding RNA elements that can program the specificity of CRISPR-mediated nucleic acid cleavage. Short segments of foreign genes (called spacers) are incorporated into the genome between the CRISPR repeats and serve as a 'memory' of past exposure. Cas9 forms a complex with the 3' end of the sgRNA, and this protein-RNA pair recognizes its genomic target by complementary base pairing between the 5' end of the sgRNA sequence and a predefined 20 bp DNA sequence (known as the protospacer). This complex is directed to the homologous locus of pathogen DNA via a region encoded in the crRNA (i.e., the protospacer) and a protospacer adjacent motif (PAM) in the pathogen genome. The non-coding CRISPR string is transcribed and cleaved into short crRNAs containing individual spacer sequences within the direct repeats, which direct the Cas nuclease to the target site (protospacer). By simply exchanging the 20 bp recognition sequence of the expressed sgRNA, the Cas9 nuclease can be directed to new genomic targets. CRISPR spacers can be used to recognize and silence exogenous genetic elements in a manner similar to RNAi in eukaryotes.

[0042] Three types of CRISPR systems are known: type I, II and III effector systems. Type II effector systems perform target-induced DNA double-strand breaks in four sequential steps using a single effector enzyme, Cas9, for dsDNA cleavage. Compared to type I and type III effector systems, which require a wide variety of separate effectors operating as a complex, type II effector systems can also function in different environments, such as eukaryotic cells. Type II effector systems consist of a long pre-crRNA (transcribed from a spacer-containing CRISPR locus), Cas9 protein and tracrRNA (required for pre-crRNA processing). The tracrRNA hybridizes to the repeat region that separates the spacer of the pre-crRNA, thus initiating dsRNA cleavage by endogenous RNase III. This cleavage is followed by a second cleavage event within each spacer by Cas9, generating the tracrRNA and mature crRNA that remains associated with Cas9, forming a Cas9:crRNA-tracrRNA complex.

[0043] The Cas9:crRNA-tracrRNA complex unwinds the DNA duplex to search for and cleave sequences that match the crRNA. Target recognition occurs upon detection of complementarity between a "protospacer" sequence in the target DNA and a residual spacer sequence in the crRNA. Cas9 mediates cleavage of the target DNA if the correct protospacer adjacent motif (PAM) is also present at the 3' end of the protospacer. To target a protospacer, the sequence must be immediately followed by a protospacer adjacent motif (PAM), a short sequence recognized by the Cas9 nuclease required for DNA cleavage. Different type II systems require different PAMs. The Streptococcus pyogenes CRISPR system may have the PAM sequence for this Cas9 (SpCas9) as 5'-NRG-3', where R is A or G, characterizing the specificity of this system in human cells. A unique capability of the CRISPR / Cas9 system is its straightforward ability to simultaneously target a wide variety of distinct genomic loci by co-expressing a single Cas9 protein with two or more sgRNAs. For example, the Streptococcus pyogenes type II system naturally prefers the use of the “NGG” sequence (where “N” can be any nucleotide), but engineered systems also tolerate other PAM sequences (e.g., “NAG”) (Hsu et al., Nature Biotechnology (2013) doi:10.1038 / nbt.2647). Similarly, Cas9 from Neisseria meningitidis (NmCas9) normally has a natural PAM of NNNNGATT, but is active against a variety of RAMs, including the highly degenerate NNNNGNNN PAM (Esvelt et al. Nature Methods (2013) doi:10.1038 / nmeth.2681).

[0044] 4. CRISPR / Cas9-based systems An engineered version of the S. pyogenes type II effector system has been shown to function in genome editing in human cells. In this system, the Cas9 protein is guided to a target site in the genome by a synthetically reconstituted "guide RNA" ("gRNA", also used interchangeably herein as chimeric single guide RNA ("sgRNA")), which is typically a crRNA-tracrRNA fusion that eliminates the need for RNaseIII and crRNA processing (see FIG. 53A). Provided herein is a CRISPR / Cas-based engineering system for use in genome editing and genetic disease therapy. The CRISPR / Cas9-based engineering system can be designed to target any gene, including genes required for genetic disease, aging, tissue regeneration, or wound healing. The CRISPR / Cas9-based system can include a Cas9 protein or a Cas9 fusion protein and at least one gRNA. The Cas9 fusion protein can include a domain with a different activity (an activity that is endogenous to Cas9), such as a transactivation domain. The target gene may be required for cell differentiation or any other process in which gene activation may be desired, or may have a mutation (e.g., a frameshift mutation or a nonsense mutation). If the target gene has a mutation that results in a premature stop codon, an aberrant splice activator site, or an aberrant splice donor site, the CRISPR / Cas9-based system can be designed to recognize and bind to the nucleotide sequence upstream or downstream of the premature stop codon, the aberrant splice activator site, or the aberrant splice donor site. The CRISPR / Cas9-based system can also be used to target splice acceptors and donors to introduce skipping of the premature stop codon to disrupt normal gene splicing or restore a disrupted reading frame. The CRISPR / Cas9-based system may or may not mediate off-target changes to protein-coding regions of the genome.

[0045] A.Cas9 CRISPR / Cas9-based systems can include Cas9 proteins or Cas9 fusion proteins. Cas9 proteins are endonucleases that cleave nucleic acids, are encoded by CRISPR loci, and are required for type II CRISPR systems. Cas9 proteins can be derived from any bacterial or archaeal species (e.g., Streptococcus pyogenes). Cas9 proteins can be mutated to inactivate nuclease activity. Inactivated Cas9 protein from Streptococcus pyogenes (iCas9, also called "dCas9"), which lacks endonuclease activity, has recently been targeted to genes in bacteria, yeast, and human cells by gRNA, silencing gene expression through steric hindrance. As used herein, "iCas9" and "dCas9" both refer to Cas9 proteins with amino acid substitutions D10A and H840A, which inactivate its nuclease activity. For example, CRISPR / Cas9-based systems can include Cas9 of SEQ ID NO: 459 or 461.

[0046] B. Cas9 fusion protein The CRISPR / Cas9-based system can include a fusion protein. The fusion protein can include two heterologous polypeptide domains, a first polypeptide domain includes a Cas protein, and a second polypeptide domain has an activity, such as a transcription activation activity, a transcription repression activity, a transcription deactivator activity, a histone modification activity, a nuclease activity, a nucleic acid binding activity, a methylase activity, or a demethylase activity. The fusion protein can include a Cas9 protein or a mutated Cas9 protein as described above, fused to a second polypeptide domain, such as a transcription activation activity, a transcription repression activity, a transcription deactivator activity, a histone modification activity, a nuclease activity, a nucleic acid binding activity, a methylase activity, or a demethylase activity. (1) Transcription activation activity The second polypeptide domain can have transcription activation activity, i.e. can be a transactivation domain.For example, gene expression of endogenous mammalian gene (e.g. human gene) can be achieved by inducing the fusion protein of iCas9 and transactivation domain together with gRNA to mammalian promoter target.The transactivation domain can include one VP16 protein, multiple VP16 proteins (e.g. VP48 domain or VP64 domain), or p65 domain of NFkappaB transcription activator activity.For example, the fusion protein can be iCas9-VP64. (2) Transcriptional repression activity The second polypeptide domain can have transcription repression activity. The second polypeptide domain can have Krüppel-associated box activity (e.g., KRAB domain), ERF repressor domain activity, Mxi1 repressor domain activity, SID4X repressor domain activity, Mad-SID repressor domain activity, or TATA box binding protein activity. For example, the fusion protein can be dCas9-KRAB.

[0047] (3) Transcription deactivation factor activity The second polypeptide domain can have transcription deactivation factor activity. The second polypeptide domain can have eukaryotic release factor 1 (ERF1) or eukaryotic release factor 3 (ERF3) activity. (4) Histone modification activity The second polypeptide domain can have histone modification activity. The second polypeptide domain can have histone deacetylase, histone acetyltransferase, histone demethylase or histone methyltransferase activity. The histone acetyltransferase can be p300 or CREB binding protein (CBP), or a fragment thereof. For example, the fusion protein can be dCas9-p300. (5) Nuclease activity The second polypeptide domain can have a nuclease activity different from that of the Cas9 protein. Nucleases or proteins with nuclease activity are enzymes that can cleave the phosphodiester bonds between the nucleotide subunits of nucleic acids. Usually, nucleases can be further divided into endonucleases and exonucleases, although some of the enzymes can be included in both categories. Well-known nucleases are deoxyribonucleases and ribonucleases.

[0048] (6) Nucleic acid binding activity The second polypeptide domain can have nucleic acid binding activity or a nucleic acid binding protein. A DNA binding domain (DBD) is an independently folding protein domain that contains at least one motif that recognizes double-stranded or single-stranded DNA. A DBD can recognize a specific DNA sequence (recognition sequence) or have a general affinity for DNA. The nucleic acid binding domain is selected from the group consisting of: helix-turn-helix region, leucine zipper region, winged helix region, winged helix-turn-helix region, helix-loop-helix region, immunoglobulin fold, B3 domain, zinc finger, HMG-box, Wor3 domain, TAL effector DNA binding domain. (7) Methylase activity The second polypeptide domain can have a methylase activity, which is involved in the transfer of a methyl group to DNA, RNA, proteins, small molecules, cytosine, or adenine. The second polypeptide domain can comprise a DNA methyltransferase. (8) Demethylase activity The second polypeptide domain can have demethylase activity. The second polypeptide domain can include an enzyme that removes methyl (CH3-) groups from nucleic acids, proteins (especially histones) and other molecules. Alternatively, the second polypeptide can convert methyl groups to hydroxymethylcytosine in a mechanism of DNA demethylation. The second polypeptide can catalyze this reaction. For example, the second polypeptide that can catalyze this reaction can be Tet1.

[0049] c.gRNA The gRNA provides the targeting for the CRISPR / Cas9-based system. The gRNA is a fusion of two non-coding RNAs (crRNA and tracrRNA). The sgRNA can target any desired DNA sequence by exchanging the sequence encoding the 20 bp protospacer (which confers targeting specificity by complementary base pairing with the desired DNA target). The gRNA mimics the naturally occurring crRNA:tracrRNA complex (required for type II effector systems). This duplex (which can include, for example, a 42 nucleotide crRNA and a 75 nucleotide tracrRNA) acts as a guide for Cas9 to cleave the target nucleic acid. "Target region," "target sequence," or "protospacer," as used interchangeably herein, refer to the region of the target gene targeted by the CRISPR / Cas9-based system. The CRISPR / Cas9-based system can include at least one gRNA, where the gRNAs target different DNA sequences. The target DNA sequences may overlap. The target sequence or protospacer is accompanied by a PAM sequence at the 3' end of the protospacer. Different type II systems require different PAMs. For example, the S. pyogenes type II system uses the "NGG" sequence (where "N" can be any nucleotide).

[0050] The number of gRNAs administered to a cell can be at least 1 gRNA, at least 2 different gRNAs, at least 3 different gRNAs, at least 4 different gRNAs, at least 5 different gRNAs, at least 6 different gRNAs, at least 7 different gRNAs, at least 8 different gRNAs, at least 9 different gRNAs, at least 10 different gRNAs, at least 11 different gRNAs, at least 12 different gRNAs, at least 13 different gRNAs, at least 14 different gRNAs, at least 15 different gRNAs, at least 16 different gRNAs, at least 17 different gRNAs, at least 18 different gRNAs, at least 18 different gRNAs, at least 20 different gRNAs, at least 25 different gRNAs, at least 30 different gRNAs, at least 35 different gRNAs, at least 40 different gRNAs, at least 45 different gRNAs, at least 50 different gRNAs.The number of gRNAs administered to a cell may be at least 50 different gRNAs from at least one gRNA, at least 45 different gRNAs from at least one gRNA, at least 40 different gRNAs from at least one gRNA, at least 35 different gRNAs from at least one gRNA, at least 30 different gRNAs from at least one gRNA, at least 25 different gRNAs from at least one gRNA, at least 20 different gRNAs from at least one gRNA, at least 16 different gRNAs from at least one gRNA, at least 12 different gRNAs from at least one gRNA, at least 8 different gRNAs from at least one gRNA, at least 4 different gRNAs from at least one gRNA, at least 50 different gRNAs from at least four different gRNAs, at least 45 different gRNAs from at least four different gRNAs, at least 40 different gRNAs from at least four different gRNAs, at least 35 different gRNAs from at least four different gRNAs, at least four different gRNAs. The number of different gRNAs may be at least 30 different gRNAs from at least 4 different gRNAs, at least 25 different gRNAs from at least 4 different gRNAs, at least 20 different gRNAs from at least 4 different gRNAs, at least 16 different gRNAs from at least 4 different gRNAs, at least 12 different gRNAs from at least 4 different gRNAs, at least 8 different gRNAs from at least 8 different gRNAs, at least 50 different gRNAs from at least 8 different gRNAs, at least 45 different gRNAs from at least 8 different gRNAs, at least 40 different gRNAs from at least 8 different gRNAs, at least 35 different gRNAs from at least 8 different gRNAs, at least 30 different gRNAs from at least 8 different gRNAs, at least 25 different gRNAs from at least 8 different gRNAs, at least 20 different gRNAs from 8 different gRNAs, at least 16 different gRNAs from at least 8 different gRNAs, or at least 12 different gRNAs from 8 different gRNAs.

[0051] The gRNA can comprise a complementary polynucleotide sequence of the target gene sequence followed by a PAM sequence. The gRNA can comprise a "G" at the 5' end of the complementary polynucleotide sequence. The gRNA can comprise at least 10 base pairs, at least 11 base pairs, at least 12 base pairs, at least 13 base pairs, at least 14 base pairs, at least 15 base pairs, at least 16 base pairs, at least 17 base pairs, at least 18 base pairs, at least 19 base pairs, at least 20 base pairs, at least 21 base pairs, at least 22 base pairs, at least 23 base pairs, at least 24 base pairs, at least 25 base pairs, at least 30 base pairs, at least 35 base pairs of the complementary polynucleotide sequence of the target DNA sequence followed by a PAM sequence. The PAM sequence can be "NGG", where "N" can be any nucleotide. The gRNA can target at least one of the promoter region, enhancer region, or transcribed region of the target gene. The gRNA can include at least one of the nucleic acid sequences of SEQ ID NOs:5-40, 65-144, 492-515, 540-563, 585-625, 462 (Figure 40), 464 (Figure 41), and 465 (Figure 41). gRNA can target any nucleic acid sequence. The nucleic acid sequence target can be DNA. The DNA can be any gene. For example, gRNA can target genes such as BRN2, MYT1L, ASCL1, NANOG, VEGFA, TERT, IL1B, IL1R2, IL1RN, HBG1, HBG2, MYOD1, OCT4, and DMD.

[0052] (1) Dystrophin Dystrophin is a rod-shaped cytoplasmic protein that is part of a protein complex that connects the cytoplasmic skeleton of muscle fibers to the surrounding extracellular matrix and across the cell membrane. Dystrophin provides structural stability to the dystroglycan complex in the cell membrane. The dystrophin gene occupies 2.2 megabases at the Xp21 locus. The primary transcript is approximately 2,400 kb, and the mature mRNA is approximately 14 kb. 79 exons code for a protein of more than 3500 amino acids. Normal skeletal muscle tissue contains only small amounts of dystrophin, but adystrophin in abnormal expression leads to severe and incurable symptoms. Some mutations in the dystrophin gene result in the production of defective dystrophin and a severe dystrophin phenotype in affected patients. Some mutations in the dystrophin gene result in a partially functional dystrophin protein and a much milder dystrophin phenotype in affected patients. DMD is the result of inherited or accidental mutations that result in nonsense or frameshift mutations in the dystrophin gene. Naturally occurring mutations and their consequences are relatively well understood for DMD. In-frame deletions occurring in the exon 45-55 region can generate a highly functional dystrophin protein, with many carriers being asymptomatic or showing mild symptoms. Furthermore, theoretically, over 60% of patients could be treated by targeting exons in this region of the dystrophin gene. Attempts have been made to restore the disrupted dystrophin reading frame in DMD patients by skipping non-essential exons during mRNA splicing, generating an internally defective but functional dystrophin protein. Deletions of internal dystrophin exons preserve the proper reading frame but cause a less severe form of Becker muscular dystrophy.

[0053] (2) CRISPR / Cas9-based system targeting dystrophin Disclosed herein is a CRISPR / Cas9-based system specific for the dystrophin gene. The CRISPR / Cas9-based system can include Cas9 and at least one gRNA that targets the dystrophin gene. The CRISPR / Cas9-based system can bind to and recognize the target gene. The target region can be selected immediately upstream of a possible out-of-frame stop codon, so that insertions or deletions during the repair process can restore the dystrophin reading frame by frame conversion. The target region can also be a splice acceptor site or a splice donor site, so that insertions or deletions during the repair process can disrupt splicing by disrupting the splice site and removing the exon, restoring the dystrophin reading frame. The target region can also be an abnormal stop codon, so that insertions or deletions during the repair process can restore the dystrophin reading frame by removing or destroying the stop codon. Targeting the mutation hotspot of exons 45-55, single or compound sgRNAs can be designed to restore the dystrophin reading frame by introducing either small insertions and deletions within exons or large deletions of one or more exons. After treatment with Cas9 and one or more sgRNAs, dystrophin expression can be restored in muscle cells of Duchenne patients in vitro. Human dystrophin was detected in vivo after transplantation of genetically corrected patient cells into immunodeficient mice. Importantly, this unique compound gene editing capability of the CRISPR / Cas9 system allows for efficient creation of large deletions in this mutation hotspot region that can correct up to 62% of patient mutations by generic or patient-specific gene editing approaches. CRISPR / Cas9-based systems can use gRNAs of various sequences and lengths. Examples of gRNAs can be found in Table 6. CRISPR / Cas9-based systems can target the nucleic acid sequence of SEQ ID NO: 65-144 or its complement. The gRNA can comprise a nucleotide sequence selected from the group consisting of SEQ ID NO: 65-144 or its complement. For example, the disclosed CRISPR / Cas9-based systems have been engineered to mediate highly efficient gene editing at exon 51 of the dystrophin gene. These CRISPR / Cas9-based systems restored expression of dystrophin protein in cells derived from DMD patients.

[0054] (a) Exons 51 and 45-55 Exon 51 is frequently adjacent to frame-breaking defects in DMD. Removal of exon 51 in the dystrophin transcript by exon skipping can be used to treat nearly 15% of all DMD patients. This class of DMD mutations is ideally suited for permanent correction by NHEJ-based genome editing and HDR. We developed the CRISPR / Cas9-based systems described herein for targeted modification of exon 51 in the human dystrophin gene. These CRISPR / Cas9-based systems were transfected into human DMD cells to mediate efficient gene modification and conversion to a corrected reading frame. Protein restoration was accompanied by frame recovery and was detected in a mixed population of CRISPR / Cas9-based system-treated cells. Similarly, removal of exons 45-55 in the dystrophin transcript was used to treat nearly 62% of all DMD patients. (3) AAV / CRISPR constructs AAV can be used to deliver CRISPR using a variety of construct structures (see Figure 39). For example, AAV can deliver Cas9 and gRNA expression cassettes in separate vectors. Alternatively, if the small Cas9 protein (derived from Staphylococcus aureus or Neisseria meningitidis species) is used, both Cas9 and up to two gRNA cassettes can be packaged together in a single AAV vector within the 4.7 kb packaging limit (see Figure 39).

[0055] 5. Combined CRISPR / Cas9-based systems The present disclosure is directed to a composite CRISPR / Cas9-based system, including a CRISPR / Cas9-based system (e.g., Cas9 or dCas9) and a variety of gRNAs targeting one or more endogenous genes. This platform utilizes a convenient Golden Gate cloning method to rapidly incorporate up to four independent sgRNA expression cassettes into a single lentiviral vector. Each sgRNA was efficiently expressed and could mediate composite gene editing at discrete loci in immortalized and primary human cell lines. It was shown that transient transcriptional activation in cell lines stably expressing dCas9-VP64 could be tailored by synergistic activation with one to four sgRNAs. Furthermore, a single lentiviral vector can induce sustained and long-term endogenous gene expression in immortalized and primary human cells. This system allows for the rapid assembly of a single lentiviral vector that enables efficient composite gene editing in model and primary cell lines. The composite CRISPR / Cas9-based system offers the potential for transcriptional activation and tunable induction of transcriptional activation. When easily generated by Golden Gate Assembly, the final vector expresses constitutive Cas9 or dCas9-VP64 in addition to one, two, three or four sgRNAs expressed from independent promoters. Each promoter can efficiently express an sgRNA, which induces similar levels of Cas9 nuclease activity. Furthermore, lentiviral delivery of a single vector expressing Cas9 and four sgRNAs targeting distinct loci results in simultaneous composite gene editing of all four loci. Tunable transcriptional activation of two endogenous genes in both transient and stable environments has been achieved using lentiviral delivery of Cas9 with or without sgRNA. Highly efficient and long-term gene activation is achieved in primary human cells. This system is therefore a promising and efficient method to generate composite gene editing and long-term transcriptional activation in human cells.

[0056] The composite CRISPR / Cas9-based system allows efficient multiplex gene editing to inactivate a wide variety of genes simultaneously. The CRISPR / Cas9-based system can simultaneously target a wide variety of separate genomic loci by co-expressing just one Cas9 protein with two or more sgRNAs, making this system unique for composite gene editing or synergistic activation applications. The CRISPR / Cas9-based system greatly facilitates the molecular targeting process to new sites by simply modifying the sgRNA molecules expressed. A single lentiviral vector can be combined with methods to achieve inducible control of these components (chemically or optogenetically) to facilitate elucidation of dynamic changes in both time and space of gene regulation. The composite CRISPR / Cas9-based system can transcriptionally activate two or more endogenous genes. The composite CRISPR / Cas9-based system can transcriptionally repress two or more endogenous genes. For example, at least two endogenous genes, at least three endogenous genes, at least four endogenous genes, at least five endogenous genes, or at least ten endogenous genes can be activated or repressed by the composite CRISPR / Cas9-based system. Two to fifteen genes, two to ten genes, two to five genes, five to fifteen genes, or five to ten genes can be activated or repressed by the composite CRISPR / Cas9-based system.

[0057] (1) Modified lentiviral vector The composite CRISPR / Cas9-based system can include a modified lentiviral vector. The modified lentiviral vector includes a first polynucleotide sequence encoding a fusion protein and a second polynucleotide sequence encoding at least one sgRNA. The fusion protein can be the fusion protein of the CRISPR / Cas9-based system described above. The first polynucleotide sequence can be operably linked to a promoter. The promoter can be a constitutive promoter, an inducible promoter, a repressible promoter, or a regulatable promoter. The second polynucleotide sequence encodes at least one sgRNA. For example, the second polynucleotide sequence can encode at least one sgRNA, at least two sgRNAs, at least three sgRNAs, at least four sgRNAs, at least five sgRNAs, at least six sgRNAs, at least seven sgRNAs, at least eight sgRNAs, at least nine sgRNAs, at least ten sgRNAs, at least eleven sgRNAs, at least twelve sgRNAs, at least thirteen sgRNAs, at least fourteen sgRNAs, at least fifteen sgRNAs, at least sixteen sgRNAs, at least seventeen sgRNAs, at least eighteen sgRNAs, at least nineteen sgRNAs, at least twenty sgRNAs, at least twenty-five sgRNAs, at least thirty sgRNAs, at least thirty-five sgRNAs, at least forty sgRNAs, at least forty-five sgRNAs, at least fifty sgRNAs.The second polynucleotide sequence may be 50 sgRNAs from one sgRNA, 45 sgRNAs from one sgRNA, 40 sgRNAs from one sgRNA, 35 sgRNAs from one sgRNA, 30 sgRNAs from one sgRNA, 25 different sgRNAs from one sgRNA, 20 sgRNAs from one sgRNA, 16 sgRNAs from one sgRNA, 8 different sgRNAs from one sgRNA, 50 different sgRNAs from four different sgRNAs, 45 different sgRNAs from four different sgRNAs, 40 different sgRNAs from four different sgRNAs, 35 different sgRNAs from four different sgRNAs, 30 different sgRNAs from four different sgRNAs, 25 different sgRNAs from four different sgRNAs, 20 different sgRNAs from four different sgRNAs, 16 different sgRNAs from four different sgRNAs, 4 ... A can encode 8 different sgRNAs, 50 different sgRNAs from 8 different sgRNAs, 45 different sgRNAs from 8 different sgRNAs, 40 different sgRNAs from 8 different sgRNAs, 35 different sgRNAs from 8 different sgRNAs, 30 different sgRNAs from 8 different sgRNAs, 25 different sgRNAs from 8 different sgRNAs, 20 different sgRNAs from 8 different sgRNAs, 16 different sgRNAs from 8 different sgRNAs, 50 different sgRNAs from 16 different sgRNAs, 45 different sgRNAs from 16 different sgRNAs, 40 different sgRNAs from 16 different sgRNAs, 35 different sgRNAs from 16 different sgRNAs, 30 different sgRNAs from 16 different sgRNAs, 25 different sgRNAs from 16 different sgRNAs, 20 different sgRNAs from 16 different sgRNAs. Each of the polynucleotide sequences encoding different sgRNAs can be operably linked to a promoter. The promoters operably linked to different sgRNAs can be the same promoter. The promoters operably linked to different sgRNAs can be different promoters. The promoters can be constitutive, inducible, repressible, or regulatable promoters. At least one sgRNA can bind to a target gene or locus. If more than one sgRNA is included, each sgRNA binds to a different target region in a target locus, or each sgRNA binds to a different target in a different gene locus. The fusion protein can include a Cas9 protein or an iCas9-VP64 protein. The fusion protein can include a VP64 domain, a p300 domain, or a KRAB domain.

[0058] 6. Position-specific nuclease The above-mentioned compositions include a nucleotide sequence that encodes a position-specific nuclease that binds to and cleaves a target region. The position-specific nuclease can be engineered. For example, the engineered position-specific nuclease can be a CRISPR / Cas9-based system, ZFN, or TALEN. The position-specific nuclease can bind to and cleave a gene or locus in the genome of skeletal or cardiac muscle cells. For example, the gene or locus can be the Rosa26 locus or the dystrophin gene. a. CRISPR / Cas9-based systems The CRISPR / Cas9-based system described above can be used to introduce site-specific double-stranded breaks into targeted genomic loci. B. Zinc finger nuclease (ZFN) The site-specific nuclease can be a ZFN. A single zinc finger contains about 30 amino acids, and the domain functions by binding to three consecutive base pairs of DNA through the interaction of one amino acid side chain per base pair. The modular structure of the zinc finger motif allows the sequential binding of several domains, allowing the recognition and targeting of stretches of multiples of three nucleotides. These targeting DNA binding domains can be combined with nuclease domains (e.g., FokI) to generate site-specific nucleases. These are called "zinc finger nucleases" (ZFNs) and can be used to introduce site-specific double-strand breaks at targeted genomic loci. This DNA break stimulates natural DNA repair mechanisms, resulting in one of two possible repair pathways (NHEJ and HDR). For example, ZFNs can target the Rosa26 locus (Perez-Pinera et al. Nucleic Acids Research (2012) 40:3741-3752) or the dystrophin gene. Examples of ZFNs are shown in Table 1 and Figures 35-38. In Table 1, the DNA recognition helices are underlined, and "Fok ELD-S" and "Fok KKR-S" refer to the FokI nuclease domain, which is fused to a zinc finger protein DNA binding domain. In Figures 35-38, the target DNA sequence within the target site (i.e., SEQ ID NOs: 442, 445, 448, and 453) and the DNA recognition helices within the ZFN amino acid sequence (i.e., SEQ ID NOs: 443, 444, 446, 447, 449-452, and 455), respectively, are underlined.

[0059] [Table 1]

[0060] c. TAL effector nucleases (TALENs) TALENs can be used to introduce site-specific double-strand breaks into targeted genomic loci. Site-specific double-strand breaks occur when two separate TALENs bind to nearby DNA sequences, thereby allowing FokI dimerization and target DNA cleavage. TALENs have advanced gene editing due to their high success rate and efficiency in gene editing. This DNA break stimulates the natural DNA repair mechanism, resulting in one of two possible repair pathways: homology-directed repair (HDR) or non-homologous end joining (NHEJ) pathways. TALENs can be designed to target any gene involved in genetic disease. A TALEN can include a nuclease and a TALE DNA binding domain that binds to a target gene within a TALEN target region. The target gene can have a mutation (e.g., a frameshift mutation or a nonsense mutation). If the target gene has a mutation that results in a premature stop codon, the TALEN can be designed to recognize and bind to a nucleotide sequence upstream or downstream of the premature stop codon. A "TALEN target region" includes binding regions for two TALENs and a spacer region (which is present between the binding regions). The two TALENs bind to different binding regions within the TALEN target region, and then the TALEN target region is cleaved. Examples of TALENs are described in International Patent Application No. PCT / US2013 / 038536, which is incorporated herein by reference in its entirety.

[0061] 7. Transcriptional Activators The above-described compositions include a nucleotide sequence encoding a transcription activator that activates a target gene. The transcription activator can be engineered. For example, the engineered transcription activator can be a CRISPR / Cas9-based system, a zinc finger fusion protein, or a TALE fusion protein. a. CRISPR / Cas9-based systems The above-mentioned CRISPR / Cas9-based system can be used to activate the transcription of target genes with RNA.The CRISPR / Cas9-based system can comprise the above-mentioned fusion protein, where the second polypeptide domain has transcription activation activity or histone modification activity.For example, the second polypeptide domain can comprise VP-64 or p300. B zinc finger fusion protein The transcriptional activator can be a zinc finger fusion protein. The zinc finger targeting DNA binding domain described above can be combined with a domain having transcriptional activation activity or histone modifying activity. For example, the domain can include VP64 or p300. c.TALE fusion protein TALE fusion proteins can be used to activate the transcription of target genes. A TALE fusion protein can include a TALE DNA binding domain and a domain with transcription activation activity or histone modification activity. For example, the domain can include VP64 or p300.

[0062] 8. Composition The present invention is directed to compositions for altering gene expression and manipulating or modifying the genomic DNA of a cell or subject. The compositions may also include viral delivery systems. a. Compositions for genome editing in muscle The present invention is directed to compositions for genome editing of target genes in skeletal or cardiac muscle of a subject animal. The compositions include a modified AAV vector and a nucleotide sequence encoding a site-specific nuclease. The compositions deliver an active form of the site-specific nuclease to the skeletal or cardiac muscle. The compositions can further include donor DNA or a transgene. These compositions can be used in genome editing, genome engineering, and correcting or mitigating the effects of genetic mutations involved in genetic diseases and / or other skeletal or cardiac muscle conditions. The target gene may be involved in cell differentiation or any other process in which gene activation inhibition or destruction is desired, or may have a mutation (e.g., a deletion, a frameshift mutation, or a nonsense mutation). If the target gene has a premature stop codon, an aberrant splice acceptor site, or an aberrant splice donor site, the site-specific nuclease may be designed to recognize and bind to a nucleotide sequence upstream or downstream from the premature stop codon, the aberrant splice acceptor site, or the aberrant splice donor site. Site-specific nucleases can also be used to disrupt normal gene splicing by targeting splice acceptors and donors to introduce skipping of premature stop codons or restore a disrupted reading frame. Site-specific nucleases may or may not mediate off-target changes to protein-coding regions of the genome.

[0063] B. Adeno-associated virus vector The compositions described above include modified adeno-associated virus (AAV) vectors. The modified AAV vectors can have enhanced cardiac and skeletal muscle tropism. The modified AAV vectors can deliver and express location-specific nucleases in mammalian cells. For example, the modified AAV vector can be an AAV-SASTG vector (Piacentino et al. (2012) Human Gene Therapy 23:635-646). The modified AAV vectors can deliver nucleases to skeletal and cardiac muscles in vivo. The modified AAV vectors can be based on one or more of several capsids, including AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9. The modified AAV vectors can be based on AAV2 pseudotypes that include alternative muscle-tropic AAV capsids. For example, AAV2 / 1, AAV2 / 6, AAV2 / 7, AAV2 / 8, AAV2 / 9, AAV2.5 and AAV / SASTG vectors efficiently transduce skeletal or cardiac muscle by systemic or localized delivery (Seto et al. Current Gene Therapy (2012) 12:139-151). c. CRISPR / Cas9-based systems The present disclosure also provides a DNA targeting system or composition of at least one CRISPR / Cas9-based system as described above. These compositions can be used in genome editing, genome engineering, and correcting or mitigating the effects of genetic mutations involved in genetic diseases. The composition comprises a CRISPR / Cas9-based system, the system comprising a Cas9 protein or a Cas9 fusion protein as described above. The CRISPR / Cas9-based system can also comprise at least one gRNA as described above. d. Combined CRISPR / Cas9-based system The present disclosure also provides a composite CRISPR / Cas9-based system as described above. These compositions can be used in genome editing, genome engineering, and correcting or mitigating the effects of genetic mutations involved in genetic diseases. These compositions can be used to target two or more genes. The compositions include modified lentiviral vectors, which include a CRISPR / Cas9-based system comprising the Cas9 protein or Cas9 fusion protein as described above, and two or more gRNAs as described above.

[0064] 9.How to use The potential applications of the compositions span many areas of science and biotechnology. The disclosed compositions can be used to repair genetic mutations that cause disease. The disclosed compositions can be used to disrupt genes, which can result in muscle regeneration or increased strength, or reduced muscle aging. The disclosed compositions can be used to introduce therapeutic genes (e.g., clotting factors or monoclonal antibodies) that are expressed systemically from skeletal or cardiac muscles. The disclosed compositions can be used to modulate mammalian gene expression. The disclosed compositions can be used to transdifferentiate or induce differentiation of cells, or correct mutated genes in cells. Examples of gene activation, genetic reprogramming, and regenerative medicine related to cell and gene therapy are provided. RNA-guided transcriptional activators can be used to reprogram cell lineage specifics. Activation of endogenous genes that code for key regulators of cell fate, rather than forced overexpression of these factors, could potentially provide a more rapid, efficient, stable, or specific method for genetic reprogramming, transdifferentiation, and / or induced differentiation.

[0065] 10. How to edit the genome in muscle The present disclosure is directed to a method for genome editing in skeletal or cardiac muscle of a subject animal. The method includes administering a composition for genome editing in skeletal or cardiac muscle described above to the skeletal or cardiac muscle of the subject animal. Genome editing can include correction of a mutated gene or insertion of a transgene. Correction of a mutated gene can include deletion, rearrangement, or replacement of the mutated gene. Correction of a mutated gene can include nuclease-mediated NHEJ or HDR.

[0066] 11. Using CRISPR / Cas9-based systems The potential applications of CRISPR / Cas9-based systems span many areas of science and biotechnology. The disclosed CRISPR / Cas9-based systems can be used to modulate gene expression in mammals. The disclosed CRISPR / Cas9-based systems can be used to transdifferentiate or induce differentiation in cells, or to correct mutated genes in cells. Examples of gene activation related to cell and gene therapy, genetic reprogramming, and regenerative medicine are provided. RNA-guided transcriptional activators can be used to reprogram cell lineage specifics. Although reprogramming was incomplete and inefficient in these experiments, there are many ways that this method could be improved. These include repeated transfection of iCas9-VP64 / gRNA combinations, stable expression of the factors, and targeted induction of a wide variety of genes (e.g., Brn2 and Mytl1) in addition to Ascl1 for transdifferentiation into neuronal phenotypes. Activation of endogenous genes encoding key regulators of cell fate, rather than forced overexpression of these factors, could potentially provide a more rapid, efficient, stable or specific method for genetic reprogramming and cellular trans- or induced differentiation. Finally, fusion of Cas9 with other domains, including repressive and epigenetic modification domains, could provide a much greater diversity of RNA-guided transcriptional regulators, complementing other RNA-based tools for mammalian cell engineering.

[0067] A. Methods for activating gene expression The present disclosure provides a mechanism for activating the expression of endogenous genes (e.g., mammalian genes). The mechanism is by targeting transcriptional activators to promoters via RNA using the CRISPR / Cas9-based system described above. This is fundamentally different from the previously described method of engineering sequence-specific DNA-binding proteins and can provide an opportunity for targeted gene regulation. Since the generation of gRNA expression plasmids simply requires the synthesis of two short custom oligonucleotides and one cloning step, many novel gene activators can be generated quickly and economically. gRNAs can also be directly transfected into cells following in vitro transcription. Although we have shown a wide variety of gRNAs targeted to a single promoter, simultaneous targeting to a wide variety of promoters may also be possible. Recognition of genomic target sites by RNA rather than protein may also circumvent the limitations of targeting epigenetically modified sites (e.g., methylated DNA). In contrast to traditional approaches that rely on engineering DNA-binding proteins, Cas9 fused to a transcription activation domain can be targeted together with a guide RNA molecule to induce expression of endogenous human genes. This straightforward and versatile approach to targeted gene activation avoids the need to engineer novel proteins and allows for the regulation of widely dispersed synthetic genes. The method may include administering to a cell or a subject a CRISPR / Cas9-based system as described above, a polynucleotide or vector encoding said CRISPR / Cas9-based system, or a DNA targeting system or composition comprising at least one CRISPR / Cas9-based system. The method may include administration of a CRISPR / Cas9-based system, such as administration of a Cas9 fusion protein comprising a transcription activation domain or a nucleotide sequence encoding said Cas9 fusion protein. The Cas9 fusion protein may comprise a transcription activation domain (e.g., VP16 protein) or a transcription coactivator (e.g., p300 protein).

[0068] (1)dCas9-VP16 The Cas9 fusion protein can include a transcription activation domain (e.g., a VP16 protein). The transcription activation domain can include at least one VP16 protein, at least two VP16 proteins, at least three VP16 proteins, at least four VP16 proteins (i.e., a VP64 activator domain), at least five VP16 proteins, at least six VP16 proteins, at least six VP16 proteins, or at least ten VP16 proteins. The Cas9 protein can be a Cas9 protein with inactivated nuclease activity. For example, the Cas9 protein of the fusion protein can be iCas9 (amino acids 36-1403 of SEQ ID NO:1), which includes amino acid substitutions D10A and H840A. The Cas9 fusion protein can be iCas9-VP64. (2) dCas9-p300 Cas9 fusion proteins can include a transcriptional coactivation domain (e.g., p300 protein). p300 protein (also known as EP300 or E1A binding protein p300) is encoded by the EP300 gene and regulates the activity of many genes in tissues throughout the body. p300 protein plays a role in regulating cell growth and division, promoting cell maturation and the presentation of specialized functions (differentiation), and preventing the growth of cancerous tumors. p300 protein activates transcription by linking transcription factors to protein complexes (which carry out transcription in the nucleus of the cell). Interaction of p300 with transcription factors is achieved by one or more p300 domains: the nuclear receptor interacting domain (RID), the CREG and MYB interacting domain (KIX), the cysteine / histidine regions (TAZ1 / CH1 and TAZ2 / CH3), and the interferon response binding domain (IBiD). The last four domains of p300 (KIX, TAZ1, TAZ2, and IBiD) bind tightly to both transactivation domains of the transcription factor p53, a sequence spanning the nine amino acid TAD, respectively. The protein functions as a histone acetyltransferase that regulates transcription through chromatin remodeling and is important in the processes of cell proliferation and differentiation. It mediates cAMP gene regulation by specifically binding to phosphorylated CREB protein.

[0069] The p300 protein can activate the following: Mothers against decapentaplegic (MAD) homolog 7, MAF, TSG101, peroxisome proliferator-activated receptor alpha, NPAS2, PAX6, DDX5, MYBL2, MAD homolog 1, MAD homolog 2, lymphoid enhancer-binding factor 1, SNIP1, TRERF1, STAT3, EID1, RAR-related orphan receptor alpha, ELK1, HIF1A, ING5, peroxisome proliferator-activated receptor gamma, SS18, TCF3, Zif268, and estrogen receptor alpha. α, GPS2, MyoD, YY1, ING4, PROX1, CITED1, HNF1A, MEF2C, MEF2D, MAML1, Twist transcription factor, PTMA, IRF2, DTX1, flap-specific endonuclease 1, myocyte-specific enhancer factor 2A, CDX2, BRCA1, HNRPU, STAT6, CITED2, RELA, TGS1, CEBPB, Mdm2, NCOA6, NFATC2, thyroid hormone receptor alpha, BCL3, TFAP2A, PCNA, p53, and TAL1. The transcriptional coactivation domain can comprise human p300 protein or a fragment thereof. The transcriptional coactivation domain can comprise wild-type human p300 protein or a mutant human p300 protein, or a fragment thereof. The transcriptional coactivation domain can comprise the central lysine acetyltransferase domain of human p300 protein, i.e., p300HAT core (also known as "p300WT core", see FIG. 58). The Cas9 protein can be a Cas9 protein in which the nuclease activity has been inactivated. For example, the Cas9 protein of the fusion protein can be iCas9 (amino acids 36-1403 of SEQ ID NO:1), which comprises amino acid substitutions of D10A and H840A. The Cas9 fusion protein can be iCas9-p300WT core.

[0070] (3) gRNA The method also includes administering to the cell or subject at least one gRNA of a CRISPR / Cas9 based system, where the gRNAs target different DNA sequences. The target DNA sequences may be overlapping. The number of gRNAs administered to a cell can be at least 1 gRNA, at least 2 different gRNAs, at least 3 different gRNAs, at least 4 different gRNAs, at least 5 different gRNAs, at least 6 different gRNAs, at least 7 different gRNAs, at least 8 different gRNAs, at least 9 different gRNAs, at least 10 different gRNAs, at least 11 different gRNAs, at least 12 different gRNAs, at least 13 different gRNAs, at least 14 different gRNAs, at least 15 different gRNAs, at least 16 different gRNAs, at least 17 different gRNAs, at least 18 different gRNAs, at least 18 different gRNAs, at least 20 different gRNAs, at least 25 different gRNAs, at least 30 different gRNAs, at least 35 different gRNAs, at least 40 different gRNAs, at least 45 different gRNAs, at least 50 different gRNAs.The number of gRNAs administered to a cell may be at least 50 different gRNAs from at least one gRNA, at least 45 different gRNAs from at least one gRNA, at least 40 different gRNAs from at least one gRNA, at least 35 different gRNAs from at least one gRNA, at least 30 different gRNAs from at least one gRNA, at least 25 different gRNAs from at least one gRNA, at least 20 different gRNAs from at least one gRNA, at least 16 different gRNAs from at least one gRNA, at least 12 different gRNAs from at least one gRNA, at least 8 different gRNAs from at least one gRNA, at least 4 different gRNAs from at least one gRNA, at least 50 different gRNAs from at least four gRNAs, at least 45 different gRNAs from at least four different gRNAs, at least 40 different gRNAs from at least four different gRNAs, at least 35 different gRNAs from at least four different gRNAs, at least 30 different gRNAs from at least four different gRNAs. different gRNAs, at least 4 different gRNAs to at least 25 different gRNAs, at least 4 different gRNAs to at least 20 different gRNAs, at least 4 different gRNAs to at least 16 different gRNAs, at least 4 different gRNAs to at least 12 different gRNAs, at least 4 different gRNAs to at least 8 different gRNAs, at least 8 different gRNAs to at least 50 different gRNAs, at least 45 different gRNAs from at least 8 different gRNAs, at least 40 different gRNAs from at least 8 different gRNAs, at least 35 different gRNAs from at least 8 different gRNAs, at least 30 different gRNAs from at least 8 different gRNAs, at least 25 different gRNAs from at least 8 different gRNAs, at least 20 different gRNAs from 8 different gRNAs, at least 16 different gRNAs from at least 8 different gRNAs, at least 12 different gRNAs from 8 different gRNAs, at least 8 different gRNAs from at least 8 different gRNAs. The gRNA can comprise a complementary polynucleotide sequence of the target DNA sequence followed by NGG. The gRNA can comprise a "G" at the 5' end of the complementary polynucleotide sequence. The gRNA can comprise at least 10 base pairs, at least 11 base pairs, at least 12 base pairs, at least 13 base pairs, at least 14 base pairs, at least 15 base pairs, at least 16 base pairs, at least 17 base pairs, at least 18 base pairs, at least 19 base pairs, at least 20 base pairs, at least 21 base pairs, at least 22 base pairs, at least 23 base pairs, at least 24 base pairs, at least 25 base pairs, at least 30 base pairs, at least 35 base pairs of the complementary polynucleotide sequence of the target DNA sequence followed by NGG. The gRNA can target at least one of the promoter region, enhancer region, or transcribed region of the target gene. The gRNA can comprise at least one of the nucleic acid sequences of SEQ ID NOs: 5-40, 65-144, 492-515, 540-563, and 585-625.

[0071] b. Methods for suppressing gene expression The present disclosure provides a mechanism for suppressing the expression of endogenous genes (e.g., mammalian genes) by targeting genomic regulatory elements (e.g., distal enhancers) via RNA using the CRISPR / Cas9-based system described above. The Cas9 fusion protein can include a transcriptional repressor (e.g., KRAB repressor). The Cas9 fusion protein can be dCas9-KRAB. dCas9-KRAB can further affect epigenetic gene regulation by recruiting heterochromatin forming factors to the targeted locus. The CRISPR / Cas9-KRAB system can be used to suppress gene transcription, but also to target genomic regulatory elements that were previously inaccessible to traditional suppression methods (e.g., RNA interference) (Figure 53B). Delivery of dCas9-KRAB targeted to distal enhancers with gRNA can disrupt expression of a wide variety of genes regulated by targeted enhancers (see Figure 53C). The targeted enhancer can be any enhancer of the gene (eg, the HS2 enhancer).

[0072] A. Transdifferentiation or Induced Differentiation Methods The present disclosure provides a mechanism to transdifferentiate or induce differentiation of cells by activating endogenous genes via RNA using the CRISPR / Cas9-based system described above. (1) Transdifferentiation CRISPR / Cas9-based systems can be used to trans-differentiate cells. Trans-differentiation (also known as lineage reprogramming or direct conversion) is the process by which cells convert from one differentiated cell type to another without passing through an intermediate pluripotent state or progenitor cell type. It is a type of metaplasia, which includes all cell fate switching, including the interconversion of stem cells. Cell trans-differentiation is potentially useful in disease modeling, drug discovery, gene therapy, and regenerative medicine. Using the above-described CRISPR / Cas9-based systems, activation of endogenous genes (e.g., BRN2, MYT1L, ASCL1, NANOG, and / or MYOD1) can result in the trans-differentiation of several cell types (e.g., fibroblasts, cardiomyocytes, hepatocytes, chondrocytes, mesenchymal progenitor cells, hematopoietic stem cells, or smooth muscle cells) into neuronal or myogenic phenotypes, respectively.

[0073] (2) Induced differentiation CRISPR / Cas9-based systems can be used to induce differentiation of cells (e.g., stem cells, cardiomyocytes, hepatocytes, chondrocytes, mesenchymal progenitor cells, hematopoietic stem cells, or smooth muscle cells). For example, stem cells (e.g., embryonic stem cells or pluripotent stem cells) can be induced to differentiate into muscle cells or vascular endothelial cells (i.e., to induce neuronal or myogenic differentiation). 12. Use of Combined CRISPR / Cas9-Based Systems The combined CRISPR / Cas9-based system can be useful for taking advantage of the simplicity and low cost of sgRNA design, and further facilitating progress in high-throughput genomic research using CRISPR / Cas9 technology. For example, the single lentivirus described herein is useful for expressing Cas9 and multiple sgRNAs in various cell lines (e.g., primary fibroblasts as described herein) (Figure 47). The combined CRISPR / Cas9-based system can be used in the same manner as the CRISPR / Cas9-based system described above. In addition to the transcription activation and nuclease functionalities described, this system will be useful for the expression of other novel Cas9-based effectors that control epigenetic modifications for a variety of purposes, including interrogation of genomic architecture and pathways of endogenous gene regulation. Because endogenous gene regulation requires a delicate balance between a wide variety of enzymes, a multiplex Cas9 system with various functionalities will allow for the testing of complex interactions between various regulatory signals. The vectors described herein should be compatible with aptamer-modified sgRNAs and orthogonal Cas9 compatibility, allowing for distinct genetic manipulations using a single set of sgRNAs.

[0074] A combined CRISPR / Cas9-based system can be used to activate at least one endogenous gene in a cell. The method includes contacting a cell with a modified lentiviral vector. The endogenous gene can be transiently activated or stably activated. The endogenous gene can be transiently repressed or stably repressed. The fusion protein can be expressed at a similar level as the sgRNA. The fusion protein can be expressed at a different level compared to the sgRNA. The cell can be a primary human cell. The complex CRISPR / Cas9-based system can be used in a method of complex gene editing of a cell. The method includes contacting the cell with a modified lentiviral vector. The complex gene editing can include correcting a mutant gene or inserting a transgene. Correcting a mutant gene can include deleting, rearranging, or replacing a mutant gene. Correcting a mutant gene can include nuclease-mediated non-homologous end joining or homology-directed repair. The complex gene editing can include deleting or correcting at least one gene, where the gene is an endogenous normal gene or a mutant gene. The complex gene editing can include deleting or correcting at least two genes. For example, at least two genes, at least three genes, at least four genes, at least five genes, at least six genes, at least seven genes, at least eight genes, at least nine genes, at least ten genes can be deleted or corrected. The combined CRISPR / Cas9-based system can be used in a method for combined modulation of gene expression in a cell. The method includes contacting a cell with a modified lentiviral vector. The method can include modulation of the gene expression level of at least one gene. The gene expression of at least one target gene is modulated when the gene expression level of the at least one target gene is increased or decreased compared to the normal gene expression level for the at least one target gene. The gene expression level can be at the RNA or protein level.

[0075] 13. A method for correcting mutant genes and treating target animals. The present disclosure is also directed to a method of correcting a mutant gene in a subject animal. The method includes administering to the skeletal or cardiac muscle of a subject animal a composition for genome editing in skeletal or cardiac muscle described above. The use of a composition for delivering a site-specific nuclease to skeletal or cardiac muscle together with a repair template or donor DNA can restore expression of a protein with full or partial function (the template or DNA can replace the entire gene or region containing the mutation). The site-specific nuclease can be used to introduce a site-specific double-stranded break at a target genomic locus. The site-specific double-stranded break is cut when the site-specific nuclease binds to the target DNA sequence, thereby allowing the target DNA to be cut. This DNA break can stimulate natural DNA repair mechanisms, resulting in one of two possible repair pathways: homology-directed repair (HDR) or non-homologous end joining (NHEJ) pathways. The present disclosure is directed to genome editing with site-specific nucleases in the absence of a repair template, which can efficiently correct the reading frame and restore expression of functional proteins involved in genetic disease. The disclosed site-specific nucleases can be engaged using homology-directed repair or non-homologous end joining (NHEJ)-based correction approaches, which allow efficient correction in growth-limited primary cell lines that are not amenable to homologous recombination or selection-based gene correction. The present approach integrates the rapid and robust assembly of active site-specific nucleases with efficient gene editing for the treatment of genetic disease caused by mutations in non-essential coding regions (resulting in frameshifts, premature stop codons, aberrant splice donor sites, or aberrant splice acceptor sites).

[0076] a. Nuclease-mediated non-homologous end joining Restoration of protein expression of endogenous mutant genes can be via template-free NHEJ-mediated DNA repair. In contrast to the transient method of targeting the RNA of the target gene, correction of the target gene reading frame in the genome by a transiently expressed site-specific nuclease can result in permanent restoration of target gene expression by each modified cell and all of its progeny. Nuclease-mediated NHEJ gene correction can correct mutated target genes and offers several potential advantages over the HDR pathway. For example, NHEJ does not require a donor template, which can result in non-specific insertional mutations. In contrast to HDR, NHEJ operates efficiently throughout the cell cycle and can therefore be efficiently utilized in both cycling and post-mitotic cells (e.g., myofibers). It offers a robust and permanent alternative to oligonucleotide-based exon skipping or pharmacologically forced read-through of stop codons for gene restoration, and could theoretically require as few steps as one-drug therapy. NHEJ-based gene correction using CRISPR / Cas9-based systems can be used together with other existing ex vivo and in vivo platforms for cell- and gene-based therapy, as well as other engineered nucleases, including meganucleases and zinc finger nucleases, in addition to the plasmid electroporation approach described herein. For example, delivery of CRISPR / Cas9-based systems by mRNA-based gene transfer or as purified cell-permeable proteins could enable a DNA-free genome editing approach that avoids any potential introduction of insertional mutations.

[0077] b. Homology-oriented repair Restoring protein expression of the endogenous mutant gene can include homology-directed repair. The method described above further includes administration of a donor template to the cell. The donor template can include nucleotides encoding a fully functional protein or a partially functional protein. For example, the donor template can include a mini-dystrophin construct (referred to as "minidys"), a fully functional dystrophin construct for restoration of the mutant dystrophin gene, or a fragment of the dystrophin gene (resulting in restoration of the mutant dystrophin gene after homology-directed repair).

[0078] c. A method for correcting mutated genes and treating target animals using CRISPR / Cas9 The present disclosure is also directed to genome editing using a CRISPR / Cas9-based system to restore expression of a fully functional or partially functional protein using a repair template or donor DNA, which can replace the entire gene or the region containing the mutation. The CRISPR / Cas9-based system can be used to introduce a site-specific double-strand break at a target genomic locus. The site-specific double-strand break occurs when the CRISPR / Cas9-based system uses a gRNA to bind to a target DNA sequence, thereby allowing the target DNA to be cut. CRISPR / Cas9-based systems have the advantage of progressive genome editing due to their high rate of successful and efficient gene modification. This DNA break stimulates the natural DNA repair mechanism, resulting in one of two possible repair pathways: homology-directed repair (HDR) or non-homologous end joining (NHEJ) pathways. For example, a CRISPR / Cas9-based system directed to the dystrophin gene can include a gRNA having a nucleic acid sequence of any one of SEQ ID NOs: 65-115. The present disclosure is directed to genome editing with a repair template-free CRISPR / Cas9-based system that can efficiently correct reading frames and restore expression of functional proteins involved in genetic diseases. The disclosed CRISPR / Cas9-based systems and methods can include steps using homology-directed repair or nuclease-mediated non-homologous end joining (NHEJ)-based correction approaches, which allow for efficient correction in growth-limited primary cell lines that are not amenable to homologous recombination or selection-based gene correction. The present approach integrates the rapid and robust assembly of an active CRISPR / Cas9-based system with efficient gene editing for the treatment of genetic diseases caused by mutations in non-essential coding regions (resulting in frameshifts, premature stop codons, aberrant splice donor sites, or aberrant splice acceptor sites).

[0079] The present disclosure provides a method for correcting a mutant gene in a cell to treat a patient suffering from a genetic disease (e.g., DMD). The method includes administering to a cell or a subject animal a CRISPR / Cas9-based system, a polynucleotide or vector encoding the CRISPR / Cas9-based system, or a composition of the CRISPR / Cas9-based system, as described above. The method can include administering a CRISPR / Cas9-based system, such as administering a Cas9 protein or a Cas9 fusion protein comprising a second domain having nuclease activity, a nucleotide encoding the Cas9 protein or Cas9 fusion protein, and / or at least one gRNA, where the gRNAs target different DNA sequences. The target DNA sequences may overlap. The number of gRNAs administered to the cell can be at least one gRNA, at least two different gRNAs, at least three different gRNAs, at least four different gRNAs, at least five different gRNAs, at least six different gRNAs, at least seven different gRNAs, at least eight different gRNAs, at least nine different gRNAs, at least ten different gRNAs, at least fifteen different gRNAs, at least twenty different gRNAs, at least thirty different gRNAs, or at least fifty different gRNAs, as described above. The gRNAs can comprise at least one nucleic acid sequence of SEQ ID NOs: 65-115. The method can include homology directed repair or non-homologous end joining.

[0080] 14. Methods for Treating Diseases The present disclosure is directed to a method of treating a subject in need thereof. The method includes administering to a tissue of the subject a composition for modifying gene expression and manipulating or modifying genomic DNA in a cell or genome editing of the subject as described above. The method includes administering to a skeletal or cardiac muscle of the subject a composition for genome editing in skeletal or cardiac muscle as described above. The subject may suffer from a condition or genetic disease of the skeletal or cardiac muscle that causes degeneration or fragility. For example, the subject may suffer from Duchenne muscular dystrophy as described above. A. Duchenne muscular dystrophy Using the methods described above, the dystrophin gene can be corrected and expression of a fully functional or partially functional protein of the mutated dystrophin gene can be restored. In some aspects and embodiments, the disclosure provides a method of alleviating the effects (e.g., clinical symptoms / signs) of DMD in a patient. In some aspects and embodiments, the disclosure provides a method of treating DMD in a patient. In some aspects and embodiments, the disclosure provides a method of preventing DMD in a patient. In some aspects and embodiments, the disclosure provides a method of preventing further progression of DMD in a patient.

[0081] 15. Constructs and Plasmids The composition described above can include a genetic construct encoding the CRISPR / Cas9-based system described above. The genetic construct (e.g., a plasmid) can include a nucleic acid encoding the CRISPR / Cas9-based system, such as a Cas9 protein and a Cas9 fusion protein, and / or at least one gRNA. The composition described above can include a genetic construct encoding a modified AAV and a nucleic acid sequence encoding a position-specific nuclease described above. The genetic construct, e.g., a plasmid, can include a nucleic acid encoding a position-specific nuclease. The composition described above can include a genetic construct encoding a modified lentiviral vector described herein. The genetic construct, e.g., a plasmid, can include a nucleic acid encoding a Cas9 fusion protein and at least one sgRNA. The genetic construct can be present in the cell as a functional extrachromosomal molecule. The genetic construct can be a linear minichromosome containing a centromere, a telomere, or a plasmid or cosmid. The genetic construct may also be part of the genome of a recombinant viral vector, including recombinant lentivirus, recombinant adenovirus, and recombinant adenovirus-associated virus. The genetic construct may be part of the genetic material of a live attenuated microorganism or a recombinant microbial vector living in a cell. The genetic construct may include regulatory elements for gene expression of the coding sequence of the nucleic acid. The regulatory elements may be promoters, enhancers, initiation codons, stop codons, or polyadenylation signals. The nucleic acid sequence can form a genetic construct, which can be a vector. The vector can be capable of expressing a fusion protein, such as a Cas9 fusion protein or a position-specific nuclease. The vector can be recombinant. The vector can contain a heterologous nucleic acid encoding a fusion protein, such as a Cas9 fusion protein or a position-specific nuclease. The vector is useful for transfecting a nucleic acid encoding a Cas9 fusion protein or a position-specific nuclease into a cell, where the transformed host cell is cultured and maintained under conditions that allow expression of the Cas9 fusion protein or the position-specific nuclease system. Coding sequences can be optimized for stability and high level expression. In some cases, codons are selected to reduce RNA secondary structure formation (e.g., formed due to intramolecular binding).

[0082] The vector can include a heterologous nucleic acid encoding a CRISPR / Cas9-based system or a site-specific nuclease, and can also include a start codon, which can be downstream of the CRISPR / Cas9-based system or site-specific nuclease coding sequence. The start and stop codons can be in frame with the CRISPR / Cas9-based system or site-specific nuclease coding sequence. The vector can also include a promoter operably linked to the CRISPR / Cas9-based system or site-specific nuclease coding sequence. The promoter operably linked to the CRISPR / Cas9-based system or the site-specific nuclease coding sequence can be a promoter derived from Simian Virus 40 (SV40), a mouse mammary tumor virus (MMTV) promoter, a human immunodeficiency virus (HIV) promoter, such as a bovine immunodeficiency virus (BIV) long terminal repeat (LTR) promoter, a Moloney virus promoter, an avian leukosis virus (ALV) promoter, a cytomegalovirus (CMV) promoter (such as a CMV immediate early promoter), an Epstein-Barr virus (EBV) promoter, or a Rous sarcoma virus (RSV) promoter. The promoter can also be a promoter derived from a human gene, such as a human ubiquitin C (hUbC), human actin, human myosin, human hemoglobin, human muscle creatine, or human metallothionein. The promoter can also be a tissue-specific promoter, such as a muscle or skin specific promoter, natural or synthetic. Examples of such promoters are described in US Patent Application Publication No. US20040175727, which is incorporated herein by reference in its entirety. The vector can also include a polyadenylation signal, which can be downstream of the CRISPR / Cas9-based system or the site-specific nucleotide. The polyadenylation signal can be the SV40 polyadenylation signal, the LTR polyadenylation signal, the bovine growth hormone (bGH) polyadenylation signal, the human growth hormone (hGH) polyadenylation signal, or the human β-globin polyadenylation signal. The SV40 polyadenylation signal can be the polyadenylation signal from the pCEP4 vector (Invitrogen, San Diego, CA).

[0083] The vector can also include an enhancer upstream of the CRISPR / Cas9-based system, i.e., Cas9 protein or Cas9 fusion protein or sgRNA, or site-specific nuclease. The enhancer may be necessary for DNA expression. The enhancer may be human actin, human myosin, human hemoglobin, human muscle creatine, or a viral enhancer (e.g., enhancer from CMV, HA, RSV, or EBV). Polynucleotide function enhancers are described in U.S. Patent Nos. 5,593,972, 5,962,428, and WO94 / 016737, the contents of each of which are incorporated herein by reference. The vector can also include a mammalian origin of replication to maintain the vector extrachromosomally and to generate multiple copies of the vector within the cell. The vector can also include a regulatory sequence, which may be well adapted for gene expression in mammalian or human cells to which the vector is administered. The vector can also include a reporter gene (eg, green fluorescent protein ("GFP")) and / or a selectable marker (eg, hygromycin ("Hygro"). The vector can be an expression vector or expression system for protein production using routine techniques and readily available starting materials (see Sambrook et al., Molecular Cloning and Laboratory Manual, Second Ed., Cold Spring Harbor, 1989, which is incorporated herein by reference in its entirety). In some embodiments, the vector can comprise a nucleic acid sequence encoding a CRISPR / Cas9-based system (including a nucleic acid sequence encoding a Cas9 protein or a Cas9 fusion protein), and a nucleic acid sequence encoding at least one gRNA comprising at least one of the nucleic acid sequences of SEQ ID NOs: 5-40, 65-144, 492-515, 540-563, and 585-625.

[0084] 16. Pharmaceutical Compositions The composition may be a pharmaceutical composition. The pharmaceutical composition may comprise about 1 ng to about 10 mg of DNA encoding the CRISPR / Cas9-based system or a CRISPR / Cas9-based system protein component (i.e., Cas9 protein or Cas9 fusion protein). The pharmaceutical composition may comprise about 1 ng to about 10 mg of DNA of a modified AAV vector and a nucleotide encoding a site-specific nuclease. The pharmaceutical composition may comprise about 1 ng to about 10 mg of DNA of a modified lentiviral vector. The pharmaceutical composition of the present invention is formulated according to the mode of administration to be used. When the pharmaceutical compositions are injectable pharmaceutical compositions, they are sterile, pyrogen-free, and particulate-free. Preferably, an isotonic formulation is used. Commonly, additives for isotonicity include sodium chloride, dextrose, mannitol, sorbitol, and lactose. In some cases, an isotonic solution (e.g., phosphate-buffered saline) is preferred. Stabilizers include gelatin and albumin. In some embodiments, a vasoconstrictor is imparted to the formulation.

[0085] The composition may further comprise a pharma- ceutically acceptable excipient. The pharma-ceutically acceptable excipient may be a molecule that functions as a vehicle, adjuvant, carrier, or diluent. The pharma-ceutically acceptable excipient may comprise a transfection facilitating agent, including surfactants, such as immunostimulating complexes (ISCOMS), Freund's incomplete adjuvant, LPS analogs (including monophosphoryl lipid A), muramyl peptides, quinone analogs, vesicles (e.g., squalane and squalene), hyaluronic acid, lipids, liposomes, calcium ions, viral proteins, polyanions, polycations, or nanoparticles, or other known transfection facilitating agents. The transfection facilitating agent is a polyanion, a polycation (including poly-L-glutamate (LGS)) or a lipid. The transfection facilitating agent is poly-L-glutamate, and more preferably, poly-L-glutamate is present in the composition for genome editing in skeletal or cardiac muscle at a concentration of less than 6 mg / mL. The transfection facilitating agent can also include surfactants, such as immune stimulating complexes (ISCOMS), Freund's incomplete adjuvant, LPS analogs (including monophosphoryl lipid A), muramyl peptides, quinone analogs and vesicles (e.g., squalane and squalene), and hyaluronic acid can also be used for administration with the gene construct. In some embodiments, the DNA vector encoding the composition can also include a transfection facilitating agent, such as a lipid, a liposome (including lecithin liposomes or other liposomes known in the art), a DNA-liposome mixture (see, e.g., WO9324640), calcium ions, viral proteins, polyanions, polycations, or nanoparticles, or other known transfection facilitating agents. Preferably, the transfection facilitating agent is a polyanion, polycation (including poly-L-glutamate (LGS)), or a lipid.

[0086] 17. Delivery Method Provided herein is a method of delivering a pharmaceutical formulation (preferably a composition as described above) to provide a genetic construct. Delivery of the composition can be by transfection or electroporation of the composition as a nucleic acid molecule that is expressed in a cell and delivered to the surface of the cell. The nucleic acid molecule can be electroporated using a BioRad Gene Pulser Xcell or Amaxa Nucleofector IIb device. Several different buffers can be used, including BioRad Electroporation Solution, Sigma Phosphate Buffered Saline Product #D8537 (PBS), Invitrogen OptiMEM I (OM), or Amaxa Nucleofector Solution V (NV). Transfection can include a transfection reagent (e.g., Lipofectamine 2000). Upon delivery of the composition to tissue and then the vector to mammalian cells, the transfected cells will express the fusion protein, for example, the CRISPR / Cas9-based system and / or the site-specific nuclease. The composition can be administered to a mammal to modify gene expression or re-engineer or modify the genome. For example, the composition can be administered to a mammal to correct the dystrophin gene in the mammal. The mammal can be a human, a non-human primate, a cow, a pig, a sheep, a goat, an antelope, a bison, a buffalo, a bovine animal, a deer, a hedgehog, an elephant, a llama, an alpaca, a mouse, a rat, or a chicken. The mammal can preferably be a human, a cow, a pig, or a chicken.

[0087] a. CRISPR / Cas9-based systems Vectors encoding the CRISPR / Cas9-based system protein components (i.e., Cas9 protein or Cas9 fusion protein) can be delivered to a mammal by DNA injection (also referred to as DNA vaccination), which may or may not utilize in vivo electroporation, liposome-mediated, nanoparticle-assisted, and / or recombinant vectors. The recombinant vector can be delivered by any viral embodiment. The viral embodiment may be a recombinant lentivirus, a recombinant adenovirus, and / or a recombinant adeno-associated virus. Nucleotides encoding CRISPR / Cas9-based system protein components (i.e., Cas9 protein or Cas9 fusion protein) can be introduced into cells to genetically correct a target gene or to change gene expression of a gene (e.g., activate or repress an endogenous gene). For example, nucleotides encoding CRISPR / Cas9-based system protein components (i.e., Cas9 protein or Cas9 fusion protein) directed to a mutant dystrophin gene by a gRNA can be introduced into myoblasts of a DMD patient. Alternatively, they can be introduced into fibroblasts of a DMD patient, and the genetically corrected fibroblasts can be treated with MyoD to induce differentiation into myoblasts (which can be transplanted into a subject animal (e.g., a damaged muscle of the subject animal) to prove that the corrected dystrophin protein is functional and / or to treat the subject animal). The cells to be modified may be stem cells (e.g., induced pluripotent stem cells), bone marrow-derived progenitor cells, skeletal muscle progenitor cells, human skeletal muscle myoblasts from DMD patients, CD133+ cells, mesoangioblasts, and MyoD- or Pax7-transduced cells, or other myogenic progenitor cells. For example, CRISPR / Cas9-based systems can induce neuronal or myogenic differentiation of induced pluripotent cells.

[0088] 18. Route of Administration The compositions can be administered to the subject animal by a variety of routes, including oral, parenteral, sublingual, transdermal, rectal, topical, inhalation, buccal, intrathoracic, intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intranasal, intrathecal, and intraarticular, or combinations thereof. For veterinary use, the compositions can be administered in any suitable acceptable formulation in accordance with normal veterinary practice. Veterinarians can readily determine the most appropriate dosing regimen and route of administration for each individual animal. The compositions can be administered by traditional syringes, needleless injection devices, "microprojectile bombardment gone gun" or physical methods (e.g., electroporation ("EP"), "hydrodynamics" or ultrasound). The composition can be delivered to the mammal by several techniques, including: DNA injection (also referred to as DNA vaccination) (which may or may not utilize in vitro electroporation), liposome-mediated, nanoparticle-assisted, recombinant vectors (e.g., recombinant lentivirus, recombinant adenovirus, and recombinant adeno-associated virus). The composition can be injected into skeletal or cardiac muscle. For example, the composition can be injected into the tibialis anterior muscle.

[0089] 19. Cell types Any of these delivery methods and / or administration routes could be used with a myriad of cell types, such as those currently being investigated for cell-based therapies. The cell types could be fibroblasts, pluripotent stem cells, cardiomyocytes, hepatocytes, chondrocytes, mesenchymal progenitor cells, hematopoietic stem cells, smooth muscle cells, or the K562 human erythroid leukemia cell line. a.DMD Cell types currently being investigated for cell-based therapy of DMD include immortalized myoblasts (e.g., wild type and DMD patient-derived lines, such as Δ48-50DMD, DMD8036 (dell48-50), C25C14 and DMD-7796 cell lines), primary DMD skin fibroblasts, induced pluripotent stem cells, bone marrow-derived progenitor cells, skeletal muscle progenitor cells, human skeletal muscle myoblasts from DMD patients, CD133+ cells, mesoangioblasts, cardiomyocytes, hepatocytes, chondrocytes, mesenchymal progenitor cells, hematopoietic stem cells, smooth muscle cells, and MyoD- or Pax7-transduced cells, or other myogenic progenitor cells. Immortalization of human myogenic cells can be utilized for clonal derivation of genetically corrected myogenic cells. Cells can be modified ex vivo to isolate and grow a clonal population of immortalized DMD myoblasts that contains a genetically corrected dystrophin gene and has no other nuclease-induced mutations in the protein coding region of the genome. Alternatively, transient in vivo delivery of nucleases by non-viral or non-integrating viral gene transfer or by direct delivery of purified protein and gRNA containing a cell entry motif can allow for highly specific in situ correction with minimal or no risk of exogenous DNA integration.

[0090] 20. Kit Provided herein are kits that can be used to edit genomes (e.g., correct mutant genes) in skeletal or cardiac muscle. The kits include a composition for genome editing in skeletal or cardiac muscle described above, and instructions for using the composition. The instructions included in the kit can be affixed to packaging materials or included as a package insert. The instructions are typically typed or printed, but are not limited to such. The present disclosure contemplates any medium capable of storing such instructions and further communicating them to an end user. Such media include, but are not limited to, electronic storage media (e.g., magnetic disks, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. As used herein, the term "instructions" can include the address of a target site providing the instructions. The composition for genome editing in skeletal or cardiac muscle can include the modified AAV vector described above and a nucleotide sequence encoding a position-specific nuclease. The position-specific nuclease can include the ZFN, TALEN, or CRISPR / Cas9-based system described above, which specifically binds to and cleaves the mutant gene. The position-specific nuclease described above is included in the kit and can specifically bind to and target a specific region of the mutant gene. The position-specific nuclease can be specific to the mutant dystrophin gene described above. The kit can further include the donor DNA, gRNA, or transgene described above.

[0091] a. CRISPR / Cas9-based systems Provided herein are kits that can be used to correct mutant genes. The kits include at least one component for correcting mutant genes and instructions for using the CRISPR / Cas9-based system. The instructions included in the kit can be affixed to packaging materials or included as a package insert. The instructions are typically typewritten or printed, but are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by the present disclosure. Such media include, but are not limited to, electronic storage media (e.g., magnetic disks, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. As used herein, the term "instructions" can include the address of a target site providing the instructions. At least one component may include at least one CRISPR / Cas9-based system as described above, which specifically targets a gene. The kit may include a Cas9 protein or a Cas9 fusion protein, a nucleotide sequence encoding said Cas9 or Cas9 fusion protein, and / or at least one gRNA. The CRISPR / Cas9-based system as described above may be included in the kit and may target a specific target region upstream, within, or downstream of the coding region of the target gene. For example, the CRISPR / Cas9-based system may be specific to the promoter region of the target gene, or the CRISPR / Cas9-based system may be specific to a mutant gene (e.g., a mutant dystrophin gene as described above). The kit may include a donor DNA as described above.

[0092] 21. Example It will be readily apparent to those skilled in the art that other suitable modifications and applications of the disclosed methods described herein can be readily applied and evaluated, and that such modifications and applications can be readily made using appropriate equivalents without departing from the scope of the disclosure or the features and embodiments disclosed herein. Having thus described the disclosure, the same will be more clearly understood with reference to the following examples, which are intended merely to illustrate certain features and embodiments of the disclosure and should not be construed as limiting the scope of the disclosure in any way. The disclosures of all references, U.S. patents, and publications cited herein are hereby incorporated by reference in their entireties. The present invention has many different features as illustrated by the following non-limiting examples.

[0093] [Example 1] Materials and Methods Cell culture and transfection HEK293T cells were obtained from the American Tissue Collection Center (ATCC) through the Duke University Cancer Center Facilities and maintained at 37°C under 5% CO2 in DMEM supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin. HEK293T cells were transfected using Lipofectamine 2000 according to the manufacturer's instructions. Transfection efficiency was routinely greater than 80% as determined by fluorescence microscopy following delivery of a control eGFP-expressing plasmid. Cas9-expressing plasmids were transfected at a 3:1 mass ratio to individual gRNA-expressing plasmids or to an equal amount of gRNA-expressing plasmids (consisting of a mixture of equal amounts of the four gRNAs). Primary mouse embryonic fibroblasts (PMEF-HL, Millipore, Billerica, MA) were seeded (7500 / well) in 24-well TCPS plates (BD, Franklin Lakes, NJ) and maintained at 37°C and 5% CO2 in complete MEF medium consisting of high glucose DMEM supplemented with 10% PreniaSelect FBS (Atlanta Biologicals, Lawrenceville, GA), 25 μg / mL gentamicin (Invitrogen), 1x GlutaMAX, non-essential amino acids, sodium pyruvate, and β-mercaptoethanol (Invitrogen). MEFs were transfected with 1 μg cm -2 Transfection was performed with a single dose of total plasmid DNA and delivered as cationic nanocomplexes following electrostatic concentration with poly(CBA-ABOL) in serum- and antibiotic-free OptiMEM as previously described (Adler et al. Molecular therapy. Nucleic acids 1, e32, 2012). OptiMEM was replaced with complete MEF medium 4 hours after transfection. 48 hours after transfection, MEFs were processed for qRT-PCR or complete MEF medium was replaced with N3 neural induction medium containing: DMEM / F-12 (Invitrogen), 1xN-2 supplement (Invitrogen), 10ng / mL human bFGF2 (Stemgent, Cambridge, MA), and 25μg / mL gentamicin (Invitrogen). Transfection conditions were optimized using a GFP reporter vector (pmax-GFP, 3486 bp, Amaxa, Cologne, Germany). The Cas9 expression plasmid was transfected at a mass ratio of 3:1 or 1:1 to an equal mixture of the four gRNA expression plasmids.

[0094] PlasmidsPlasmids encoding wild-type and H804A Cas9 were obtained from Addgene (plasmid #39312 and plasmid #39316; Jinek, et al. Science 337, 816-821, 2012). H840A Cas9 was cloned into vector pcDNA3.1 using a primer pair introducing the D10A mutation in frame with the FLAG epitope tag and nuclear localization sequence (NLS) at the N-terminus. The VP64 domain, NLS and HA epitope were cloned in frame with the Cas9 ORF at the C-terminus (Figure 1a, Figure 9a). TracrRNA and crRNA expression cassettes (Cong et al. Science 339, 819-823, 2013) were ordered as gBlocks (Integrated DNA Technologies, IDT) and cloned into pZDonor plasmids (Sigma) using the KpnI and SacII sites. Chimeric guide RNA expression cassettes (Mali et al. Science 339, 823-826, 2013) were also ordered as gBlocks and modified to include a BbsI restriction site to facilitate rapid cloning of novel guide RNA spacer sequences (Figure 9b). Oligonucleotides containing target sequences were obtained from IDT, hybridized, phosphorylated, and cloned into the appropriate plasmids using the BbsI site. Target sequences are provided in Table 2.

[0095] [Table 2]

[0096] Western blotCells were lysed with: 50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 0.5% Triton X-100 and 0.1% SDS. Lysates were mixed with loading buffer and boiled for 5 min, and equal volumes of protein were run on NuPAGE™ Novex 4-12% or 10% Bis-Tris Gel polyacrylamide gels and transferred to nitrocellulose membranes. Nonspecific antibody binding was blocked with 5% nonfat milk in 50 mM Tris / 150 mM NaCl / 0.1% Tween-20 (TBS-T) for 30 min. The membrane was incubated with the following primary antibodies (HRP-conjugated anti-Flag (Cell Signaling, Cat#2044) diluted 1:1000 in 5% BSA in TBS-T overnight; anti-GAPDH (Cell Signaling, clone 14C10) diluted 1:5000 in 5% milk in TBS-T for 30 min; anti-ASCL1 (Santa Cruz, clone sc-48449) diluted 1:500 in 5% BSA; or anti-g-globin (Santa Cruz, clone 51-7) diluted 1:500 in 5% milk) and the membrane was washed with TBS-T. The primary antibody-labeled membrane was incubated with anti-rabbit HRP-conjugated antibody (Sigma-Aldrich) diluted 1:5000 for 30 min, or anti-goat antibody (1:3000), or anti-mouse antibody (1:5000) and further washed with TBS-T for 30 min. Immun-Star Western C TM Membranes were visualized using a kit (Bio-Rad) and ChemiDoc TM Images were captured using the XRS+ System and processed using ImageLab software (Bio-Rad).

[0097] ELISASerum-free culture medium (OPTI-MEM) was collected and frozen at -80°C. Human IL-1ra secretion into the culture medium was quantified by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's protocol (R&D Systems, Cat. No. DY280). Recombinant human IL-1ra was diluted in OPTI-MEM to prepare a standard curve, and IL-1ra in the culture medium was measured undiluted. Samples were concentrated approximately 8-fold by centrifugation through 3 kDa MWCO filters (Amicon Ultra, Cat # UFC500396) for 20 min. Reported values ​​were corrected for the concentration factor of each sample. Optical density was measured at 450 nm (wavelength corrected at 540 nm). Each standard and sample was assayed in duplicate. Duplicate readings were averaged and normalized by subtracting the optical density of the mean zero standard. Standard curves were generated by log-transforming the data and performing linear regression of IL-1ra concentration versus optical density. Values ​​reported are the mean and standard error of the mean from three separate experiments (n=3) performed on different days with technical duplication and averaged for each experiment. qRT-PCR Total RNA was isolated using the RNeasy Plus RNA isolation kit (Qiagen). cDNA synthesis was performed using SuperScript™ VILO TM A cDNA synthesis kit (Invitrogen) was used for the analysis. Real-time PCR using PerfeCTa™ SYBR™ Green FastMix was performed with a CFX96 Real-time PCR Detection System (Bio-Rad) using the oligonucleotide primers reported in Table 3. The primers were designed using Primer3Plus software and purchased from IDT.

[0098] [Table 3] The specificity of the primers was confirmed by agarose gel electrophoresis and melting curves. Reaction efficiencies over an appropriate dynamic range were calculated to ensure linearity of the standard curve (Figure 10). The results were TThe methods are expressed as fold increase in mRNA expression of the gene of interest normalized to GAPDH expression. Values ​​reported are the mean and standard error of the mean of three separate experiments (n=3) performed on different days with technically identical results and averaged for each experiment.

[0099] RNA-seq : Constructing an RNA-seq library. Briefly, first-strand cDNA was synthesized from oligo-dT Dynabead™-captured mRNA using the SuperScript™ VILO™ cDNA Synthesis Kit (Invitrogen). The second strand was synthesized using DNA polymerase I (New England Biolabs). The cDNA was purified using Agencourt AMPure XP beads (Beckman Coulter) and the cDNA was simultaneously fragmented using Nextera transporase (Illumina; 55°C for 5 min) to insert a sequencing primer into the double-stranded cDNA. The transfer reaction was stopped using QG buffer (Qiagen) and the fragmented cDNA was purified on AMPure XP beads. Indexed sequencing libraries were generated by 6-cycle PCR. Libraries were sequenced using 50bp single-end reads on a dual-lane Illumina HiSeq 2000 instrument, generating 29-74 million reads per library. Reads were aligned to human RefSeq transcripts using Bowtie (Langmeade et al. Genome biology 10, R25, 2009). Statistical significance of differential expression (including correction for multivariate hypothesis testing) was calculated using DESeq (Anders et al. Genome biology 11, R106, 2010). Raw RNA-seq reads and the number of aligned reads to each RefSeq transcript have been submitted for public access to Gene Expression Omnibus (GEO) (accession numbers are currently being adjusted).

[0100] Immunofluorescence staining For detection of Tuj1 and MAP2 expression, transfected MEFs were fixed at room temperature (RT) for 20 min on day 10 of culture in N3 medium containing 4% PFA (EMS, Hatfield, PA). Cells were then incubated with rabbit anti-Tuj1 (Covance, Princeton, New Jersey, clone TUJ1 1-15-79, 1:500) or mouse anti-MAP2 (BD, clone Ap20, 1:500) in blocking buffer (containing 0.2% Triton X-100, 3% w / v BSA, and 10% goat serum (Sigma-Aldrich, Saint Louis, MO) for 2 h at room temperature, or with mouse anti-Ascl1 (BD, clone 24B72D11.1, 1:100) for an additional 24 h at 4°C. Cells were then washed three times with PBS and incubated with Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 594 goat anti-rabbit IgG (Invitrogen, 1:200) in blocking buffer for 1 h at room temperature and washed three times with PBS. Stained MEFs were then imaged using a Nikon Eclipse Fluor 488 ELISA kit equipped with a ProScanII motorized stage (Prior Scientific, Rockland, MA). A mosaic image of each complete culture area was generated by scanning with a TE2000-U inverted fluorescence microscope, and these mosaics were processed using a FIJI macro to automatically and uniformly threshold according to local contrast, remove small debris, and count the number of Tuj1+ cells in each well. statistics Statistical analysis was performed by Tukey's test with an alpha equal to 0.05 in JMP 10 Pro.

[0101] [Example 2] result To generate a CRISPR / Cas9-based transcription activation system, the catalytic residues of Cas9 (D10A, H840A) were mutated to generate iCas9, which was further fused to a C-terminal VP64 acidic transactivation domain (Fig. 1a, b). Active iCas9-VP64 expression was observed from the transfected plasmid in human embryonic kidney (HEK) 293T cells by Western blot of the N-terminal Flag epitope tag (Fig. 3). The CRISPR system recognizes its target by base pairing a 20 bp sequence in the gRNA with a complementary DNA target followed by a NGG protospacer adjacent motif (PAM) sequence, where N is any base pair. The combination of synthetic transcription factors targeted to endogenous human promoters results in synergistic and active activation of gene expression. Thus, four gRNAs followed by a NGG PAM sequence were identified in the promoter of the IL1RN gene within 500 bp of the transcription start site (Figure 4, Table 2). To compare the crRNA- and gRNA-based targeting methods, the four target site sequences were inserted into the crRNA and gRNA expression plasmids. 17The gRNAs were introduced into the cells and transfected together with the iCas9-VP64 expression plasmid into HEK293T cells. Substantial induction of IL1RN expression was not observed by qRT-PCR in the crRNA combination-treated samples, whereas much higher levels were achieved with the gRNA combination (Fig. 1c). No changes in gene expression were observed in cells treated with the expression plasmid of iCas9 without gRNA and VP64, indicating the crucial role of the activation domain in regulating gene expression (Fig. 1c). Nuclease activity at these target sites was confirmed to be abolished in the iCas9-VP64 system by performing a surveyor assay, which detects DNA repair events in samples treated with iCas9-VP64 and wild-type Cas9 (Fig. 5). By transfecting each of the four gRNAs individually or together, targeting of a wide variety of sites in the promoter by the gRNA combination showed a strong increase in gene expression (Fig. 1d). High levels of IL1RN expression were observed only when the gRNA combination was co-transfected with iCas9-VP64, as observed for other classes of engineered transcription factors (Fig. 1d). Similarly, production of IL-1 receptor antagonist (IL-1ra) protein, encoded by the IL1RN gene, was only observed in three of six samples treated with the gRNA combination across three separate experiments, but was never detected in samples treated with a single gRNA or a control plasmid (Fig. 1e). To examine the specificity of gene activation by iCas9-VP64, global gene expression was determined by RNA-seq in HEK293T cells treated with the four gRNA combination (Fig. 1f). Notably, only one gene was significantly increased in expression relative to the control (false discovery rate of 3x10 -4 (see below) are the four isoforms expressed from the IL1RN locus (Fig. 4 ), demonstrating a high level of specificity of gene activation.

[0102] To demonstrate the versatility of this system, four gRNAs were designed to target each of the promoters of eight other genes of relevance to medicine and biotechnology, including ASCL1, NANOG, HBG1 / 2, MYOD1, VEGFA, TERT, IL1B, and IL1R2 (Figure 4, Table 2). Forced expression of ASCL1 and MYOD1 results in trans-differentiation of several cell types into neuronal and myogenic phenotypes, respectively. NANOG is a marker of pluripotency, which is also used in genetic reprogramming methods. Activation of the homologs HBG1 and HBG2 (which encode γ-globin during fetal development) can be used as a therapeutic approach against β-globin mutations in sickle cell disease. Upregulation of VEGFA by synthetic transcription factors has been explored as a way to enhance tissue regeneration and wound healing. Forced expression of telomerase (encoded by the TERT gene) can be used to immortalize cell lines. IL1B encodes the IL-1β cytokine, which mediates inflammation and autoimmunity. IL-1β signaling can be blocked by expression of IL-1ra or the decoy receptor (encoded by IL1R2). Expression of each of these genes was enhanced by co-transfection of iCas9-VP64 and expression plasmids for the four gRNAs into HEK293T cells, as determined by qRT-PCR (Figure 2). In some cases, expression of a single gRNA was sufficient to induce gene expression, but in all cases, co-transfection of the four gRNAs resulted in a synergistic effect (Figure 2a-d). Of note, chromatin accessibility, as determined by DNase-seq, was not a predictor of successful gene activation (Figure 4). RNA-seq was performed in cells transfected with iCas9-VP64 and the four gRNAs (targeting HBG1, three of which also target HBG2). This showed a specific and reproducible increase in expression of both HBG1 and HBG2 (indistinguishable by RNA-seq), although statistical significance was not achieved due to low total expression levels (Figure 6).After treatment with iCas9-VP64 and the four gRNAs, increased protein expression of Ascl1 and γ-globin was detected by Western blot (Figure 7), confirming the higher mRNA levels observed by qRT-PCR (Figure 2). Low baseline levels of Ascl1 and γ-globin protein were detectable in the empty vector control. As preliminary evidence that activation of gene targets by iCas9-VP64 can lead to secondary changes in gene networks and cell phenotypes, expression plasmids for iCas9-VP64 and the four gRNAs targeting ASCL1 were co-transfected into murine embryonic fibroblasts (MEFs) (Figure 8). Forced expression of Ascl1 in MEFs was shown to partially activate neuronal gene networks, including the downstream target Tuj1. Since the gRNA target site is conserved in the human and mouse ASCL1 promoters (Figure 8a), activation of ASCL1 expression was also observed in MEFs treated with iCas9-VP64 and the plasmids encoding the four gRNAs (Figure 8b). Furthermore, cells expressing Ascl1 and the neuronal marker Tuj1 were readily detected in iCas9-VP64 / gRNA-treated samples by immunofluorescence 12 days after transfection (Figure 8c-h). No Tuj1-positive cells were observed in control plasmid-treated cells.

[0103] So far, there has been no comprehensive investigation of the specificity of Cas9 / CRISPR activity in mammalian cells. Using RNA-seq, we showed that targeted gene activation was highly specific, with no detectable off-target gene activation (Fig. 1f, Fig. 6). IL1RN and HBG1 / 2 were chosen for this specificity analysis because their gene products (IL-1ra and γ-globin) could not produce secondary effects on gene expression in HEK293T cells. In contrast to the use of only one strong activator, exploiting the synergistic activity of a wide variety of weak transcriptional activators may enhance specific gene regulation, since a wide variety of adjacent off-target sites are less likely to exist at different gene loci. Interestingly, the IL32 gene was moderately downregulated (false discovery rate < 0.03) in both samples treated with iCas9-VP64 and IL1RN-targeted or HBG1 / 2-targeted gRNAs, compared to control samples treated with empty expression plasmid alone (Fig. 1f, Fig. 6). Because both IL1RN-targeted and HBG1 / 2-targeted samples were similarly affected, it is unlikely that this is the result of off-target iCas9-VP64 activity related to the identity of the target sequence. To evaluate the specificity of iCas9-VP64 binding to the genome, ChIP sequencing was performed using anti-HA antibody on cells treated with iCas9-VP64 and four gRNAs targeting the IL1RN promoter. The experiment showed that iCas9 targets the IL1RN promoter (Figure 15). Furthermore, the experiment showed a very high level of specificity (Figure 15). iCas9 had only 10 potential off-target binding sites (FDR<5%). To further investigate the specificity, RNA sequencing experiments were performed on iCas9 EGEM and found that only the IL1RN gene isoform increased expression compared to the control (FDR was 3x10.4 or less).

[0104] [Example 3] CRISPR targeting the dystrophin gene - Materials and Methods Plasmid constructs: Expression cassettes of S. pyogenes sgRNA and human codon-optimized Cas9 (hCas9) nuclease were used as previously described (Perez-Pinera et al., Nat Methods 10:973-976, 2013). To generate a fluorescent reporter system to enrich for CRISPR / Cas9 modified cells, a GeneBlok (IDT) was synthesized and subsequently cloned into the hCas9 expression vector (the GeneBlok contains a portion of the 3' end of the Cas9 coding sequence fused to a T2A skipping peptide immediately upstream of the multiple cloning site). The eGFP reporter gene was then cloned into the T2A vector, allowing the Cas9 and eGFP proteins to be translated together from the same expression vector (hCas9-T2A-GFP, SEQ ID NO:116). Cell culture and transfection HEK293T cells were obtained from the American Tissue and Cell Depository Center (ATCC) via the Duke Cell Culture Facility and maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin. Immortalized myoblasts (Mamchaoui, K. et al. Skelet Muscle 1, 1-11, 2011) (one from a wild-type donor and two from Δ48-50 DMD patients) were maintained in skeletal muscle culture medium (PromoCell) supplemented with the following: 20% fetal bovine serum (Sigma), 50 μg / mL fetuin, 10 ng / mL human epidermal growth factor (Sigma), 1 ng / mL human basement membrane fibroblast growth factor (Sigma), 10 μg / mL human insulin (Sigma), 1% GlutaMAX (Invitrogen), and 1% penicillin / streptomycin (Invitrogen). Primary DMD skin fibroblasts were obtained from the Coriell Cell repository (GM05162A, Δ46-50) and maintained in DMEM supplemented with 10% fetal bovine serum, 1 ng / mL human basement membrane fibroblast growth factor, and 1% penicillin / streptomycin. All cell lines were maintained at 37°C and 5% CO2. HEK293T cells in 24-well plates were transfected with 400 ng of each expression vector using Lipofectamine 2000 (Invirogen) according to the manufacturer's protocol. Immortalized myoblasts and primary fibroblasts were transfected with 5 μg of each expression vector by electroporation using a Gene Pulser XCell (BioRad) with optimized conditions for each line and PBS as electroporation buffer (Figure 1) (Ousterout et al. Mol Ther 21:1718-1726, 2013). Transfection efficiencies were measured by delivery of an eGFP-expressing plasmid (pmaxGFP, Clontech) and the use of flow cytometry. These efficiencies were routinely greater than 95% for HEK293T cells and greater than 70% for primary fibroblasts and immortalized myoblasts. The indicated masses of electroporated plasmids correspond to the amounts used for each CRISPR / Cas9-based system.

[0105] Cel-I quantification of endogenous gene modifications (Surveyor assay) CRISPR / Cas9-based system-induced damage at endogenous target sites was quantified by Surveyor Nuclease Assay (Guschin, DY et al. Meth Mol Biol 649, 247-256, 2010), which can detect mutations characteristic of nuclease-mediated NHEJ. After transfection, cells were incubated at 37°C for 3 to 10 days and genomic DNA was extracted with DNeasy Blood Tissue Kit (Qiagen). Target loci were amplified by 35 cycles of PCR with AccuPrime High Fidelity PCR Kit (Invitrogen). Primers specific for each locus were used, e.g., 5'-GAGTTTGGCTCAAATTGTTACTCTT-3' (SEQ ID NO: 60) and 5'-GGGAAATGGTCTAGGAGAGTAAAGT-3' (SEQ ID NO: 61) (see Table 4).

[0106] [Table 4-1]

[0107] [Table 4-2]

[0108] The resulting PCR products were randomly melted and reannealed in a thermal cycler using the following program: 95°C for 240 s, followed by 85°C for 60 s, 75°C for 60 s, 65°C for 60 s, 55°C for 60 s, 45°C for 60 s, 35°C for 60 s, and 25°C for 60 s (the interstep rate was -0.3°C / s). Following reannealing, 8 μL of PCR products were mixed with 1 μL of Surveyor Nuclease S and 1 μL of Enhancer S (Transgenomic) and incubated at 42°C for 1 h. After incubation, 6 μL of digested products were loaded onto a 10% TBE polyacrylamide gel and run at 200V for 30 min. Gels were stained with ethidium bromide and quantified by densitometry using ImageLab (Bio-Rad) as previously described (Guschin, et al. Meth Mol Biol 649, 247-256, 2010). Fluorescence-activated cell sorting of myoblasts DMD myoblasts were electroporated with 5 micrograms each of hCas9-T2A-GFP and sgRNA expression vectors and incubated at 37°C and 5% CO2. Three days after electroporation, cells were trypsinized and collected for FACS sorting using a FACSvantage II sorter. GFP-positive cells were collected and expanded for analysis. PCR-based assays to detect genomic deletionsThe exon 51 or exon 45-55 locus was amplified from genomic DNA by PCR (Nvitrogen AccuPrime High Fidelity PCR kit) using primers flanking each locus. The flanking primers were CeI-CR1 / 2-F and CeI-CR5-R for exon 51 analysis, or CeI-CR6-F and CeI-CR36-R for exon 45-55 analysis (Table 4). PCR products were separated on TAE agarose gels and stained with ethidium bromide for analysis.

[0109] PCR-based detection of translocations : Loci with predicted possible translocations were amplified by two-step nested PCR (Invitrogen AccuPrime High Fidelity PCR kit for each step) of genomic DNA from cells transfected with Cas9 alone (control) or Cas9 together with sgRNA. In the first step, possible translocations at each on-target and off-target sgRNA target site were amplified by 35 cycles of PCR. A combination of surveyor primers for each locus was used, which were modified to include restriction sites to facilitate cloning and sequencing analysis (Table 4). One microliter of each PCR reaction was subjected to a second round of amplification by 35 cycles of PCR, using nested primer sets custom designed for each individual predicted translocation (Table 4). Each of the second nested PCR primers binds to approximately the same region within the primary amplicon, but each pair was optimized using Primer3 online bioinformatics software to ensure specific detection of each translocation. PCR amplicons that matched the expected length of the predicted translocation and were present only in cells treated with sgRNA were purified (QIAGEN gel extraction kit) and analyzed by Sanger sequencing.

[0110] mRNA analysis: Immortalized myoblasts were differentiated into myofibers by replacing the growth medium with DMEM supplemented with 1% insulin-transferrin-selenium (Invitrogen #51500056) and 1% penicillin / streptomycin (Invitrogen #15140) for 5 days, after which the cells were harvested by trypsin digestion. Total RNA was isolated from the cells using the RNeasy Plus Mini kit (QIAGEN) according to the manufacturer's instructions. RNA was reverse transcribed into cDNA using the VILO cDNA synthesis kit (Life Technologies #11754) and 1.5 micrograms of RNA at 42°C for 2 hours according to the manufacturer's instructions. Target loci were amplified by 35 cycles of PCR using the AccuPrime High Fidelity PCR kit (Invitrogen). Primers annealing to exon 44 and exon 52 were used for detection of exon 51 by CR1 / 5 or CR2 / 5, or primers annealing to exons 44 and 60 were used for detection by CR6 / 36 (Table 4). PCR products were run on TAE agarose gels and stained with ethidium bromide for analysis. Resolved PCR bands were cloned and analyzed by Sanger sequencing to confirm the expected exon junctions. Table 5 lists the primer sequences used in Example 4.

[0111] [Table 5-1]

[0112] [Table 5-2]

[0113] [Table 5-3]

[0114] [Table 5-4]

[0115] Western blot analysis : To determine dystrophin protein expression, immortalized myoblasts were differentiated into myofibers by replacing the growth medium with DMEM supplemented with 1% insulin-transferrin-selenium (Invitrogen) and 1% antibiotic / antimycotic (Invitrogen) for 4-7 days (e.g., 6 or 7 days). Fibroblasts were transdifferentiated by inducing MyoD overexpression and further incubating the cells with DMEM supplemented with 1% insulin-transferrin-selenium (Invitrogen), 1% antibiotic / antimycotic (Invitrogen) and 3 μg / mL doxycycline for 15 days. Dystrophin expression was determined 3 days after transfection of HEK293T cells. Cells were harvested by trypsin digestion and lysed in RIPA buffer (Sigma) supplemented with protease inhibitor cocktail (Sigma). Total protein was quantified using the bicinchoninic acid assay according to the manufacturer's instructions (Pierce). Samples were then mixed with NuPAGE loading buffer (Invitrogen) and 5% β-mercaptoethanol and heated at 85°C for 10 minutes. Twenty-five micrograms of protein were separated on a 4-12% NuPAGE Bis-Tris gel (Invitrogen) using MES buffer (Invirogen). Proteins were transferred to nitrocellulose membranes for 1-2 hours in transfer buffer containing 10-20% methanol (e.g., 10% methanol) and 0.01% SDS. Blots were then blocked with 5% milk-TBST for 1 hour at room temperature. Blots were probed with the following primary antibodies: MANDYS8 (1:100, Sigma D8168) for dystrophin detection and rabbit anti-GAPDH (1:5000, Cell Signaling 2118S). Blots were then incubated with mouse or rabbit horseradish peroxidase-conjugated secondary antibodies (Santa Cruz) and visualized using the ChemiDoc chemiluminescence system (BioRad) and Western-C ECL substrate (BioRad). Transplantation into immunodeficient miceAll animal experiments were performed according to protocols approved by the Duke Institutional Animal Care & Use Committee. Cells were harvested by trypsin digestion and washed with 1x Hank's Buffered Salt Solution (HBBS, Sigma). Two million cells were pelleted and resuspended in 5 μL of 1x HBBS (Sigma) supplemented with cardiotoxin (Sigma #C9759) immediately prior to injection. The cells were implanted into the hindlimb tibialis anterior muscle of NOD.SCID.gamma (NSG) mice (Duke CCIF Breeding Core) by intramuscular injection. Four weeks after injection, mice were euthanized and TA muscles were harvested.

[0116] Immunofluorescence staining: Harvested TA muscles were incubated in 30% glycerol overnight at 4°C, then mounted and frozen in OCT compound (Optimal Cutting Temperature compound). Serial 10-micron sections were obtained by freeze-splitting the embedded muscle tissue at -20°C. Cryosections were then washed with PBS to remove the OCT compound, and subsequently blocked at room temperature for 30-60 min in PBS containing 10% heat-inactivated fetal bovine serum for spectrin detection, or PBS containing 5% heat-inactivated fetal bovine serum for dystrophin detection. Cryosections were incubated overnight at 4°C with the following primary antibodies specific only to human epitopes: anti-spectrin (1:20, Leica NCL-SPEC1) or anti-dystrophin (1:2, Leica NCL-DYS3). After primary staining, spectrin or dystrophin expression was detected using a tyramide-based immunofluorescence signal amplification detection kit (Life Technologies, TSA Kit #22, Catalog #T-20932). Briefly, cryosections were incubated with goat anti-mouse biotin-XX secondary antibody (Life Technologies #B2763) at 1:200 in blocking buffer for 1 h at room temperature. The signal was then amplified with streptavidin-HRP conjugate (1:100, TSA kit) in blocking buffer for 1 h at room temperature. Finally, cryosections were incubated with tyramide-AlexaFluor488 conjugate (1:100, TSA kit) in the amplification buffer provided by the manufacturer for 10 min at room temperature. Stained cryosections were then mounted in ProLong AntiFade (Life Technologies #P36934) and visualized under a conventional fluorescent microscope. Cytotoxicity assayTo quantitatively determine potential sgRNA or SpCas9 nuclease-associated cytotoxicity, HEK293T cells were transfected with 10 ng of GFP reporter and 100 ng of SpCas9 expression vector and 100 ng of sgRNA expression vector using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). The percentage of GFP-positive cells was determined by flow cytometry on days 2 and 5. Viability was calculated as the decrease in GFP-positive cells from day 2 to day 5 and normalized to cells transfected with an empty nuclease expression vector as described (Cornu et al., Meth Mol Biol 649:237-245, 2010).

[0117] [Example 3] CRISPR Targeting Dystrophy Genes - Results A CRISPR / Cas9-based system was designed to target the dystrophin gene. Various gRNAs were selected based on NNNNN NNNNN NNNNN NNNNN NGG and GNNNN NNNNN NNNNN NNNNN NGG to target different regions of the human and mouse dystrophin genes (see Tables 6, 7, and 8).

[0118] [Table 6-1]

[0119] [Table 6-2]

[0120] [Table 7]

[0121] [Table 8]

[0122] In particular, 400 ng of Cas9 was co-transfected into HEK293T cells with 400 ng of empty vector or gRNA targeting the region encompassing exon 51 (i.e., CR1, CR2, CR3, CR4 and CR5) (see FIG. 11(b)). Genomic DNA was harvested two days after transfection and analyzed using the Surveyor assay (see FIG. 11(a) and FIG. 11(c)). The CRISPR / Cas9-based system was used in DMD8036(del48-50) cells to determine whether the system could repair the mutant dystrophin gene. 5 μg of Cas9 was co-transfected with 7.5 μg of empty vector or gRNA into DMD8036(del48-50) cells. In particular, 7.5 μg of CR1 ("DCR1"), 7.5 μg of CR5 ("DCR5"), 15 μg of CR3 ("DCR3"), or a combination of 7.5 μg of CR1 and CR5 (DCR1+DCR5) were used. Genomic DNA was collected 3 days after transfection and analyzed using a surveyor assay (Figure 12) or PCR analysis across the entire locus (Figure 13). The locus was amplified by PCR. Using primers flanking the regions containing the genomic targets for CR1 and CR5 (forward primer: 5'-gagaggttatgtggctttacca (SEQ ID NO: 457), reverse primer: 5'-ctgcgtagtgccaaaacaaa (SEQ ID NO: 458)), the expected size of a 1447 bp band for the wild type locus or approximately 630 bp for the deletion locus was obtained. After 7 days of differentiation, a Western blot of treated cells shows expression of dystrophin protein (see Figure 14).

[0123] [Example 5] Targeting CRISPR / Cas9 to hotspots in the human dystrophin gene To utilize the CRISPR / Cas9 gene editing platform to correct a wide range of dystrophin mutations, we generated multiple sgRNAs targeted to the hotspot mutation region between exons 45-55 (Figure 16). We used a S. pyogenes system that utilizes human codon-optimized SpCas9 nuclease and a chimeric single guide RNA (gRNA) to guide efficient site-specific gene editing. Similar to the TALEN targeting of exon 51 in Example 4, protospacers were selected to target the 5' and 3' ends of exons 45 to 55 (which meet the 5'-NRG-3' PAM requirement of SpCas9). Small insertions or deletions caused by NHEJ-based DNA repair within these exons can generate targeted frameshift mutations, which correspond to the diverse dystrophin mutations surrounding each exon (Figures 16A-16B). For example, CR3 was designed to correct dystrophin mutations or deletions around exon 51 by introducing small insertions or deletions at the 5' end of exon 51 to restore the downstream dystrophin reading frame (Figure 16B). In addition, sgRNAs exploited the multiplexing capabilities of the CRISPR / Cas9 system, as well as the method of oligonucleotide-based exon skipping, to further specifically delete individual exons or sets of exons to restore the dystrophin reading frame. To this end, sgRNAs targeted the intronic regions surrounding exon 51 (Figure 16C) or exons 45-55 (Figure 16D). These sgRNAs were purposefully targeted to the sites closest to the downstream or upstream exons intended to be included in the resulting transcript, minimizing the probability that background patient deletions would include the intronic sgRNA target site.

[0124] [Example 6] Screening for sgRNAs targeting the dystrophin gene in human cells Gene editing frequencies in human HEK293T cells were determined to rapidly determine the targeting efficiency of different sgRNAs. HEK293T cells were transfected with constructs encoding human codon-optimized SpCas9 and the indicated sgRNAs. Each sgRNA was designed to modify the dystrophin gene as indicated. Gene modification frequencies were determined by Surveyor assay at 3 or 10 days post-transfection. The ratio of the measured Surveyor signals at 3 and 10 days was calculated to quantify the stability of gene editing for each sgRNA in human cells. As quantified by Surveyor assay at 3 days post-transfection, 29 / 32 (~90%) of the tested sgRNAs were able to mediate highly efficient gene modification at the intended locus (Table 9, Figure 17). Gene editing was stable for almost all sgRNAs (signal change less than 25% from day 3 to day 10, Table 9, Figure 18), indicating that gene editing mediated by each individual sgRNA was well tolerated. A notable exception was CR33, which showed no detectable activity at day 10 (although activity was likely below the sensitivity of the Surveyor assay (estimated ∼1%)).

[0125] [Table 9]

[0126] [Example 7] Enrichment of gene-edited cells using a fluorescence-based reporter system We selected sgRNAs to correct specific mutations in myoblast cell lines from DMD patients. Unexpectedly, low or undetectable gene modification activity was observed after transfection of DMD myoblasts as measured by the Surveyor assay (Figure 19C, mixed population). Flow cytometry was used to sort transfected cells that co-expressed GFP via the 2A ribosome skipping peptide linked to the SpCas9 protein (Figure 19A). The addition of this fluorescent reporter to the SpCas9 expression vector did not appear to significantly affect gene editing activity in HEK293T cells (Figure 19B). Despite the high transfection efficiency of the control GFP-expressing plasmid (typically over 70%, Figure 19D, pmaxGFP), a low percentage of transfected myoblasts (~0.5-2%) expressed the fluorescent reporter 3 days after electroporation. Given the high levels of CRISPR / Cas9 activity in easily transfectable HEK293T cells, inefficient transgene expression after electroporation of SpCas9-T2A-GFP and sgRNA constructs into DMD cells could explain the low gene editing efficiency observed in unsorted cells. After sorting of GFP-positive DMD myoblasts, a substantial increase in detectable activity was observed at most sgRNA-targeted loci (Figure 19C). Therefore, all subsequent experiments used cells sorted for SpCas9 expression by expression of this fluorescent reporter.

[0127] [Example 8] Dystrophin gene restoration by targeted frameshifting Small insertions and deletions generated by NHEJ DNA repair can be used to generate target-induced frameshifts to correct the aberrant reading frame. The sgRNA, CR3, was designed to correct the reading frame of dystrophin by introducing small insertions and deletions within exon 51 (Figures 16B, 20A). The types of insertions and deletions generated by CRISPR / Cas9 at this locus were determined by Sanger sequencing of alleles derived from genomic DNA of HEK293T cells co-transfected with expression plasmids for SpCas9 and CR3 sgRNA (Figure 20B). Notably, the insertions and deletions resulted in conversions to all three reading frames (Figures 20B, 20C). To demonstrate gene correction in relevant patient cell lines, expression plasmids for SpCas9 and CR3 sgRNA were electroporated into a DMD myoblast cell line carrying a deletion of exons 48-50, which can be corrected by generating a frameshift in exon 51. Treated cells were selected to demonstrate gene modification activity by surveyor assay (CR3, Fig. 19C sorted population) and further differentiated into myotubes to test for restoration of dystrophin expression. Expression of dystrophin protein was observed concomitant with detectable nuclease activity (Fig. 20D). The S. pyogenes CRISPR / Cas9 system provides a powerful method to rapidly generate targeted frameshifts and restore expression of the human dystrophin gene in response to diverse patient mutations.

[0128] [Example 9] Combined CRISPR / Cas9 gene editing mediates exon 51 deletion and restores dystrophin protein expression The combined capabilities of the CRISPR / Cas9 system provide a novel method to efficiently generate unique exon gene deletions for targeted correction. DMD patient myoblasts with background deletions that can be corrected by exon 51 skipping were treated with two combinations of sgRNAs flanking exon 51 (CR1 / CR5 or CR2 / CR5) and sorted to enrich for gene-edited cells as in Figure 19. As detected by end-point PCR of genomic DNA from these treated cells, the expected genomic deletion was only present when both sgRNAs were electroporated into cells with SpCas9 (Figure 21A). Sanger sequencing confirmed the expected linkage of distal chromosomal segments for both deletions (Figure 21B). After differentiation of sorted myoblasts, deletion of exon 51 from mRNA transcripts was only detected in cells treated with both sgRNAs (Figure 21C). Finally, restoration of dystrophin protein expression was detected in treated cells, concomitant with the observation of genomic and mRNA deletion of exon 51 (FIG. 21D).

[0129] [Example 10] Restoration of dystrophin by large multi-exon genomic deletions Although addressing patient-specific mutations is a powerful application of the CRISPR / Cas9 system, it would be beneficial to develop a single method that can address a large number of common patient deletions. For example, a promising method is the removal of the entire region of exons 45-55 as a way to correct up to 62% of known patient deletions. Combined CRISPR / Cas9-based gene editing was tested to determine whether it could have the capacity to generate an efficient deletion of exons 45-55 in human cells. After transfection into HEK239T cells, the predicted deletion of ~336,000 bp was detected by PCR of genomic DNA (Figure 22A). Similarly, this deletion was detected by PCR of genomic DNA of SpCas9 / sgRNA-treated cells of DMD patients carrying a background deletion of unknown length of exons 48-50 (Figure 22A). Sanger sequencing of this deletion band from genomic DNA of treated DMD cells revealed the expected junction of intron 44 and intron 55 immediately adjacent to the sgRNA target site (Figure 22B). After differentiation of treated DMD, the expected deletion of exons 45-55 was detected in the dystrophin mRNA transcript and confirmed as a fusion of exons 44 and 56 by Sanger sequencing (Figure 22C). Restored protein expression was observed by Western blot in sorted cell populations (containing CRISPR / Cas9-induced deletion of exons 45-55 from the genome and the resulting mRNA transcripts) (Figure 22D). These data indicate that combined CRISPR / Cas9 editing provides a universal single method to restore the dystrophin reading frame in more than 60% of DMD patient mutations.

[0130] [Example 11] Transplantation of corrected myoblasts into immunodeficient mice A promising approach for the treatment of DMD is to correct a patient's own muscle progenitor cell population, which can be transplanted into the patient's skeletal muscle to restore dystrophin expression. To demonstrate the in vivo expression capacity of corrected cells, DMD myoblast populations treated with sgRNAs CR1 and CR5 (flanking exon 51) were transplanted as before and sorted for GFP expression (Figure 19, Figure 23). After 4 weeks, human spectrin (expressed in both corrected and uncorrected cells) positive myofibers were detected in frozen sections of injected mouse tissue (Figure 24). Many of these fibers were also positive for human dystrophin, which is expressed and localized to the sarcolemma, indicating functional gene correction in these cells (Figure 24, Figure 25). No human dystrophin positive fibers were observed in sections of mice injected with untreated DMD myoblasts (Figure 24, Figure 25), indicating that the CRISPR / Cas9 modified cells are the source of human dystrophin expression.

[0131] [Example 12] Off-target and cytotoxic activity A flow cytometry-based GFP retention assay was applied to determine the relative cytotoxicity of the CRISPR / Cas9 system in human cells for selected sgRNAs as previously described (Ousterout et al., Mol Ther 21:1718-1726, 2013). Minimal cytotoxicity was observed for SpCas9 expressed with or without sgRNA after transfection of human cells (Figure 26A). A publicly available tool is available to assess and rank potential CRISPR / Cas9 activity at off-targets based on the expected positional bias of certain mismatches in the sgRNA protospacer sequence and the total number of mismatches with the intended target site (Hsu et al., Nat Biotechnol 31:827-826, 2013). This public web server was used to predict the most likely off-target sites for the sgRNA used to correct the dystrophin gene in this experiment (Table 4). The top 10 off-target sites were determined by Surveyor assay in HEK293T cells treated with SPCas9 and individual sgRNA expression cassettes for CR1, CR3, CR5, CR6, or CR36. CR1, CR3, and CR36 have one of these 10 predicted off-target loci, which show significant levels of genetic modification (Table 4 and Figure 27). Interestingly, the CR3 off-target sequence had substantial homology to the intended on-target and a similar modification frequency (13.3% at the intended site versus 9.3% at OT-1) (Table 4 and Figure 27). Notably, CR3-OT1 was the only one of these three off-targets to show significant levels of activity in the Surveyor assay-screened hDMD cells (Figure 26B). Nuclease activity at off-target sites can cause unintended chromosomal rearrangements by distal religation between the cleaved target and off-target loci on separate chromosomes. This raises significant concerns for deletion-based gene correction methods due to the increased potential off-target activity by using two or more nucleases (e.g., in combined CRISPR / Cas9 gene editing). Potential translocations were probed using a highly sensitive nested genomic PCR assay to detect translocations at established off-target loci in both single CRISPR / Cas9 and combined CRISPR / Cas9 editing methods. Using this assay, translocations were readily detected between on-target and off-target sites in a model HEK293T cell line, which also shows high levels of off-target activity (Figure 26C and Figures 28A, 28B). Sanger sequencing of PCR amplicons confirmed the identity of the expected translocation events for each primer pair (Figures 29-30). A subset of translocations detected in HEK293T cells were also detectable by nested PCR in selected hDMD myoblasts, although the signal was significantly weaker and sequence identity was not confirmed due to low product yields (Figure 26D and Figures 28A, 28C). Translocations were not detected using this assay in HEK293T cells or selected hDMD cells treated with CR6 or CR6 / CR36, respectively (Figure 28), which had low levels of off-target activity with CR6-OT3 only in HEK293T cells (Table 4). These results highlight the importance of selecting highly specific sgRNAs (especially for complex editing applications) and indicate that this approach could benefit from ongoing efforts to improve the specificity of the CRISPR / Cas9 system. These data suggest that the selected sgRNAs have the ability to correct the dystrophin gene without significant toxicity and with only one clearly predicted off-target site with detectable levels of activity.

[0132] [Example 13] Consideration Genome editing is a powerful tool to correct genetic diseases, and the recent development of the CRISPR / Cas9 system has progressed at a dramatic rate in this field. We have presented a correction for DMD, the most common genetic disease with no approved treatment options currently. With many gene- and cell-based therapies for DMD in preclinical development and clinical trials, genome editing methods can be compatible with many of these approaches. For example, genome editing can be combined with cell-based therapeutic approaches for patient-specific DMD. The CRISPR / Cas9 system can function in human pluripotent stem cells and other human cell lines, as well as in human skeletal myoblasts, as presented. Importantly, gene editing with CRISPR / Cas9 does not halt the myogenic potential of these cells, as shown by efficient dystrophin expression in vitro and in vivo after transplantation into immunodeficient mice. Thus, this approach should be compatible with cell-based therapeutic approaches for DMD. In addition, enriched pools of gene-corrected cells showed human dystrophin expression in vivo following transplantation into immunodeficient mice. CRISPR / Cas9 gene editing does not have any notable deleterious effects in human myoblasts as observed by the stable gene editing frequency and minimal cytotoxicity of some sgRNAs. However, gene editing activity was confirmed at 3 of 50 predicted off-target sites across five sgRNAs, and CRISPR / Cas9-induced chromosomal translocations between on-target and off-target sites could be detected. CRISPR / Cas9 technology is an efficient and versatile method to correct a significant portion of dystrophin mutations and can serve as a versatile platform for genetic disease therapy. In addition, in contrast to the plasmid-based delivery method used herein, direct transfection of sgRNA and Cas9 mRNA can be used to increase specificity and safety by shortening the duration of Cas9 expression and by eliminating the possibility of random plasmid integration. Alternatively, direct delivery of the CRISPR / Cas9 system to skeletal and / or cardiac muscle by virus, plasmid or RNA delivery vectors can be used for in vivo genome editing and adaptation of this approach. The large size (~4.2 kilobases) of the S. pyogenes Cas9 gene presents a challenge for its use in size-limited adeno-associated virus vectors. However, Cas9 genes from other species (e.g., Neisseria meningitidis and S. thermophilus) are short enough to efficiently package both Cas9 and sgRNA expression cassettes into one AAV vector for in vivo gene editing applications.

[0133] The CRISPR / Cas9 system allows for efficient modification of nearly 90% of the tested targets, consistent with other reports of robust activity of this system at diverse loci. The power and versatility of this technology represents a major advancement toward flexible implementation of patient-specific gene editing. Low levels of dystrophin (including as little as 4% wild-type expression) may be sufficient to improve survival, motor function, and myocardial function in mouse models. This level of CRISPR / Cas9 activity may be sufficient for therapeutic benefit. The use of combined CRISPR / Cas9 for exon deletion also offers a unique combination of opportunities and challenges. In contrast to repairing the reading frame of the dystrophin gene with small indels generated by the action of a single nuclease followed by NHEJ-based DNA repair, deletion of a complete exon of the genome was performed to restore dystrophin expression. In contrast to the protein product of the edited gene, which can be predicted and is already characterized in Becker muscular dystrophy patients with naturally occurring deletions, random indels generated by the action of a single nuclease within an exon will result in the generation of novel epitopes derived from each DNA repair event. Furthermore, the product resulting from exon deletion will result in restored dystrophin for every successful gene editing, whereas modification of the gene with random indels within an exon will only restore the correct reading frame in one-third of the editing events that result in the correct reading frame. Not all sgRNAs tested were associated with significant cytotoxic effects in human cells. Three potential off-target sites were identified to restore dystrophin expression out of a total of 50 sites examined for the five sgRNAs used. Furthermore, chromosomal translocations between the intended on-target site and these off-target sites were detectable by a highly sensitive nested PCR assay in HEK293T cells expressing high levels of Cas9 and sgRNA. Of note, the off-target activity and translocations identified in HEK293T cells (an immortalized aneuploid cell line expressing very high levels of Cas9 and sgRNA) did not occur at high levels and were undetectable in some cases in hDMD myoblasts. Importantly, this level of specificity may be acceptable given the severity of DMD and the lack of obvious cytotoxicity in human cells.

[0134] [Example 14] An engineered AAV capsid, designated SASTG (SEQ ID NOs: 436 and 437), was developed for enhanced cardiac and skeletal muscle tissue tropism (Piacentino et al. (2012) Human Gene Therapy 23:635-646). ZFNs targeting the Rosa26 locus ("Rosa26 ZFN", FIG. 33; SEQ ID NOs: 434 and 435) were shown to be highly active in mouse cells (Perez-Pinera et al. Nucleic Acids Research (2012) 40:3741-3752). An AAV-SASTG vector encoding the Rosa26 ZFN protein was designed and subsequently generated and further purified by the UNC Viral Vector Core. Using the Surveyor assay (Guschin et al., Methods Mol Biol 649, 247-256, 2010), we demonstrated NHEJ mutagenesis at the Rosa26 locus following delivery of AAV-SASTG Rosa26 ZFN in cultured C2C12 myoblasts (which were undergoing active cell cycling or forced differentiation by serum withdrawal) (data not shown). To demonstrate that adult postmitotic skeletal muscle is targeted by Rosa26 ZFNs following AAV transduction, AAV-SASTG vectors encoding Rosa26 ZFNs were directly injected into the tibialis anterior muscle of 6-week-old C57BL6 / J mice at titers of 1e10 vector genomes (vg) or 2.5e10 vg / muscle. Four weeks after injection, mice were sacrificed and TA muscles were harvested and separated into several fragments for genomic DNA extraction and analysis (Figure 31). Genomic DNA was PCR amplified and subjected to Surveyor assays to detect NHEJ mutations characteristic of ZFN mutagenesis at the Rosa26 target site (Figure 32). Figure 32 shows Surveyor analysis of Rosa26 ZFN activity in vitro and in vivo in skeletal muscle following delivery of AAV-SASTG-ROSA. Proliferating C2C12 were transduced with the indicated amounts of virus and harvested 4 days post-infection (Figure 32a). C2C12 were incubated in differentiation medium for 5 days and subsequently transduced in 24-well plates with the indicated amount of AAV-SASTG-ROSA virus (Fig. 32b). Samples were collected 10 days after transduction. The indicated amount of AAV-SASTG-ROSA was directly injected into the tibialis anterior muscle of C57BL6 / J mice, and the muscles were harvested 4 weeks after infection. The harvested TA muscles were divided into eight separate strips (each shown in a separate lane) for genomic DNA analysis (Fig. 32c). Notably, high levels of gene modification were detected in all fragments at the highest dose (2.5e10vg).

[0135] [Example 15] AAV-CRISPR constructs targeting the mutant dystrophin gene AAV constructs were designed for therapeutic correction of the dystrophin gene, which causes Duchenne muscular dystrophy and degeneration of skeletal and cardiac muscles. AAV can be used to deliver a CRISPR / Cas9 system to restore the dystrophin reading frame by deleting exon 51, deleting exons 45-55, disrupting splice donor or acceptor sites, or generating a frameshift within exon 51 (Ousterout et al., Molecular Therapy 2013), restoring the dystrophin reading frame and protein expression. The CRISPR / Cas9 system will include a Cas9 with the sequence of SEQ ID NO: 64 or 114 (see Figures 40 and 41). gRNAs (targeting their corresponding PAM sequences) that can be combined with these Cas9s are provided (see Figures 40 and 41, also see Tables 2 and 3).

[0136] [Example 16] Generation of induced neurons (iNs) Generating induced neurons (iNs) from other cell lineages has potential applications in regenerative medicine and neurological disease research. Direct conversion of mouse embryonic fibroblasts (MEFs) into functional neuronal cells can occur by delivery of a cocktail of three neuronal transcription factors (BRN2, ASCL1 and MYT1L) (BAM factors, Figure 48). Other methods can include additional factors to induce diverse subtypes. These experiments require ectopic delivery of transcription factors and activation of endogenous loci corresponding to maintenance of neuronal phenotype. We engineered the CRISPR / Cas9 system as a versatile transcription factor to activate endogenous genes in mammalian cells, with the ability to target any promoter in the genome by an RNA-guided mechanism (Figures 49A, 49B). Materials and Methods Using CRISPR / Cas9 transcription factors, we activated the endogenous genes encoding ASCL1 and BRN2 to directly reprogram MEFs into functional induced neurons. cell culture: MEFs were seeded on 24-well TCPS plates or poly-D-lysine / laminin-coated coverslips. Following dCas9-VP64 transduction and gRNA transfection (see Tables 10 and 11 for gRNA sequences), cells were cultured in MEF medium (Adler et al. Mol Ther Nucleic Acids 1:e32, 2012) for 24 hours and then transferred to N3 neural induction medium (Vierbuchen et al. Nature 463:1035-1041 (2010) for the duration of the experiment (Figure 49B).

[0137] [Table 10]

[0138] [Table 11]

[0139] qRT-PCR and IF Activation of endogenous ASCL1 was determined by qRT-PCR and immunofluorescence of MEFs (day 3 after delivery of dCas9-VP64 and gRNA, ASCL1 cDNA or a negative control encoding luciferase). iN development was assessed by co-staining for TUJ1 and MAP2 and identification of cells with neuronal morphology and extended processes. Live cell reporters After 7-8 days in :N3 medium, MEFs cultured on poly-D-lysine / laminin-coated coverslips were transduced with viruses carrying the hSyn-REP and MAP2-GCamP5 reporters, and the most mature iNs were identified for functional characteristics by calcium imaging and electrophysiology (Figure 49B). resultdCas9-VP64 and gRNAs (targeting the ASCL1 promoter) activated endogenous genes in MEFs. Co-delivery of eight gRNAs activated endogenous genes 400-fold, a significant increase over the 100-fold activation induced by co-delivery of four gRNAs (p<0.05). Nuclear-localized Ascl1 protein was detected by immunofluorescence in MEFs. Ectopic Ascl1 expression produced more Ascl1 protein than dCas9-VP64 in conjunction with either gRNA cocktail, but did not activate the endogenous locus by day 3 (Figure 50A, 50B). TUJ1 and MAP2 co-positive cells with elongated processes were identified after 13 days in neurogenesis cultures following delivery of dCas9-VP64 and ASCL1 and BRN2 promoter-targeting gRNAs (Figure 4A, first row). Similar numbers of TUJ1 and MAP2 co-positive cells were identified with ectopic expression of BAM factors (Figure 51A, second row). Cells with neuronal-like morphology expressing the hSyn-RFP reporter could be seen as early as day 11 in culture in neurogenic medium (Figure 51B). Cells expressing the MAP2-GCaMP5 calcium indicator showed KCl-induced depolarization detected by fluorescence microscopy (Figures 52A, 52B). Direct conversion of mouse embryonic fibroblasts into TUJ1 and MAP2 co-positive cells with neuronal-like morphology was achieved through activation of endogenous BRN2 and ASCL1 by CRISPR / Cas9-based transcription factors. Although dCas9-VP64 produces less protein than ectopic expression of ASCL1 (Figure 50B), the development of neuronal-like cells is similar. Activation of endogenous loci can induce a reprogramming cascade of events that are not mechanistically identical to those produced by ectopic expression. dCas9-VP64 was able to penetrate heterochromatin and activate stably silent endogenous genes (a feature of only a subset of "pioneer" transcription factors). As a result, conversion of cell lineages with CRISPR / Cas9 transcription factors overcomes epigenetic barriers to reprogramming better than ectopic expression of transcription factors, especially in difficult-to-reprogram cell types (e.g., adult cells). This could be clinically important in the field of regenerative medicine, since the use of autologous sources is often desired in cell replacement therapies.

[0140] [Example 17] Combined CRISPR / Cas9-based genome editing - Materials and methods Plasmid constructs Expression cassettes for S. pyogenes sgRNA and human codon-optimized Cas9 (hCas9) were used as described above. The following additional promoters were synthesized using GeneBlock (IDT) (mU6 (Ohshima et al., Nucleic Acids Res 9:5145-5158, 1981), H1 (Myslinski et al., Nucleic Acids Res 29:2502-2509, 2001), and 7SK (Murphy et al., Cell 51:81-87, 1987) pol-III promoters) and cloned in place of the hU6 sgRNA expression cassette. GeneBlock (IDT) was cloned at the 3' end of the Cas9 coding sequence and fused to the T2A skipping peptide and eGFP genes immediately after Cas9 to monitor the expression of the vector. The coding region for hCas9-T2A-GFP (SEQ ID NO: 145) was then transferred to a lentiviral expression vector that contained the human Ubiquitin C (hUbC) promoter driving expression of hCas9-T2A-GFP and a restriction site immediately upstream of the hUbc promoter to facilitate Golden Gate cloning of the sgRNA expression cassette (Figure 42A). Custom Lentiviral Vector Assembly ProtocolAssembly of custom lentiviral vectors expressing up to four selected sgRNAs and active Cas9, dCas9, or dCas9-VP64 was accomplished in less than five days. The cloning method utilized Golden Gate cloning and type IIS restriction enzymes, which cut outside their recognition sequences to create unique overhangs. Golden Gate assembly facilitated cloning as all four expression cassettes were ligated into the final lentiviral vector in one step. Lentiviral vectors expressed active Cas9, cCas9, or dCas9-VP64 in addition to one, two, three, or four sgRNAs (expressed from independent promoters).

[0141] Process 1: Single-stranded oligos, each containing a 20 bp protospacer, were annealed in a manner that produced sticky ends and ligated to the desired pZDonor-promoter vector. Order two single-stranded oligos for each desired genomic target. To anneal complementary oligos, mix: 8 μL sense oligo + 8 μL antisense oligo (both at 10 mM) + 2 μL 10x ligase buffer. The oligos were melted and reannealed in a PCR machine according to the following program: 96°C for 300 seconds, followed by 85°C for 20 seconds, 75°C for 20 seconds, 65°C for 20 seconds, 55°C for 20 seconds, 45°C for 20 seconds, 35°C for 20 seconds, and 25°C for 20 seconds (the speed between steps is -0.3°C / sec). For phosphorylation of sticky ends, 1 μL of 25 mM ATP + 1 microliter of T4 polynucleotide kinase (NEB) was added and incubated at 37°C for 60 min, followed by heat inactivation of the enzyme at 65°C for 20 min. Each protospacer was ligated to the desired expression vector using T4 DNA ligase (NEB) with incubation at 16°C for 60 min (50 ng of vector and 1 μL of annealed oligonucleotides were used in a 10 μL reaction volume according to the manufacturer's instructions). Five microliters of each ligation was transformed into XL1 Blue chemically competent bacteria (Agilent) according to the manufacturer's instructions. Transformations were plated on LB agar plates (containing 50 μg / mL kanamycin (Sigma)) and incubated overnight at 37°C. In our experience, more than 90% of the colonies will contain the desired ligation product. Sequencing using M13 reverse standard sequencing primer was performed to verify each of the final sgRNA constructs before moving to step 2.

[0142] Step 2: Construction of four promoter-gRNA cassettes into a lentiviral destination vector using Golden Gate assembly: After completion of step 1, there will be four independent plasmids, each expressing a different sgRNA from a different promoter. To assemble the four different promoter-sgRNA constructs into the desired destination vector, 200 ng of each sgRNA expression plasmid and the desired lentiviral destination vector are mixed in a 20 μL reaction volume with 1 μL T4 DNA ligase (NEB), 1 μL BsmBI FastDigest (Fisher Scientific), and 2 μL 10xT4 ligase buffer (NEB). The reactions are incubated as follows: 10 min at 37°C, 15 min at 16°C, 30 min at 37°C, and 5 min at 80°C. 5 μL of the ligation reaction is transformed into SURE2 chemically competent cells (Agilent) according to the manufacturer's instructions. The transformations are plated on LB agar plates (containing 100 μg / mL ampicillin) and incubated overnight at 37°C. Optionally, colonies may be screened by lacZ-based blue / white screening using IPTG and X-gal, but in our experience, over 90% of transformants contain the correct ligation product. Due to the inverted repeats formed by the opposing sgRNA expression cassettes, the final construct is unstable, therefore we recommend maintaining these plasmids in the SURE2 cell line and screening the final plasmids with a sense primer (5'-TCGGGTTTATTACAGGGACAGCAG-3' (SEQ ID NO: 464)) and an antisense primer (5'-TCTAAGGCCGAGTCTTATGAGCAG-3' (SEQ ID NO: 465)). These primers amplify across the four promoter-gRNA regions. Due to its repetitive nature, distinct banding patterns should be observed with a maximum product of approximately 1800 bp in size.

[0143] Cell culture and transfectionHEK293T cells were obtained from the American Tissue and Cell Depository Center (ATCC, Manassas, VA) through the Duke University Cancer Center facility and maintained in DMEM supplemented with 10% FBS and 1% penicillin / streptomycin. Primary human dermal fibroblasts (catalog ID: GM03348) were obtained from the Coriell Institute (Camden, New Jersey) and maintained in DMEM supplemented with 10% FBS and 1% penicillin / streptomycin. All cells were cultured at 37°C and 5% CO2. HEK293T cells were transfected with 200 ng of each sgRNA expression cassette (800 ng total pDNA) using Lipofectin 2000 (Life Technologies) in 24-well plates according to the manufacturer's instructions. Virus production and transduction : All lentiviral vectors used in this experiment were second generation and produced using standard virus production methods. Briefly, 3.5 million HEK293T cells were plated per 10 cm dish. The following day, cells were transfected with 20 μg of transfer vector, 6 μg of pMD2G and 10 μg of psPAX2 by calcium phosphate transfection method. The culture medium was changed 12-14 hours after transfection. The viral supernatant was collected 24 and 48 hours after the medium change, filtered through a 0.45 micron filter and pooled. For transduction, the cell culture medium was replaced with viral supernatant (supplemented with 4 μg / mL polybrene). The viral supernatant was replaced with fresh culture medium 12-24 hours later. Reverse transcription PCRRNA was isolated using the miRNeasy Mini RNA Isolation Kit (Qiagen). DNase digestion was performed using a DNA-free kit (Applied Biosystems). cDNA synthesis was performed using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). cDNA was amplified using Taq DNA polymerase (NEB) and the resulting products were run on a TAE agarose gel. Images were captured using a ChemiDoc XRS+ System and processed using ImageLab software (Bio-Rad).

[0144] Quantitative real-time PCR RNA was isolated using the RNeasy Plus RNA Isolation Kit (Qiagen). cDNA synthesis was performed using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). Real-time PCR with PerfeCTa SYBR Green FastMix (Quanta Biosciences) was performed on a CFX96 Real-Time PCR Detection System (Bio-Rad). Primer specificity was confirmed by agarose gel electrophoresis and melting curve analysis. Reaction efficiencies over the appropriate dynamic range were calculated to ensure linearity of standard curves. Results are expressed as fold increase in mRNA expression of the gene of interest normalized to β-actin expression using the ΔΔCt method. Values ​​reported are the mean and SEM from two separate experiments (n=2), where technical replicates were averaged for each experiment. Western blotCells were lysed with RIPA buffer (Sigma) supplemented with protease cocktail (Sigma). Protein concentrations were measured using BCA protein assay reagent (Thermo Scientific) and a BioTek Synergy 2 Multi-Mode microplate reader. Lysates were mixed with loading buffer and boiled for 5 min, and 25 μg of protein was run on a NuPage 10% Bis-Tris Gel polyacrylamide gel (Bio-Rad) and transferred to a nitrocellulose membrane. Nonspecific antibody binding was blocked with TBST (50 mM Tris, 150 mM NaCl, and 0.1% Tween-20) containing 5% nonfat milk for 1 h at room temperature. The membrane was incubated with the following primary antibodies: anti-Myogenin (Santa Cruz Sc-32758) at 1:250 in 5% BSA, overnight at 4°C in TBST; anti-FLAF-HRP (Cell Signaling 2044) at 1:1000 in 5% milk, 60 min at room temperature in TBST; anti-GAPDH (Santa Cruz Sc-32758) at 1:5000 in 5% milk, 30 min at room temperature in TBST. The membrane was then washed three times with TBST for a total of 15 min. The membrane was incubated with anti-rabbit HRP-conjugated antibody (Sigma, A6154) or anti-mouse HRP-conjugated antibody (Santa Cruz, SC-2005) (diluted 1:5000) and washed three times with TBS (15 min each time). Immun-Star WesternC TM Membranes were visualized using a chemiluminescence kit (Bio-Rad) and ChemiDoc TM Images were captured using the XRS+ System and processed using ImageLab software (Bio-Rad).

[0145] Cel-I quantification of endogenous gene modificationsCRISPR / Cas9 nuclease damage at endogenous target sites was quantified using the Surveyor assay, which can detect mutations characteristic of nuclease-mediated NHEJ. After transfection or transduction, cells were incubated at 37°C for 3 to 10 days and genomic DNA was extracted with the DNeasy Blood Tissue Kit (Qiagen). Target loci were amplified by 35 cycles of PCR with the AccuPrime High Fidelity PCR Kit (Invitrogen). The resulting PCR products were randomly melted and reannealed in a PCR machine using the following program: 95°C for 240 seconds, followed by 85°C for 60 seconds, 75°C for 60 seconds, 65°C for 60 seconds, 55°C for 60 seconds, 45°C for 60 seconds, 35°C for 60 seconds, and 25°C for 60 seconds (step-to-step speed of -0.3°C / s). Following reannealing, 8 μL of PCR product was mixed with 1 μL Surveyor Nuclease S and 1 μL Enhancer S (Transgenomic) and incubated for 1 h at 42°C. After incubation, 6 μL of digestion product was loaded onto a 10% TBE polyacrylamide gel and run at 200 V for 30 min. Gels were stained with ethidium bromide and quantified by densitometry using ImageLab (Bio-Rad) (Perez-Pinera et al., Nucleic Acids Res 40:3741-3751, 2012). Statistical analysis: Means and standard errors of the mean from at least two separate experiments were compiled. Effects were evaluated by multivariate ANOVA and Dunnett's post-hoc test using JMP10Pro.

[0146] [Example 18] Development of a single lentiviral vector for multiple CRISPR / Cas9 applications A limitation of the conventional CRISPR / Cas9 gene editing system (especially the transactivator system) is the simultaneous and efficient delivery of the wide variety of sgRNAs and Cas9 proteins used in complex gene editing and synergistic gene activation, especially in difficult-to-transfect cell types. To overcome this limitation, we developed a single lentiviral vector that efficiently expresses Cas9 and up to four sgRNAs. To maximize the expression efficiency of each sgRNA, this vector expresses four sgRNAs from four independent pol III promoters (human U6 promoter, mouse U6 promoter, 7SK, and H1). We verified that sgRNAs were expressed from each promoter by detecting sgRNAs targeting the AAVS1 locus using end-point RT-PCR (Figure 42A). To test the activity of each sgRNA expression construct, we co-transfected each promoter construct independently expressing sgRNAs targeting AAVS1 with an active Cas9 expression construct into human HEK293T cells. Notably, we detected consistent and high levels of genetic modification at the target locus for each sgRNA, comparable to well-characterized zinc finger nucleases with high activity at the AAVS1 locus (Figure 42B). Furthermore, lentiviral delivery of various Cas9-based constructs, including active Cas9 nuclease, dead Cas9, and dead Cas9 fused to the VP64 transactivation domain, resulted in expression of full-length Cas9 protein in HEK293T cells, as determined by Western blot (Figure 42C).

[0147] Using these components, we developed the Golden Gate cloning method to facilitate rapid and efficient cloning of a wide variety of sgRNA expression cassettes into a single lentiviral vector expressing the desired Cas9 effector (Figure 43). In the first step, oligonucleotides encoding sgRNA protospacer sequences are cloned separately into various expression vectors (each with a distinct promoter driving sgRNA expression). In the second step, each sgRNA expression construct is subcloned by Golden Gate assembly into a lentiviral Cas9 expression vector of choice. This method allows robust and rapid cloning of up to four sgRNAs into a single lentiviral vector for use in gene editing or gene activation. To express fewer than four sgRNAs, a poly-T terminator sequence is cloned downstream of the unused promoter to prevent transcription from the unused promoter. Each vector co-expresses the selected Cas9 with eGFP via a 2A skipping peptide, allowing for fluorescence-activated flow sorting and enrichment of cells with high infection numbers. Finally, the entire region containing the sgRNA and Cas9 expression cassette is flanked by loxP sites to mediate removal by Cre-lox excision.

[0148] [Example 19] A single lentiviral sgRNA / Cas9 expression vector demonstrates efficacy for complex genome engineering To demonstrate the independent activity of each sgRNA, we assembled a single lentiviral vector expressing active Cas9 and four sgRNAs, each targeting a distinct locus (Figure 44A). As a control vector, we assembled a construct expressing only one sgRNA with a poly-T protospacer at the other three positions. We transduced HEK293T cells and primary fibroblasts with lentiviruses expressing the indicated sgRNAs and monitored gene modification frequencies 7 or 10 days after transduction, respectively (Figure 44b). In both cell types, the single lentiviral vector mediated highly efficient composite gene editing at all four loci (Figure 44B). Interestingly, in three out of four loci in fibroblasts, expression of all four sgRNAs together resulted in higher modification frequencies than a single sgRNA alone (Figure 44B). We observed efficient composite gene editing in fibroblasts, a cell type that is generally difficult to transfect. These data indicate that a single lentivirus efficiently expresses four active sgRNAs and that using this lentiviral platform, four separate loci can be targeted for composite CRISPR / Cas9 gene editing.

[0149] [Example 20] Transient RNA-guided gene activation in cell lines stably expressing a lentiviral Cas9-based transactivator Next, we were interested in developing a system that would allow transient gene activation by transfecting sgRNAs into model cell lines stably expressing Cas9. HEK293T were transduced with different Cas9-T2A-GFPs and GFP expression was monitored using flow cytometry. After normal passaging every 2-3 days, each cell line showed stable GFP expression up to 35 days after transduction. Transduced HEK293T were subsequently transfected with one to four separate sgRNA expression constructs (targeting either the IL1RN or HBG1 promoter). Transient transfection of these sgRNA constructs in stable dCas9-VP64 expressing cell lines resulted in tunable endogenous gene activation (Figure 45A, 45B). Gene activation following transient transfection of sgRNA constructs in cell lines expressing dCas9-VP64 reached maximal activation levels at approximately 3-6 days post-transfection and dropped to undetectable levels by 20 days post-transfection (Figures 45C, 45D). Furthermore, we were able to reactivate each gene by a second transfection of all four sgRNAs targeting each promoter, although the activation levels were significantly lower than those observed in the first transfection (Figures 45C, 45D). The reduced activity after the second transfection may be due to reduced expression of the vector or competitive growth of non-transduced cells. Nevertheless, these data indicate that lentiviral Cas9 combined with transient sgRNA delivery can be used as a universal system to regulatably and transiently activate and reactivate target genes in cell lines stably transduced with Cas9.

[0150] [Example 21] Stable gene activation in HEK293T cells using a single lentiviral sgRNA / Cas9 transactivator expression vector Lentiviral delivery may enable stable and long-term gene activation by CRISPR / Cas9 transactivation. To test this, we transduced HEK293T with a single lentiviral vector encoding dCas9-VP64 and one to four sgRNA expression cassettes. Similar to our transient transfection results (Figure 45), we were able to regulatably and robustly activate the expression of endogenous IL1RN and HBG1 genes (Figures 46A, 46B). Gene activation induced by co-transfection of HEK293T cells with dCas9-VP64 and four sgRNAs (targeting the IL1RN and HBG1 promoters) peaked 3-5 days after transfection, and gene expression returned to background levels 15-20 days after transfection (Figure 4c). In contrast, lentiviral delivery of dCas9-VP64 and the same four IL1RN- or HBG1-targeting sgRNAs induced gene activation that lasted longer than 20 days after transduction (Figure 46C, 46D). Thus, single lentiviral delivery of the composite dCas9-VP64 transactivator is a useful platform for efficiently and stably upregulating target endogenous genes.

[0151] [Example 22] dCas9-KRAB targeting the HS2 enhancer The HS2 enhancer is a well-characterized distal regulatory element required for activation of the globin locus. dCas9-KRAB was delivered with gRNAs targeting the HS2 enhancer to determine whether this system represses γ-, ε-, and β-globin expression in K562 human erythroid leukemia cell line (Figure 54). A set of gRNAs was generated that targets various sites along with the core region of the HS2 enhancer (SEQ ID NO: 467). See Table 12.

[0152] [Table 12]

[0153] Screening of single gRNAs at globin loci by CRISPR / Cas9 : dCas9 and dCas9-KRAB effectors were delivered by lentivirus 5-8 days before electroporation of 5 μg of plasmid encoding U6-sgRNA expression (Figure 55A). Cells without gRNA electroporation (no gRNA) and cells treated with gRNA targeting different loci (IL1RN) were included as controls. A wide variety of gRNAs showed strong repression of ε-, γ-, and β-globin genes when assayed 3 days after transfection, achieving up to 80% knockdown (Figures 55B, 55C, 55D). Gene expression of the globin locus was repressed by expressing gRNA together with dCas9 or dCas9-KRAB. Overall, treatment with dCas9-KRAB resulted in stronger repression for a given gRNA compared to dCas9 alone, suggesting a critical role for the KRAB domain in recruiting heterochromatin factors to enhance repression. The level of suppression achieved depends on the amount of gRNA plasmid delivered by transfection only in dCas9-KRAB treated cells (Figures 56A, 56B, 56C). Increasing the dose of Cr4 gRNA plasmid to 10 μg increases the level of globin gene silencing in dCas9-KRAB treated cells. Stable silencing of globin genes by dCas9-KRAB: dCas9 / dCas9-KRAB was co-expressed in K562 with a single gRNA by lentivirus (Figure 57A). Cells not treated with lentivirus (NT), cells treated with dCas9 / dCas9-KRAB without gRNA (no gRNA), and cells treated with dCas9 / dCas9-KRAB and gRNA targeting a different locus (IL1RN) were included as controls. Lentivirus-treated cells were selected from 4 to 7 days. A wide variety of gRNAs showed strong transcriptional repression of ε-, γ-, and β-globin genes when assayed 7 days after transduction, achieving up to 95% knockdown (Figures 57B, 57C, 57D). Expression of ε-globin was most strongly silenced in response to gRNA targeting the HS2 enhancer. Treatment with gRNA and dCas9-KRAB resulted in dramatically stronger repression than treatment with dCas9 and gRNA. These findings indicate that dCas9-KRAB targeted to the HS2 enhancer by gRNA achieves potent repression of the distal globin gene. This is the first example of epigenetic targeted control of a distal regulatory element by the CRISPR / Cas9 system in mammalian cells. Enhancers regulate development and disease, and this disclosure provides a method to probe and control enhancer function, which can be used to determine the ability of dCas9-KRAB to access chromatin at specific locations and its effect on genome-wide expression.

[0154] [Example 23] dCas9-p300 A dCas9-p300 fusion protein was designed and compared to a dCas9-VP64 fusion protein (see Figure 59). The amino acid construct of the dCas9 structure is shown in Figures 61A-61C. Human embryonic kidney tissue culture line HEK293T (ATCC; CRL-11268) was seeded one day prior to transfection (using Lipofectamine 2000 transfection reagent (Life Technologies)) in 24-well tissue culture dishes at a density of 1.5e5 cells / well. After 24 hours, cells were transfected with 1 μL Lipofectamine 2000, 375 ng of dCas9 expression constructs (dCas9, dCas9VP64, or dCas9p300, respectively), and 125 ng of pooled gRNA expression plasmids (four of each in an equimolar ratio). Table 13 shows information about the gRNAs.

[0155] [Table 13]

[0156] Cells were harvested 3 days after transfection and assayed for mRNA expression by RT-PCR. RT-PCR primer sequences are shown in Table 14.

[0157] [Table 14]

[0158] RT-QPCR was normalized to GAPDH expression using the ΔΔC1 method. Results are expressed as the fold increase in expression of the gene of interest relative to cells treated with Lipofectamine alone without DNA transfection ("NO DNA") (Figures 60A-60C). Figure 62 shows that mutating residues in the p300 HAT domain abolishes its ability to activate gene expression. Figure 63 shows that a wide variety of gRNAs function synergistically with dCas9-p300, as shown with dCas9-VP64.

[0159] [Example 24] Figure 66 shows that TALENs mediate mini-dystrophin integration into the 5'UTR of the Dp427m skeletal isoform of dystrophin in skeletal myoblasts from human DMD patients carrying various deletions in the dystrophin gene. Constructs encoding TALEN pairs active at the 5'UTR locus and donor templates carrying mini-dystrophin genes were transfected into DMD patient cells. Figure 66(a) shows a schematic diagram of how mini-dystrophin was integrated into the 5'UTR. Figure 66(b) shows the isolation of hygromycin-resistant clonal cell lines and screening by PCR for successful site-specific integration in the 5'UTR using the primers shown in Figure 66(a). The star indicates the clone selected for further analysis in Figure 66(c). Figure 66(c) shows that clonally isolated DMD myoblasts with detected integration events were differentiated for 6 days and evaluated for expression of the HA tag fused to the C-terminus of mini-dystrophin.

[0160] It is understood that the foregoing detailed description and the accompanying examples are merely illustrative and should not be taken as limiting the scope of the invention, the scope of which is determined solely by the appended claims and their equivalents. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications (including, but not limited to, with respect to chemical structure, substituents, derivatives, intermediates, synthesis, compositions, formulations, or methods of using the invention) can be made without departing from the spirit and scope of the invention. Addendum

[0161] JPEG2025062594000021.jpg242170

[0162] TIFF2025062594000022.tif224152 TIFF2025062594000023.tif81152

[0163] TIFF2025062594000024.tif34170

[0164] TIFF2025062594000025.tif213150

Claims

1. A fusion protein comprising two heterologous polypeptide domains, wherein a first polypeptide domain comprises an assembled regularly interspaced short palindromic repeats-associated (Cas) protein and a second polypeptide domain has an activity selected from the group consisting of transcriptional activator activity, transcriptional repressor activity, transcription deactivator activity, histone modifying activity, nuclease activity, nucleic acid binding activity, methylase activity, and demethylase activity.

2. The fusion protein of claim 1 , wherein the Cas protein comprises Cas9.

3. The fusion protein of claim 2, wherein Cas9 comprises at least one amino acid mutation that knocks out the nuclease activity of Cas9.

4. The fusion protein of claim 3, wherein the at least one amino acid mutation is at least one of D10A and H840A.

5. The fusion protein of claim 3 or 4, wherein the Cas9 protein comprises iCas9 (amino acids 36-1403 of SEQ ID NO:1).

6. The fusion protein according to any one of claims 1 to 5, wherein the second polypeptide domain has transcription activation activity.

7. The fusion protein of claim 6 , wherein the second polypeptide domain comprises at least one VP16 transcriptional activation domain repeat.

8. The fusion protein of claim 7 , wherein the second polypeptide domain comprises a VP16 tetramer ("VP64") or a p65 activation domain.

9. 9. The fusion protein of claim 1, further comprising a linker connecting the first polypeptide domain to the second polypeptide domain.

10. The fusion protein of any one of claims 1 to 9, wherein the fusion protein comprises iCas9-VP64.

11. A DNA targeting system comprising a fusion protein according to any one of claims 1 to 10 and at least one guide RNA (gRNA).

12. The DNA targeting system of claim 11, wherein the at least one gRNA comprises a 12-22 base pair complementary polynucleotide sequence of the target DNA sequence followed by a protospacer adjacent motif.

13. The DNA targeting system of claim 11 or 12, wherein the at least one gRNA targets a promoter region of a gene, an enhancer region of a gene, or a transcribed region of a gene.

14. The DNA targeting system of claim 13, wherein the at least one gRNA targets an intron of a gene.

15. The DNA targeting system of claim 13, wherein the at least one gRNA targets an exon of a gene.

16. The DNA targeting system of claim 11 or 12, wherein the at least one gRNA targets a promoter region of a gene selected from the group consisting of ASCL1, BRN2, MYT1L, NANOG, VEGFA, TERT, IL1B, IL1R2, IL1RN, HBG1, HBG2 and MYOD1.

17. The DNA targeting system of any one of claims 10 to 16, wherein the at least one gRNA comprises at least one of SEQ ID NOs: 5-40, 65-144, 492-515, 540-563 and 585-625.

18. A DNA targeting system comprising Cas9 and at least one guide RNA (gRNA) that binds to the dystrophin gene.

19. The DNA targeting system of claim 18, wherein the at least one gRNA targets an intron of the dystrophin gene.

20. The DNA targeting system of claim 18, wherein the at least one gRNA targets an exon of the dystrophin gene.

21. The DNA targeting system of claim 18, wherein the at least one guide RNA comprises at least one of SEQ ID NOs: 5-40, 65-144, 492-515, 540-563 and 585-625.

22. 22. A DNA targeting system described in any one of claims 11 to 21, comprising 1 to 10 different gRNAs.

23. 23. An isolated polynucleotide encoding a fusion protein according to any one of claims 1 to 10 or a DNA targeting system according to any one of claims 11 to 22.

24. A vector comprising the isolated polynucleotide of claim 23.

25. 25. A cell comprising the isolated polynucleotide of claim 23 or the vector of claim 24.

26. A method for regulating mammalian gene expression in a cell, the method comprising the step of contacting the cell with a fusion protein described in any one of claims 1 to 10, a DNA targeting system described in claims 11 to 22, an isolated polynucleotide described in claim 23, or a vector described in claim 24.

27. 27. The method of claim 26, wherein the gene expression is induced.

28. A method for transdifferentiating a cell or inducing differentiation of a cell, the method comprising the step of contacting a cell with a fusion protein described in any one of claims 1 to 10, a DNA targeting system described in any one of claims 11 to 17, an isolated polynucleotide described in claim 23, or a vector described in claim 24.

29. 29. The method of claim 28, wherein the cell is a fibroblast or an induced pluripotent stem cell.

30. 30. The method of claim 29, wherein the fibroblasts are transdifferentiated into neuronal or myogenic cells.

31. The method of any one of claims 28 to 30, wherein the DNA targeting system of any one of claims 11 to 20 is contacted with a cell, and at least one gRNA targets the promoter region of at least one gene selected from the group consisting of ASCL1, BRN2, MYOD1 and MYT1L.

32. The method of claim 31 , wherein the DNA targeting system comprises at least one gRNA targeting the promoter region of the ASCL1 gene and at least one gRNA targeting the promoter region of the BRN2 gene.

33. The method of claim 31 or 32, wherein the DNA targeting system comprises 1 to 20 different gRNAs.

34. The method of claim 33, wherein the DNA targeting system comprises 8 to 16 different gRNAs.

35. The method of any one of claims 28 to 34, wherein the DNA targeting system comprises dCas9-VP64.

36. 36. The method of any one of claims 28 to 35, wherein the DNA targeting system is delivered to the cell virally or non-virally.

37. 25. A method for correcting a mutated gene in a cell, the method comprising administering to a cell a DNA targeting system described in any one of claims 11 to 22, an isolated polynucleotide described in claim 23 or a vector described in claim 24.

38. 38. The method of claim 37, wherein correction of the mutated gene comprises homology-directed repair.

39. 40. The method of claim 38, further comprising administering donor DNA to the cell.

40. 38. The method of claim 37, wherein the mutated gene comprises a frameshift mutation resulting in a premature stop codon and a truncated gene product.

41. 41. The method of claim 40, wherein correction of the mutated gene comprises nuclease-mediated non-homologous end joining.

42. 38. The method of claim 37, wherein the correction of the mutated gene comprises deletion of a premature stop codon, disruption of a splice acceptor site, deletion of one or more exons, or disruption of a splice donor sequence.

43. 43. The method of claim 42, wherein the deletion of one or more exons results in a corrected reading frame.

44. A method for treating a subject animal carrying a mutant dystrophin gene in need thereof, the method comprising administering to the subject animal a DNA targeting system described in any one of claims 11 to 22, an isolated polynucleotide described in claim 23, or a vector described in claim 24.

45. 45. The method of claim 44, wherein the subject animal is afflicted with Duchenne muscular dystrophy.

46. 27. A method for correcting a mutated dystrophin gene in a cell, the method comprising the step of administering to a cell containing a mutated dystrophin gene a DNA targeting system described in any one of claims 18 to 22, an isolated polynucleotide described in claim 23, a vector described in claim 24, or a cell described in claim 25.

47. 47. The method of claim 46, wherein the mutated dystrophin gene contains a premature stop codon, a disrupted reading frame due to a gene defect, an aberrant splice acceptor site, or an aberrant splice donor site, and the target region is located upstream or downstream of the premature stop codon, disrupted reading frame, aberrant splice acceptor site, or aberrant splice donor site.

48. 47. The method of claim 46, wherein the correction of the mutant dystrophin gene comprises homology directed repair.

49. 49. The method of claim 48, further comprising administering donor DNA to the cell.

50. 47. The method of claim 46, wherein the mutated dystrophin gene contains a frameshift mutation resulting in a premature stop codon and a truncated gene product.

51. 51. The method of claim 50, wherein correcting the mutant dystrophin gene comprises nuclease-mediated non-homologous end joining.

52. 47. The method of claim 46, wherein correcting the mutant dystrophin gene comprises deleting a premature stop codon, correcting a disrupted reading frame, or modulating splicing by disrupting a splice acceptor site or disrupting a splice donor sequence.

53. 53. The method of claim 52, wherein the correction of the mutant dystrophin gene comprises a deletion of exons 45-55 or exon 51.

54. A kit comprising a fusion protein according to any one of claims 1 to 10, a DNA targeting system according to claims 11 to 22, an isolated polynucleotide according to claim 23, a vector according to claim 24, or a cell according to claim 25.

55. 11. A method for regulating mammalian gene expression in a cell, comprising contacting the cell with a polynucleotide encoding a DNA targeting system, the DNA targeting system comprising a fusion protein according to any one of claims 1 to 10 and at least one guide RNA (gRNA).

56. The method of claim 55, wherein the DNA targeting system comprises 1 to 10 different gRNAs.

57. 57. The method of claim 56, wherein the different gRNAs bind to different regions within the target gene.

58. 58. The method of claim 57, wherein the target regions are separated by at least one nucleotide.

59. 58. The method of claim 57, wherein the target regions are separated by about 15 to about 700 base pairs.

60. 57. The method of Claim 56, wherein each of the different gRNAs binds to at least one different target gene.

61. 61. The method of claim 60, wherein the different target genes are located on the same chromosome.

62. 61. The method of claim 60, wherein the different target genes are located on different chromosomes.

63. 63. The method of any one of claims 55 to 62, wherein at least one target region is present within a non-open chromatin region, an open chromatin region, a promoter region of a target gene, an enhancer region of a target gene, a transcribed region of a target gene, or an upstream region of a transcription start site of a target gene.

64. 63. The method of any one of claims 55 to 62, wherein at least one target region is located about 1 to about 1000 base pairs upstream of the transcription start site of the target gene.

65. 63. The method of any one of claims 55 to 62, wherein at least one target region is located from about 1 to about 600 base pairs upstream of the transcription start site of the target gene.

66. 63. The method of any one of claims 55 to 62, wherein the gene expression is induced.

67. 63. The method of any one of claims 55 to 62, wherein the DNA targeting system comprises 2 different gRNAs, 3 different gRNAs, 4 different gRNAs, 5 different gRNAs, 6 different gRNAs, 7 different gRNAs, 8 different gRNAs, 9 different gRNAs, or 10 different gRNAs.

68. 63. The method of any one of claims 55 to 62, wherein at least one guide RNA targets a promoter region of a gene selected from the group consisting of ASCL1, BRN2, MYT1L, NANOG, VEGFA, TERT, IL1B, IL1R2, IL1RN, HBG1, HBG2 and MYOD1.

69. 69. The method of any one of claims 55 to 68, wherein at least one guide RNA comprises at least one of SEQ ID NOs: 5-40, 65-144, 492-515, 540-563 and 585-625.

70. 66. The method of any one of claims 55 to 65, wherein at least one target region is present within an intron or exon of the target gene.

71. 11. A composition for inducing mammalian gene expression in a cell, comprising a fusion protein according to any one of claims 1 to 10 and at least one guide RNA (gRNA).

72. 11. A composition for inducing mammalian gene expression in a cell, comprising an isolated polynucleotide sequence encoding a fusion protein according to any one of claims 1 to 10 and at least one guide RNA (gRNA).

73. 73. The composition of claim 71 or 72, wherein at least one guide RNA targets a promoter region of a gene selected from the group consisting of ASCL1, BRN2, MYT1L, NANOG, VEGFA, TERT, IL1B, IL1R2, IL1RN, HBG1, HBG2 and MYOD1.

74. 73. The composition of claim 71 or 72, wherein the at least one guide RNA comprises at least one of SEQ ID NOs: 5-40, 65-144, 492-515, 540-563 and 585-625.

75. 75. A cell comprising the composition of any one of claims 71 to 74.

76. 75. A kit comprising a composition according to any one of claims 71 to 74 or a cell according to claim 74.

77. 76. A kit for inducing mammalian gene expression in a cell, comprising a composition according to any one of claims 71 to 74 or a cell according to claim 75.

78. A composition for genome editing in the muscle of a target animal, comprising a modified adeno-associated virus (AAV) vector and a nucleotide sequence encoding a site-specific nuclease, wherein the muscle is a skeletal muscle or cardiac muscle.

79. The composition of claim 78, wherein the modified AAV vector has enhanced tropism for cardiac and skeletal muscle tissue.

80. The composition of claim 78 or 79, wherein the site-specific nuclease comprises a zinc finger nuclease, a TAL effector nuclease, or a CRISPR / Cas9 system.

81. 81. The composition of any one of claims 78 to 80, wherein the site-specific nuclease binds to a gene or locus in a muscle cell.

82. 82. The composition of claim 81 , wherein the gene or locus is the dystrophin gene.

83. 83. The composition of any of claims 78 to 82, further comprising donor DNA or a transgene.

84. 84. A method for genome editing in a muscle of a subject animal, comprising administering a composition described in any one of claims 78 to 83 to the muscle, wherein the muscle is a skeletal muscle or a cardiac muscle.

85. 85. The method of claim 84, wherein the genome editing comprises correction of a mutated gene or insertion of a transgene.

86. 86. The method of claim 85, wherein correction of the heterologous gene comprises a deletion, rearrangement or replacement of the mutated gene.

87. 87. The method of any one of claims 85 or 86, wherein correction of the heterogeneous gene comprises nuclease-mediated non-homologous end joining or homology-directed repair.

88. 84. A method of treating a subject animal, comprising administering a composition described in any one of claims 78 to 83 to a muscle of the subject animal, wherein the muscle is a skeletal muscle or a cardiac muscle.

89. 89. The method of claim 88, wherein the subject animal suffers from a skeletal muscle condition or genetic disease.

90. 90. The method of claim 89, wherein the subject animal is afflicted with Duchenne muscular dystrophy.

91. 84. A method for correcting a mutant gene in a subject animal, comprising administering a composition described in any one of claims 78 to 83 to a muscle of the subject animal, wherein the muscle is a skeletal muscle or a cardiac muscle.

92. 92. The method of any one of claims 84 to 91, wherein the composition is injected into a skeletal muscle of the subject animal.

93. 92. The method of any one of claims 84 to 91, wherein the composition is injected systemically into the subject animal.

94. 93. The method of claim 92, wherein the skeletal muscle is the tibialis anterior muscle.

95. 84. A kit comprising the composition of any one of claims 78 to 83.

96. A modified lentiviral vector for genome editing in a subject animal, comprising a first polynucleotide sequence encoding a fusion protein described in any one of claims 1 to 10 and a second polynucleotide sequence encoding at least one sgRNA.

97. The modified lentiviral vector of claim 96, wherein the first polynucleotide sequence is operably linked to a first promoter.

98. The modified lentiviral vector of claim 97, wherein the first promoter is a constitutive promoter, an inducible promoter, a repressible promoter, or a regulatable promoter.

99. The modified lentiviral vector of any one of claims 96 to 98, wherein the second polynucleotide sequence encodes 1 to 10 different sgRNAs.

100. The modified lentiviral vector of any one of claims 96 to 99, wherein the second polynucleotide sequence encodes two different sgRNAs, three different sgRNAs, four different sgRNAs, five different sgRNAs, six different sgRNAs, seven different sgRNAs, eight different sgRNAs, nine different sgRNAs, or ten different sgRNAs.

101. The modified lentiviral vector of claim 100, wherein each of the polynucleotide sequences encoding the different sgRNAs is operably linked to a promoter.

102. The modified lentiviral vector of claim 101, wherein each of the promoters operably linked to different sgRNAs is the same promoter.

103. The modified lentiviral vector of claim 101, wherein each of the promoters operably linked to different sgRNAs is a different promoter.

104. The modified lentiviral vector of claim 101, wherein the promoter is a constitutive promoter, an inducible promoter, a repressible promoter, or a regulatable promoter.

105. A modified lentiviral vector described in any one of claims 95 to 103, wherein the sgRNA binds to a target gene.

106. The modified lentiviral vector of claim 105, wherein each of the sgRNAs binds to a different target region within a single target locus.

107. The modified lentiviral vector of claim 105, wherein each of the sgRNAs binds to a different target within a different locus.

108. The modified lentiviral vector of claim 105, wherein the fusion protein comprises a Cas9 protein or an iCas9-VP64 protein.

109. The modified lentiviral vector of claim 105, wherein the fusion protein comprises a VP64 domain, a p300 domain or a KRAB domain.

110. The modified lentiviral vector of claim 108, wherein two or more endogenous genes are transcriptionally activated.

111. The modified lentiviral vector of claim 108, wherein two or more endogenous genes are suppressed.

112. A method for activating an endogenous gene in a cell, the method comprising contacting the cell with a modified lentiviral vector described in any one of claims 96 to 111.

113. The method of claim 112, wherein the endogenous gene is transiently activated.

114. The method of claim 112, wherein the endogenous gene is stably activated.

115. The method of claim 112, wherein the endogenous gene is transiently suppressed.

116. The method of claim 112, wherein the endogenous gene is stably suppressed.

117. The method of claim 112, wherein the fusion protein is expressed at a similar level as the sgRNA.

118. The method of claim 112, wherein the fusion protein is expressed at a different level than the sgRNA.

119. 113. The method of claim 112, wherein the cell is a primary human cell.

120. A method of complex gene editing in a cell, comprising contacting the cell with a modified lentiviral vector described in any one of claims 96 to 107.

121. 121. The method of claim 120, wherein the complex gene editing comprises correction of at least one mutated gene or insertion of a transgene.

122. 122. The method of any one of claims 120 or 121, wherein the correction of the mutated gene comprises a deletion, rearrangement or replacement of at least one mutated gene.

123. 122. The method of any one of claims 120 or 121, wherein correction of the at least one mutated gene comprises nuclease-mediated non-homologous end joining or homology-directed repair.

124. 121. The method of Claim 120, wherein the compound gene editing comprises a deletion of at least one gene, said gene being an endogenous normal gene or a mutated gene.

125. The method of claim 124, wherein the composite gene editing comprises deletion of at least two genes.

126. The method of claim 124, wherein the complex gene editing comprises deletion of between 2 and 10 genes.

127. A method for modulating gene expression of at least one target gene in a cell, the method comprising contacting the cell with a modified lentiviral vector described in any one of claims 96 to 107.

128. 128. The method of claim 127, wherein gene expression of at least two genes is modulated.

129. The method of claim 127, wherein gene expression of between 2 genes and 10 genes is modulated.

130. The method of claim 127, wherein gene expression of the at least one target gene is modulated when the gene expression level of the at least one target gene is increased or decreased compared to a normal gene expression level of the at least one target gene.

Images